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Abstract 
 
Design and Synthesis of Novel Sigma Receptor Ligands Through 
Scaffold Minimization and Their Application Towards Targeted Drug 
Delivery 
 
Kathryn Taylor Linkens, M.A. 
The University of Texas at Austin, 2017 
 
Supervisor:  Stephen F. Martin 
 
Sigma receptors are a class of proteins in which both subtypes (sigma 1 and sigma 2) have 
been implicated in the pathology of most central nervous system disorders and various lines 
of cancer. A series of norbenzomorphan compounds were recently discovered to bind 
sigma receptors with tunable subtype selectivity depending on the substitution pattern. To 
further probe the structure-activity relationship of this new class of sigma ligands, a 
collection of isoindoline, tetrahydroisoquinoline, and benzazepine derivatives were 
prepared. This new set of compounds showed affinity for sigma receptors, and have been 
useful tools in refining the pharmacophore model of the binding sites. Additionally, these 
novel sigma receptor ligands were applied towards a ligand-targeted cancer therapeutic. 
By chemically conjugating an anticancer agent to a ligand that will selectively target cancer 
cells, the therapeutic index of the drug will be improved. Herein, a sigma receptor ligand 
has been chemically conjugated to the chemotherapeutic, gemcitabine, and is undergoing 
cellular uptake and cytotoxicity tests.  
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CHAPTER 1: DESIGN OF NOVEL SIGMA RECEPTOR LIGANDS 
THROUGH SCAFFOLD MINIMIZATION  
1.1 Introduction 
The sigma receptors (SigRs), which once were considered enigmatic proteins, have 
become increasingly implicated in the pathology of many diseases, including most central 
nervous system (CNS) disorders as well as some lines of cancer. Martin et al. originally 
proposed sigma receptors as a subclass of the opioid receptor while studying the 
physiological responses of nondependent and morphine-dependent chronic spinal dog to 
benzomorphan derivatives. During their study, they found that the morphine-like 
derivative, (±)SKF-10047, displayed a unique pharmacology for an opiate. Namely, unlike 
most opioids, (±)SKF-10047 showed hallucinogenic effects and delirium rather than 
analgesic effects alone.1 Upon resolution of (±)SKF-10047, it was shown that (+)-SKF-
10047 (1.1) was more selective for the sigma receptors and the levorotary isomer was 
selective for the opioid receptors (Figure 1.1). Additionally, naloxone (1.2), a prototypical 
opioid antagonist, did not block the effects of (+)-SKF-10047 (1.1), thus separating the 
sigma receptor from the opioid receptors.2–4 Further confusion over the identity of the 
sigma receptor occurred when it was found that (+)-SKF-10047 (1.1) binds with high 
affinity to the phenylcyclidine (PCP (1.3)) binding site of the NMDA receptor. However 
extensive binding assays using sigma selective ligands, like (+)-pentazocine (1.4), 
successfully differentiated the sigma receptor from the PCP site.5 Further studies, by 
Hellewell and Bowen, of selective sigma ligands (like DTG (1.5) and (+)-3-PPP (1.6)) lead 
to the elucidation of two subtypes (Sig1R and Sig2R).6 Using [3H]-DTG to radiolabel 
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sigma sites, Hellewell and Bowen, exclusively labeled a protein of 25 kDa in guinea pig 
brain, but in PC12 cells exclusively labeled a protein of 18kDa and 21kDa. Additionally, 
the sigma site labeled in PC12 sites showed atypical affinity for dextrorotary 
benzomorphans, and was thus identified as the sigma 2 receptor.  
 
Figure 1.1: Sigma receptor selective ligands utilized in the identification and elucidation 
of the sigma 1 and sigma 2 receptors 
Sig1R is a transmembrane protein that is 25.3 kDa in size and is found throughout 
the body with high concentrations in the liver, heart, pancreas, and the CNS with the highest 
densities in limbic structures and sensory regions of the brain.7 It has been cloned from 
numerous mammalian sources, including human brain tissue, and has recently been 
characterized by X-ray crystallography.8–10 The 223 amino acid sequence of the protein 
shows about 90% identity between species but shows no homology with any other known 
mammalian protein.11 Sig1R is located primarily at the mitochondria associated 
endoplasmic reticulum (ER) membrane (MAM) where it acts as a molecular chaperone to 
regulate intracellular Ca2+ homeostasis. Upon activation or cellular stress, it acts as a 
molecular chaperone at the inositol 1,4,5-triphosphate receptors, where it sustains the 
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correct conformation to ensure proper Ca2+ transport between the ER and mitochondria. It 
is also known to translocate from the ER to the cell membrane to help regulate ion flow at 
K+, Ca2+, and Cl- channels as well as neurotransmitter release.12,13  
No endogenous ligand has been discovered for Sig1R; however, some 
neurosteroids, like progesterone, have been proposed as a possible candidate. Although it 
binds Sig1R with high nanomolar affinities, there is no evidence suggesting any 
physiological role played by these interactions.14 It has also been suggested that 
dimethyltryptamine, may be an endogenous ligand, but studies showed that its binding 
affinity (KD= 14.75 μM) is much lower than expected for an endogenous ligand.15 Without 
a verified endogenous ligand, it is difficult to define an agonist or antagonist response of a 
ligand, and unfortunately, to date there is no operationally simple in vitro functional assay. 
However, it is generally agreed upon that agonists induce dystonia in rats, and any ligand 
that reverses those effects are considered antagoists.16 Because Sig1R exhibits no known 
homology to other receptors, genetic manipulation also can be used in experimental 
systems giving a more accurate idea of functional activity. By convention, an antagonist of 
Sig1R are compounds that recapitulate the gene knockdown phenotype; conversely, 
agonists of Sig1R are compounds that recapitulate the phenotypes of receptor 
overexpression.17 
Since the discovery of Sig1R, several therapeutic drugs for treatment of depression, 
schizophrenia, Parkinson’s disease (PD), and Alzheimer’s disease (AD) were identified as 
having affinity for Sig1R, suggesting Sig1R may be involved in pathology of CNS 
disorders (Figure 1.2).18–20 It has been shown that many antipsychotics (haloperidol (1.7)), 
 4 
selective-serotonin reuptake inhibitors (fluoxetine, (1.8)), and monoamine oxidase 
inhibitors (clorgyline, (1.8)) have high affinities for sigma receptors, particularly Sig1R, 
suggesting that Sig1R may play a role in schizophrenia and depression.21 Although the 
exact role of Sig1R in schizophrenia and depression is unknown, it is generally accepted 
that antagonists are associated with antipsychotic effects and agonists are associated with 
antidepressant properties.7 Sig1R also plays a role in neuropathic pain; studies in Sig1R 
knock out mice show decreased pain response in both a formalin test and a capsaicin 
hypersensitization assay.22 It is believed that Sig1R activation plays a role in brain 
plasticity during reinforcement and addictive processes. In studies on both cocaine and 
alcohol addiction, administration of a Sig1R antagonist showed a reduction in the drug-
induced conditioned place preference.23,24 The possible therapeutic benefit of targeting 
Sig1R for treating neurodegenerative disorders, like AD, PD, Amyotrophic Lateral 
Sclerosis (ALS), and Huntington’s Disease (HD), is also being investigated.25–28 Sig1R has 
been shown modulate many of the mechanisms associated with neuronal degradation such 
as excitotoxicity, Ca2+ dysregulation, oxidative stress, ER and mitochondria 
dysfunction.17,29 Interestingly, Sig1R selective agonists as well as non-selective Sig1R 
agonists like donepezil (1.10) (a clinically approved AChE inhibitor for treatment of AD) 
have shown to block Aβ peptide toxicity, a hallmark of the pathology of AD, and attenuate 
learning and memory deficits in mice models.25,30  
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Figure 1.2: Representative neuroleptics shown to bind sigma receptors 
Due to the vast therapeutic potential of the sigma receptors, much work has gone 
into developing sigma receptor subtype selective ligands.31 Figure 1.3 illustrates a sample 
of some of the most potent and selective Sig1R ligands, which display significant structural 
diversity.32–35 Features that other Sig1R ligands have that are not shown in the table include 
a series of piperazine sulfonamide moieties, substituted cyclopropanes and mannose-
morphan derived structures.31  Despite the wide array of Sig1R ligands, there is a proposed 
pharmacophore model for Sig1R. Glennon and coworkers used the SAR of N-substituted 
phenyl-2aminopropanes to develop the pharmacophore model.36 They proposed that the 
binding site requires a proton donor that is in a region that tolerates only small groups. 
There is a primary hydrophobic site that is 6-10 Å away from the proton donor site, and 
the highest affinity was observed when this hydrophobic group was 8.3 Å away. Lastly, 
they proposed a secondary hydrophobic site 2.5-3.9 Å away from the proton donor site that 
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tolerates bulky substituents. Most potent and selective Sig1R ligands that have been 
identified seem to have the features proposed in this model.  
 
Figure 1.3: Sig1R selective ligands from several structural classes 
Recently, Kruse and coworkers reported the crystal structure of the sigma 1 
receptor.10 The structure was obtained in complex with two chemically divergent ligands, 
antagonist, PD144418 (1.16) and agonist, 4-IBP (1.17) (Figure 1.4). The Sig1R exists as a 
timer with a single transmembrane domain. The binding pocket features primarily 
hydrophobic residues with Glu172 responsible for the major ionic interaction. Both 
structures show very little deviation in the receptor conformation despite the structural 
differences in the bound ligands. The major interaction was a charge-charge interaction 
with Glu172 and the basic nitrogen atom of the ligand. A secondary interaction between 
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Tyr103 and Glu172 is also important for binding. The hydrogen bond between the two 
residues stabilizes Glu172; in a mutant without Tyr103, a significant loss in binding affinity 
is observed. Additionally, a second acidic residue, Asp126, which forms a hydrogen bond 
to Glu172 is also required for binding. Now that the crystal structure of Sig1R is available, 
structure-based design, rather than pharmacophore based design, can be used towards the 
development of Sig1R ligands.  
 
Figure 1.4: X-ray crystal structure of PD144418 and 4-IBP bound to Sig1R 
The extensive structure-activity relationship (SAR) investigations of the Sig1R 
ligands have resulted in several compounds progressing to clinical trials (Figure 1.5).  
S1RA (1.18) is a selective Sig1R antagonists (Ki = 17.0 ± 7.0 nM) that is currently in phase 
II clinical trials for the treatment of neuropathic pain.37 ANAVEX2-73 (1.19) binds both 
Sig1R and muscarinic acetylcholine receptors with low micromolar binding affinities. It is 
showing great therapeutic potential for the treatment of AD and is currently pending the 
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phase II clinical trials.38 Lastly, cutamesine (1.20) is currently in phase II clinical trials for 
the treatment of ischemic stroke. Early in vivo assays showed that cutamesine (1.20) 
inhibited hypoxia/hypoglycemia induced neurotoxicity.39 It is also suggested that 
cutamesine (1.20) may play a role in inhibition of motor neuron degeneration and symptom 
progression in ALS.27 
 
Figure 1.5: Compounds targeting Sig1R currently undergoing clinical trials 
Despite its discovery in the early 1990’s, little is known about the identity of Sig2R 
because, for decades, it has evaded cloning, sequencing, and crystallization. From 
photoaffinity labeling experiments, it is known to have a molecular weight of ~21 kDa 
protein and is found in some periphery tissues such as the liver and kidneys as well as the 
brain, but to a lesser extent than Sig1R. Sig2R is found in a high abundance on lipid rafts, 
and while exact mechanisms are unknown it seems to play major roles in intracellular Ca2+ 
release, and cellular proliferation and survival.9,40 It is overexpressed in many cancer cell 
lines, where activation of Sig2R promotes cell death pathways.40 In an attempt to determine 
the molecular identify of Sig2R, Mach and coworkers conducted several photoaffinity, 
proteomic, and binding studies, and their findings suggested that Sig2R is part of the same 
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bio-molecular complex as progesterone receptor membrane component 1 (PGRMC1).41 
However, subsequent reports suggested that Sig2R and PGRMC1 (a well characterized 
heme binding protein) are two distinct molecular entities.42–44 These reports have shown 
that overexpression of PGRMC1 does not increase Sig2R binding and that knockdown or 
knockout experiments do not decrease Sig2R binding of a variety of different Sig2R 
ligands and fluorescent Sig2R ligands.  
Recently, Kruse et al., in collaboration with the Martin group, have identified the 
gene that codes for the Sig2R.45 Using chemical biology techniques, the Sig2R was 
identified as transmembrane protein 97 (TMEM97). Of the proteins identified from affinity 
purification, only TMEM97 overexpressing cells resulted in a significant increase in [3H]-
DTG binding. Furthermore, the binding affinities measured for both Sig2R and TMEM97 
selective ligands were identical when measured in MCF-7 cells (classical Sig2R cell line) 
or sf9 insect membranes expressing TMEM97, and knockdown of TMEM97 decreased 
binding of Sig2R ligands. TMEM97 is an ER-resident transmembrane protein, and like 
Sig2R, the molecular function of TMEM97 is poorly understood. It is involved in 
cholesterol homeostasis and is overexpressed in several lines of cancer where RNA 
silencing of TMEM97 can inhibit gastric cancer cell growth, both of which correlate to 
roles in which Sig2R is implicated.46–49 The identification of Sig2R as TMEM97 has 
opened the door to study this protein and begin to understand its mechanistic roles in the 
body through modern molecular biology techniques rather than pharmacological studies.  
Though the molecular identity of Sig2R remained elusive for so long, significant 
progress has been made towards understanding the cellular roles Sig2R plays through the 
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use of Sig2R selective ligands. Unfortunately, without knowing the molecular identify or 
the endogenous ligands, a uniformly-accepted definition of functional activity has not yet 
been adopted. In addition, there currently exists no efficient functional assay. To date, the 
best functional assay for Sig2R activity was developed by Mach and coworkers, and uses 
cell viability assays and caspase-3 activity to determine agonists and antagonists.50 Using 
the cell viability assay, agonists are defined if the cytotoxicity is >90% relative to 
siramesine (1.24) and antagonists are defined if the cytotoxicity is <10%. Anything ligand 
with cytotoxicity between 90-10% is defined as a partial agonist. Results from the caspase-
3 assay were comparable to the cell viability assay, but were not used for defining 
agonism/antagonism.  
Given the presence of Sig2R in the brain and its binding affinity for neuroleptics,  
it is unsurprising that Sig2R has become increasingly implicated in the pathology of CNS 
disorders.51 The potent Sig2R selective ligand, siramesine (1.24), exhibits an anxiolytic 
and anti-depressant effect. In rats, siramesine reversed shock-induced drinking 
suppression, a common parameter to measure depression and anxiety.52,53 It should be 
noted that siramesine retains high affinity for Sig1R, so it is unclear whether the effects 
observed are solely due to activity at Sig2R. There is also evidence showing that activation 
of Sig2R may play a role is modulating the activity of dopaminergic neurons.54 When 
treated with DTG, a dose dependent rise in dopamine was observed in the rat nucleus 
accumbens shell, an effect attenuated in a dose-dependent manner by Sig2R selective 
antagonists but not Sig1R antagonists. This suggests that Sig2R may play a role in addictive 
behavior through dopamine modulation, and Sig2R antagonists may offer promise in 
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developing addiction therapies.55 Dysregulated Ca2+ levels in the cells plays a major role 
in neurodegenerative pathways like excitotoxicity (Ca2+ overload), ER stress, and 
mitochondria dysfunction. It has been suggested that Sig2R plays a role in modulating Ca2+ 
homeostasis, suggesting it may be a possible target for neuroprotective agent. DTG (1.5) 
has shown cytoprotective effects against excitotoxic mechanisms, although the exact 
mechanism is unknown. Additionally, Sig2R agonists have been reported promote caspase-
dependent apoptosis at the mitochondria, which provides a logical link that antagonists 
may be neuroprotective.29 Recent work by Cognition Therapeutics has shown that 
Sig2R/PGRMC1 plays a role in the pathology of AD. These studies showed that Aβ 
oligomers bind to Sig2R/PGRMC1, thereby inducing changes that lead to synapse loss and 
neuronal death; Sig2R antagonists reduced synapse loss and cognitive deficits caused by 
Aβ oligomers in vitro.56 Their compound, CT1812, is currently undergoing Phase 1 clinical 
trials, marking the first compound targeting Sig2R for AD to make it to the clinic.  
To expand our understanding of the biological roles Sig2R plays, the development 
of highly selective Sig2R ligands is essential. Like Sig1R, Sig2R also binds a range of 
ligands from many different structural classes, including tetrahydroisoquinolines, tropanes, 
cyclohexyl piperazines, indoles, benzylidenes, benzamides, and more.40,51 In general, 
Sig2R ligands can be divided into two very different classes: flexible and constrained. 
Generally, flexible ligands have two regions of functionality connected by a flexible chain 
of varying length. By contrast, constrained ligands contain a ridged amine containing 
bicycle from which functionality is appended. Because there is less structural information 
about the Sig2R, development of Sig2R selective ligands has not been straightforward. 
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More often than not, Sig2R ligands have been identified from projects targeting other 
receptors such as acetylcholine receptors, serotonin receptors, dopamine receptors, etc. 
Despite the challenges for developing Sig2R selective ligands, many highly potent and 
selective Sig2R ligands have been developed (Figure 1.6).57–60 In particular, Mach and 
coworkers have developed many highly potent benzamide and napthamide analogs that 
have impressive selectivity, which they are utilizing for cancer imaging, therapy, and 
targeted delivery of cancer therapies.61–64  
 
Figure 1.6: Sig2R selective ligands from several structural classes 
Due to the diversity of Sig2R ligands and the lack of structural information, the 
binding requirements for designing selective Sig2R ligands remain unclear. There have 
been several proposed pharmacophore models for the Sig2R ligands; however, these were 
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based on a limited set of Sig2R ligands.65–67 Recently, Rhoads and coworkers proposed a 
more comprehensive pharmacophore model based on 50 Sig2R ligands from seven 
different structural classes.68 These seven structural classes were used to generate a series 
of pharmacophore models that were used to represent different receptor binding modes. 
Through clustering of these binding modes, they were able to produce a robust model of 
the Sig2R binding site. The analysis suggests that the Sig2R binding pocket is 21 Å long, 
11 Å wide, and 10 Å deep. It includes two large hydrophobic regions, four negative charged 
/hydrogen bond acceptors (NG/HBA), and at least two hydrogen donor groups, which they 
say contribute little to Sig2R binding. The two hydrophobic groups are separated by ~9 Å, 
and the first hydrophobic region is necessary for Sig2R binding. One of the NG/HBA 
groups is adjacent to the second hydrophobic group, another is in the center of the binding 
pocket, and the remaining NG/HBA groups are positioned around the pocket. In general, 
it seems that ligands with high affinity for Sig2R contain a basic nitrogen atom and at least 
one hydrophobic group. Any additional nitrogen atoms or hydrophobic groups are not 
essential but do enhance binding. It should be noted that there was a lot of deviation within 
the different binding modes of which they based their comprehensive model, and therefore 
the conclusions may still not be an accurate view of the binding pocket.  
In addition to cloning Sig2R, Kruse and coworkers ran a series of experiments to 
give insight into the binding pocket of Sig2R/TMEM97 (Figure 1.7).45 To map the ligand 
binding site, a series of mutagenesis experiments were run on all Glu and Asp residues, 
hypothesizing that these acidic residues interact with the basic amine found in all Sig2R 
ligands. Like Sig1R, two acidic residues, Asp29 and Asp56, are required for ligand 
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binding. Based on their predicted structural model, these two residues are close in 
proximity and may interact directly via a hydrogen bond network with the basic amine like 
the Sig1R binding pocket. Despite the recent identification of Sig2R, it remains important 
to continue to develop Sig2R selective ligands in hopes of furthering the understanding of 
what drives selectivity for one subtype over another.  
 
Figure 1.7: Structural analysis of TMEM97 and mapping of the ligand binding site 
1.2 Martin Group Work 
 As part of an effort towards identifying novel bioactive compounds, the Martin 
group developed a platform for the rapid synthesis of drug-like scaffolds with functional 
handles for rapid diversification.69 In this multicomponent assembly process, aryl 
aldehydes and primary amines were combined to form a diverse array of imines, which 
could undergo reactions with a variety of acylating reagents and nucleophiles to give highly 
functionalized intermediates in a single operation. Subsequent cyclization reactions to 
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increase skeletal complexity led to the generation of a variety of heterocyclic scaffolds 
(Figure 1.8). 
 
Figure 1.8: General overview of the Martin group multicomponent assembly process 
 From this effort, a diverse library of compounds was synthesized and screened 
against a comprehensive panel of CNS proteins, including 45 GPCRs, ion channels, and 
neurotransmitter transporters. This screen identified a subclass of substituted 
norbenzomorphans  that displayed high affinity for the sigma receptors, as well as 
selectivity between sigma subtypes.70 Interestingly, these compounds are structurally 
distinct from all other identified sigma ligands. Due to the possible involvement of Sig2R 
in neurodegenerative disorders, it was of interest to see if any of the initial compounds 
could be used as a pharmacological tool for studying Sig2R modulation in AD.71 
 
Figure 1.9: Several sigma receptor hits from initial norbenzomorphan library of 
compounds 
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 Several Sig2R-selective norbenzomorphans (Figure 1.9) were advanced into an in 
vivo AD model using transgenic C. elegans with a single copy of human amyloid precursor 
protein (APP). These worms have neurons which are easily visualized and begin to display 
symptoms of neurodegeneration of cholinergic neurons in 5-7 days making this an ideal 
platform for assaying neurodegeneration. While these compounds were identified as Sig2R 
ligands, we found that in C. elegans, these compounds modulate a PGRMC1-related 
pathway through PGRMC1 ortholog, vem1 (Figure 1.10). Worms treated with compound 
JVW-1009 (1.27) and SAS-0132 (1.28) for five days showed decreased neurodegeneration 
on day five compared to the vehicle-treated group. Therefore, these two compounds were 
putatively assigned as Sig2R antagonists. Conversely, worms treated with DKR-1005 
(1.26) showed increased neurodegeneration on day five compared to vehicle and were thus 
putatively assigned as Sig2R agonists.  
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A) Transgenic worm and PCRMC1/vem-1 knockout: C. elegans vem-1 knockout exhibits reduced neurodegeneration 
relative to WT. B) Transgenic worm treated with Sig2R ligands: DKR-1005 show increased neurodegeneration whereas 
JVW-1009 and SAS-0132 show reduced neurodegeneration compared to control. C) Transgenic worm and 
PGRMC1/vem-1 RNAi: Neurodegeneration in APP strain treated with PGRMC1-directed RNAi and/or SAS0132 shows 
that SAS-0132 proceeds via a PGRMC1-mediated pathway. 
Figure 1.10: Effects of norbenzomorphan compounds on neurodegeneration in C. 
elegans 
It was also of interest to study how modulation of Sig2R would affect cognition in 
transgenic APP mice. SAS-0132 (1.28) emerged as an attractive target for these in vivo 
tests because not only was it identified as an antagonist but it exhibits 9-fold selectivity for 
Sig2R and has low off-target affinity for other CNS receptors. In several behavioral and 
learning tests, SAS-0132 (1.28) showed cognitive enhancement in sociability, spatial 
memory, and long-term memory (Figure 1.11). In a chronic dose-response study, SAS-
0132 (1.28) improves AD-related deficits in the social discrimination test and improves 
spatial memory in the Y-maze test. In a chronic dose-response study, SAS-0132 (1.28) 
improves spatial and long-term memory in both APP and wildtype mice in the Morris water 
maze. All tests were performed a day after treatment, suggesting that the effects are due to 
chronic treatment with SAS-0132 (1.28) and not acute effects because SAS-0132 (1.28) is 
A) B) C) 
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cleared from the brain in 24 h. Additionally, SAS-0132 (1.28) has good bioavailability, 
was well tolerated and brain penetrant.  
 
A) Social discrimination test: APP mice treated with SAS-0132 (10 mg/kg) showed normal sociability unlike vehicle 
treated APP mice which showed lack of sociability. B) Y-maze test: APP mice treated with vehicle showed impared 
spontaneous alternation performace and APP mice treated with SAS-0132 (10 mg/kg) showed spontaneous alternation 
behavior at a level comparable to WT  mice  
Figure 1.11: Effects of SAS-0132 on cognitive ability of APP mice in a chronic dose 
study 
With lead compounds exhibiting therapeutic potential in in vivo models of AD, a 
SAR campaign was launched to optimize the binding affinity and selectivity of our 
compouds.72 SAR analysis of our library of norbenzomorphans (Figure 1.12) shows that 
subtype selectivity can be tuned depending on the placement of the aryl subsituent.72 This 
finding is unique to our norbenzomorphan compounds; no other known classes of sigma 
ligands show a reversal in subtype selectivity by making a small structural change to the  
ligand. When the C(8) position of the norbenzomorphan is substituted with a piperazine 
moiety, high levels of Sig2R selectivity are achieved. Subtype selectivity for Sig2R can 
also be tuned depending on the nature of the substitution of the piperazine. While the N-
 
A) B) 
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alkyl groups on the piperazine have small changes in the Sig2R affinity, the nature of the 
alkyl group can cause pronounced changes in the Sig1R binding affinity. In addition, Sig2R 
selectivity significantly spikes when a polar group is on the piperazine nitrogen atom and 
R1 is a benzyl carbamate. While some of the most selective Sig2R ligands were achieved 
when R1= -Cbz and R2= piperazine, Sig2R selectivity could be improved 2-3 fold when R1 
was a sulfonamide. Additionally, when C(8) was subsituted with a morpholine moiety, 
high affinity and selectivity for Sig2R was achieved as long as there was another ionizable 
nitrogen in the molecule (i.e. R1= 3,5-dichlorobenzyl). Conversely, high affinity and 
selectivity for Sig1R was achieved when C(7) was  substituted. While R3 tolerated similar 
alkyl piperazine substituents as R2, the best selectivity obtained for Sig1R was for 
compounds with aryl or morpholine moieties at R3 and benzyl groups at R
1. 
 
Figure 1.12: Chemical space explored off the norbenzomorphan scaffold 
To further understand the SAR of this class of compounds, we were interested in 
probing the effects of scaffold minimization. Scaffold hopping strategies often simplify the 
synthetic strategy and lead to improved binding and pharmacokinetic properties.73 By 
systematically reducing the structural complexity of the carbon framework of the 
norbenzomorphan, a new library of isoindoline (n = 1), tetrahydroisoquinoline (n = 2), and 
tetrahydro-2-benzazepine (n = 3) derivatives were envisioned. (Figure 1.13). By removing 
the bridging methylene group, a feature that conformationally locks the norbenzomorphan 
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scaffold, we introduce flexibility in the molecule and the ability to vary the ring size. Both 
increased flexibility and ring contraction change the spatial orientation of the substituents 
on the nitrogen atom. This may allow access to a more favorable binding mode within the 
binding pocket, as it is thought that the Sig2R may be able to adopt a variety of acceptable 
binding conformations due to the structural diversity of high affinity ligands. These new 
derivatives were modeled after the most potent and selective norbenzomorphan 
derivatives. Holding the substitution patterns constant while changing the carbon 
framework of the compounds will help determine the necessary features of the 
norbenzomorphan scaffold for sigma receptor binding.  
 
Figure 1.13: Removal of bridging methylene to access new classes of derivatives 
1.3 Results and Discussion 
With the goal of creating a novel library of compounds of general type 1.30 with 
varying ring size, we first sought to synthesize the requite scaffolds with suitable functional 
handles for derivatization. The synthetic approach for the preparation of the isoindoline 
scaffold 1.33 is outlined in Scheme 1.1. Bromination of phthalic anhydride (1.31) 
proceeded in 36% yield, and subsequent imide formation afforded 1.32 in 98% yield over 
two-steps.74,75 Borane reduction followed by -Cbz protection provided the isoindoline 
scaffold, 1.31, in 55% yield over two steps.76 
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Scheme 1.1: Synthetic route to access isoindoline scaffold 
 We envisioned the tetrahydroisoquinoline scaffold could arise from a Pictet-
Spengler reaction of bromo-phenethylamine and paraformaldehyde. The necessary 
phenethylamines were synthesized via Henry reactions77 of 1.34 and 1.35, respectively 
(Scheme 1.2). Borane reduction of the resulting nitrostyrenes 1.36 and 1.37 afforded 
amines 1.38 and 1.39 in 70% and 63% yields, respectively.78 Because both 1.38 and 1.39 
are electron poor arenes, attempts to cyclize via a Pictet-Spengler reaction using 
paraformaldehyde were unsuccessful. Acylation of the amine to generate the highly 
reactive N-acyliminium ion intermediate is a known strategy to overcome poor reactivity 
in Pictet-Spengler reactions.79 Therefore, trifluoroacetamide 1.40 was synthesized and 
subjected to cyclization with paraformaldehyde to give 1.42 in 68% yield. Pictet-Spengler 
cyclization of 1.41 afforded an inseparable mixture (1:2) of regioisomers 1.43 and 1.44. 
Fortunately, removal of the -TFA group with Na2CO3 in MeOH allowed for 
chromatographic separation of the two isomeric amines. Protection of 1.44 proceeded 
smoothly to give 1.45 in 82% yield (Scheme 1.2). 
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Scheme 1.2: Tetrahydroisoquinoline scaffold synthesis 
 As previously mentioned, benzyl carbamate derivatives displayed high Sig2R 
affinity and selectivity. therefore, it was of interest to prepare the benzyl carbamate 1.46 
and subject it to Pictet-Spengler cyclization conditions. 1.46 was prepared via -Cbz 
protection of 1.38 (Scheme 1.3). Initial attempts under the same conditions used to 
synthesize 1.43, resulted in hydrolysis of the benzyl carbamate. After some effort, it was 
found that cooling the acid mixture prior to addition of paraformaldehyde and 1.46, and 
gave tetrahydroisoquinoline 1.47 in 76% yield. Unfortunately, Pictet-Spengler cyclization 
of benzyl (3-bromophenethyl) carbamate gave an inseparable mixture of regioisomers. 
 23 
 
Scheme 1.3: Acyl Pictet-Spengler reaction with benzyl carbamate 
With isoindoline 1.33 and tetrahydroisoquinolines 1.45 and 1.47 in hand, we set 
our sights on the synthesis of the benzazepine scaffolds. This series is the most important 
data point in our investigation on scaffold simplification, as it directly probes the effects of 
the bridging methylene group in the norbenzomorphan scaffold. The benzazepine scaffold 
is also currently being investigated for its sigma receptor binding properties by other 
groups. Wunsch and coworkers have synthesized a library of functionalized tetrahydro-2-
benzazepines and -3-benzazepines (Figure 1.14).80–82 Derivatives of compound 1.48 
showed high affinity for Sig1R; in particular, when R1= CH2CHC(CH3)2 and R2= Bn the 
Ki for Sig1R was 3.6 nM with 71-fold selectivity.
80 Conversely derivatives of 1.49 and 1.50 
only had micromolar affinity for both receptors.81 Their work has shown that benzazepine 
scaffold has an intrinsic affinity for the sigma receptors to some degree. This knowledge, 
coupled with our finding on regiochemical selectivity may allow us to synthesize high 
affinity sigma ligands with tunable selectivity.  
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Figure 1.14: Representative benzazepine derivatives with high binding affinity for SigRs 
designed by Wunsch et al.  
  Initial attempts to access the benzazepine scaffold began with a reductive amination 
of 1.52 with allylamine and NaBH(OAc)3, followed by treatment with Cbz-Cl and Hünig’s 
base in CH2Cl2 to give 1.53 in 78% over two steps (Scheme 1.4). A Suzuki cross coupling 
reaction with the corresponding boroxime then gave 1.54 in 79% yield on small scale. 
 
Scheme 1.4: Second generation synthesis towards benzazepine scaffold 
However, upon scale up, this result was not reproducible; instead significant amount of a 
byproduct was formed. This by-product was the result of a competing intramolecular Heck 
reaction to give 1.55. In an attempt to suppress the competing Heck reaction a screen of 
conditions was performed that included: changing the boron reagent to a more nucleophilic 
boron reagent83, changing the base, and changing the amount of base to increase the 
basicity of the solution which is known to accelerate Suzuki reaction (Equation 1.1). 
Although the product ratio was improved from 1.2:1 of 1.54 and 1.55 to 3:1 1.54 and 1.55, 
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it became clear that the Suzuki cross-coupling step needed to be performed before the 
reductive amination. 
 
(1.1) 
The Suzuki cross-coupling of 1.52 and 1.56 proceeded in 80% yield to give 1.57 
and in 75% yield to give 1.58 (Scheme 1.5). Initially, the reductive amination between the 
vinyl benzaldehyde and allyl amine with NaBH(OAc)3 as the reducing agent followed by 
-Cbz protection gave 1.59 in only 35% yield over two-steps. Unfortunately, NaBH(OAc)3 
was not a strong enough reducing agent for this substrate; after 24 h there was still 
incomplete reduction of the imine attributing to the low yield of 1.59. It was well 
established in literature that with these vinyl benzaldehydes, preformation of the imine 
followed by reduction with NaBH4 will give the desired amine in high yield.
84 Hence, 
treating the 1.57 and 1.58 with allyl amine in CH2Cl2 with MgSO4 followed by reduction 
with NaBH4 and -Cbz protection gave 1.59 and 1.60 76% yield and 80% yield respectively, 
over two-steps. Ring closing metathesis of 1.59 and 1.60 with Grubbs 2nd generation 
catalyst gave 1.61 in 84% yield and 1.62 in 71% yield. Subsequent hydrogenation of 1.61 
and 1.62 with Adam’s catalyst gave the desired benzazepine scaffolds 1.63 and 1.64 in 
94% and 91% yields, respectively.  
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Scheme 1.5: Preparation of benzazepine scaffolds 
With all three scaffolds in hand, a diverse library of compounds was synthesized. 
The desired biaryl compounds were synthesized via Suzuki cross-coupling reactions of 
1.33, 1.45, and 1.64 to give 1.65, 1.69, and 1.74. Buchwald-Hartwig aminations were 
performed on 1.31, 1.45, 1.47, 1.63, and 1.64 using a premixed solution of JohnPhos and 
Pd(OAc)2, with a slight excess of amine to give the desired aniline derivatives 1.66-1.68, 
1.70-1.73, and 1.75-1.78 (Scheme 1.6-1.8). For piperazine derivatives at least five 
equivalents of the amine were used to prevent coupling at both nitrogen atoms of 
piperazine. 
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Scheme 1.6: Suzuki and Buchwald-Hartwig cross-coupling reactions on isoindoline 
scaffold 
 
Scheme 1.7: Suzuki and Buchwald-Hartwig cross-coupling reactions on 
tetrahydroisoquinoline scaffold 
 
Scheme 1.8: Suzuki and Buchwald-Hartwig cross-coupling reactions on benzazepine 
scaffold 
With the necessary intermediates 1.65-1.78 in hand, an initial library based on 1 
norbenzomorphan compounds was prepared. These model compounds were carefully 
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selected to represent different classes of compounds explored around the norbenzomorphan 
SAR study. A variety of functionalized piperazine, benzyl carbamate norbenzomorphan 
model derivatives that showed varying degrees of Sig2R affinity and selectivity were 
selected and analogous substitution patterns were prepared in all three scaffold sizes 
(Scheme 1.9). Allylamines 1.79-1.84 were prepared through standard alkylation conditions 
from intermediates 1.67, 1.71, and 1.76. Reductive amination of 1.67, 1.71, and 1.76. with 
a variety of aldehydes or ketones in the presence of NaBH(OAc)3 gave 1.85-1.90. Finally, 
1.67, 1.71, and 1.76. was treated with ethyl acrylate to give 1.91-1.93.  
 
Scheme 1.9: Piperazine derivatization reactions 
 29 
To probe whether the effects of scaffold swapping was more general, compounds, 
based on both Sig2R and Sig1R selective norbenzomorphan compounds, containing 
benzylamines or sulfonamides substitution patterns were prepared on the three scaffolds. 
Treatment of tetrahydroisoquinolines 1.69 or 1.73 with TMSI, followed by a basic workup 
gave benzylamines 1.94 and 1.95 in ~30% yield (Equation 1.2). Benzylamine derivatives 
1.96-1.102 were prepared via reductive amination in a two-step procedure (Equation 1.3 
and 1.4).  
 
(1.2) 
 
(1.3) 
 
(1.4) 
Sulfonamide derivatives 1.103-1.108 were prepared in a two-step procedure 
beginning with -Cbz deprotection followed by sulfonylation with the appropriate sulfonyl 
chloride (Equation 1.5). For allyl derivatives, the -Cbz group was removed via treatment 
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with TMSI followed by an acidic work-up to prevent reduction of the allyl group under 
hydrogenation conditions (Equation 1.6).  
  
 
(1.5) 
 
(1.6) 
This new library of compounds containing all three scaffold classes have been 
screened by the Psychoactive Drug Screening Program (PDSP) at The University of North 
Carolina at Chapel Hill against a panel of CNS receptors. The sigma receptor binding data 
for the isoindoline compounds are presented in Table 1.1. Compounds 1.96 and 1.98, which 
were based on Sig1R norbenzomorphans, maintained high affinity (Ki= 5.9 nM and 4.1 nM 
respectively) and moderate selectivity for Sig1R. The isoindoline scaffold overlays the 
substituents similarly to the norbenzomorphan, so the retention of Sig1R affinity is 
unsurprising. The remaining derivatives in the isoindoline series were designed based on 
Sig2R norbenzomorphan ligands and suffered from a significant decrease in affinity and 
selectivity for Sig2R. The isoindoline scaffold is symmetrical about the nitrogen atom, 
eliminating the possibility of regioisomers. The loss of subtype selectivity in this series 
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suggests that the regiochemistry of the substituent on the arene is important for Sig2R 
selectivity. 
Table 1.1: Binding affinity data for isoindoline series
 
The tetrahydroisoquinoline series reintroduces the potential for regioisomers, and 
the binding data for these compounds are presented in Table 1.2. Unsurprisingly, the 
regiochemistry of the tetrahydroisoquinoline predictably lead to preferential Sig1R or 
Sig2R binding, consistent with the selectivity observed with the analogous 
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norbenzomorphan compounds. While the tetrahydroisoquinoline series restored some of 
Sig2R selectivity that was lost with the isoindoline scaffold, a significant decrease in 
selectivity between the two subtypes was observed for all derivatives in this series when 
compared to the analogous norbenzomorphan. Notably, compound 1.86 shows single digit 
nanomolar affinity for Sig2R (Ki= 2.7 nM) with 19-fold selectivity. Despite the decrease 
in selectivity, compounds 1.94 and 1.95 have comparable affinity for Sig1R as the 
norbenzomorphan (Ki= 1.7 nM and 4.9 nM respectively). When switching to the 
tetrahydroisoquinoline scaffold from the norbenzomorphan scaffold, the nitrogen atom 
shifts in space as a consequence of ring contraction and diminished conformation 
constraint. This change in spatial arrangement of the substituents going from the 
norbenzomorphan to the tetrahydroisoquinoline could potentially explain the observed 
decrease in selectivity. These data suggest that the orientation of the substituents in these 
classes of compounds is important for high Sig2R subtype selectivity. 
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Table 1.2: Binding affinity data for tetrahydroisoquinoline series
 
The binding affinity data for the series of benzazepine compounds is presented in 
Table 1.3 and gives insight into the importance of the bridging methylene group, the feature 
which locks the norbenzomorphan in its rigid conformation. Unsurprisingly, compounds 
1.97 and 1.99, which were modeled after Sig1R compounds, show preferential binding to 
Sig1R over Sig2R, like the corresponding isoindoline and tetrahydroisoquinoline 
derivatives. Although the remaining compounds (modeled after Sig2R selective 
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norbenzomorphan ligands) have comparable Sig2R binding affinity as the corresponding 
tetrahydroisoquinolines, these compounds also have a more favorable interaction with 
Sig1R. This led to a series of compounds having little subtype selectivity, like the 
isoindoline series. These data suggest that the conformational rigidity imparted by the 
bridging methylene of the norbenzomorphan scaffold preorganizes the substituents in an 
appropriate conformation that is necessary for high affinity and selective Sig2R binding.  
Table 1.3: Binding affinity data for benzazepine series
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Collectively, these series of compounds were more potent for Sig1R and had 
moderate to little selectivity for Sig2R compared to the comparable norbenzomorphan 
compounds. These findings suggest that to achieve high levels of subtype selectivity for 
Sig2R in these classes of compounds, the relative orientation between the substituents on 
the scaffold is important (Figure 1.15). The bridging methylene group of the 
norbenzomorphan creates a sharp U-shape in the molecule when C8 is functionalized 
which may not place the basic nitrogen of the molecule favorably in the linear Sig1R 
binding pocket (Figure 1.15D). Based on the crystal structure of the Sig1R binding pocket, 
the ionic interaction of a basic amine with Glu172 is responsible for high affinity Sig1R 
binding. This suboptimal ionic interaction, as seen with a Sig2R selective 
norbenzomorphan, may explain the high degrees of selectivity obtained for our 
norbenzomorphan compounds. In contrast, the isoindoline and the C(7) functionalized 
tetrahydroisoquinoline scaffolds have a more linear orientation between the substituents 
and overlay poorly with C(8) functionalized norbenzomorphan. This may allow these 
compounds to fit more favorably in the Sig1R binding pocket. Although C(8) 
functionalized benzazepines overlay nicely with C(8) functionalized norbenzomorphans, 
the benzazepine scaffold has more conformation flexibility, and easily adopt different 
conformations for binding that the norbenzomorphan. This may explain the increase in 
affinity for Sig1R of the benzazepine compounds.  
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Structures were minimized in Avogadro using Force Field MMFF94s with a conjugate gradients algorithm. These outputs 
were saved and compounds were overlaid in Chem3D using fast overlay program: A) Overlay of compound 1.28 and 
1.66. B) Overlay of compound 1.28 and 1.70. C) Overlay of compound 1.28 and 1.75. D) Docking of norbenzomorphan 
Sig2R selective ligand SAS1121 in Sig1 binding pocket done by the Kruse group. 
Figure 1.15: Overlay of norbenzomorphan sigma 2 selective ligand 1.28 with 
compounds 1.66, 1.70, and 1.75 
 Despite the observed decreased selectivity, most compounds were still potent 
binders for sigma receptors. Interestingly, compounds 1.66 and 1.79 were modeled after 
Sig2R selective ligands, yet they showed higher affinity for Sig1R (Ki = 250 nM and 92 
A) B) 
C) D) 
Glu172 
SAS1121 
6.6 
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nM respectively). Analogous derivatives were made on scaffolds 1.45 and 1.64 to see if 
introducing the regiochemistry would increase Sig1R binding and selectivity (Scheme 1.10 
and 1.11). These new novel compounds 1.110-1.112 and 1.114-1.116 did show some 
selectivity for Sig1R with compound 1.111 being the most potent and selective for Sig1R 
(Ki= 36 nM, 6.5-fold selectivity). Overall little improvement was observed with most of 
these new compounds having comparable or lower affinity for Sig1R compared to the 
parent compounds 1.66 and 1.79.   
 
Scheme 1.10: Synthesis of piperazines derivatives on 6-bromo-tetrahydroisoquinoline 
scaffold in an attempt to optimize binding 
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Scheme 1.11: Synthesis of piperazines derivatives on 7-chloro-benzazepine scaffold in 
an attempt to optimize binding 
In the tetrahydroisoquinoline series, compound 1.86 was the most potent Sig2R 
binder with a (Ki= 2.7 nM, 18.9- fold selectivity). From this result, the cyclobutyl- and 
cyclohexyl-piperazine derivatives were made to see how ring size might affect binding in 
this position, in hopes of optimizing binding (Equation 1.7). Again, little change was 
observed, with compound 1.117 having lower affinity and compound 1.118 having 
comparable binding affinity for Sig2R than 1.86. Additionally, both compounds were less 
selective than 1.86.  
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(1.7) 
To further probe how the relative orientation of the substituents on the ring plays a 
role in the design of Sig2R selective compounds, the chemical space around the 
tetrahydroisoquinoline ring was explored. The collection of tetrahydroisoquinolines with 
C7 functionalized suffered from a loss of selectivity compared to the norbenzomorphan 
compounds; however, these two scaffolds place the substituents off of the scaffold in very 
different areas of space (Figure 1.16). Instead of functionalizing the tetrahydroisoquinoline 
off C7, we could instead functionalize C8. These compounds bring the substituents closer 
in space by contracting the distance between the nitrogen atom of the scaffold and the 
substituent on the arene, creating a shape more similar to the norbenzomorphan 
compounds.  
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Structures were minimized as defined in Figure 1.15: A) Overlay of compound 1.28 and 1.70. B) Overlay of compound 
1.28 and 1.120. 
Figure 1.16: Overlay comparison of norbenzomorphan and tetrahydroisoquinoline 
derivatives with both C7 and C8 functionalized 
Starting from compound 1.43, several new derivatives were made via Buchwald-
Hartwig cross-coupling, followed by reductive amination or conjugate addition of ethyl 
acrylate (Scheme 1.12). These three compounds were modeled after the best 
norbenzomorphan and the best tetrahydroisoquinoline compounds. While little 
improvement was achieved for 1.121 compared to 1.86, the affinity and selectivity for 
Sig2R for 1.120 and 1.122 improved. Going from 1.70 to 1.120 resulted in a five-fold 
increase in binding affinity for Sig2R. Even more encouraging, when C7 of the 
tetrahydroisoquinoline contained -CH2CH2CO2Et substituted piperazine, the binding 
affinity (Ki) for Sig2R was 198 nM, but at C8 the Sig2R binding affinity increased to 11.7 
nM in 1.122, resulting in a 17-fold improvement in binding affinity. In addition to 
A) B) 
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improved Sig2R binding, all three compounds suffered a decrease in binding affinity for 
Sig1R compared to the corresponding C7 substituted tetrahydroisoquinoline compounds. 
This resulted in a six-fold increase in selectivity for Sig2R for 1.120 compared to 1.70, and 
a 57-fold increase in selectivity for Sig2R for 1.122 compared to 1.86. This result seems to 
support that high affinity and selective Sig2R ligands of this class need to have a close 
spatial orientation between the two substituents off the scaffold. Furthermore, the loss in 
affinity in these compounds for Sig1R supports that high Sig1R affinity and selectivity is 
driven by linearity in the molecule. It is important to note that compounds 1.120-1.122 are 
not a comprehensive data set, but these results offer a point for further exploration into the 
SAR of these classes of compounds.  
Scheme 1.12: Synthesis of C(8) functionalized tetrahydroisoquinoline derivatives 
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In summary, we have prepared a library of isoindoline (n = 1), 
tetrahydroisoquinoline (n = 2), and tetrahydro-2-benzazepine (n = 3) compounds to explore 
the SAR of a novel class sigma ligands. Through scaffold minimization, we were able to 
begin to build a pharmacophore model for these new classes of ligands for both Sig2R and 
Sig1R. For achieving Sig1R selectivity, we have shown that there is little dependence on 
the scaffold (Figure 1.17). As long as the scaffold can arrange the substituents in a linear 
manner, analogous substitution patterns showed very similar binding profiles.  
 
 
A) Docking of compounds 1.94, 1.96, and 1.123 in the Sig1R binding pocket done by the Kruse group. B) Overlay of 
compounds 1.94, 1.96, 1.97 and 1.123: structures were minimized as defined in Figure 1.15. 
Figure 1.17: Sig1R selective compounds docked in Sig1R binding pocket and structural 
overlay of Sig1R selective compounds from all four scaffold classes 
Glu172 
Tyr103 
Asp126 
A) B) 
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Conversely, we discovered that the orientation between the substituents off the 
scaffold plays an important role in achieving high Sig2R. When the scaffold is symmetrical 
(isoindolines), there is no selectivity for Sig2R, and if the scaffold is too conformationally 
flexible (benzazepines), there is also a loss in selectivity for Sig2R. However, when on a 
more conformationally ridged scaffold (tetrahydroisoquinoline), the carbon of which the 
piperazine substituent is off of seems to play an important role for driving Sig2R 
selectivity. Together these results suggest that Sig2R selective compounds of these classes 
must place substituents on the scaffold close in space. Despite achieving only moderate 
levels of subtype selectivity, this new library of compounds were still potent binders of 
both sigma receptors. Recently, experiments have suggested that compounds that can bind 
both sigma receptors may be useful in both the diagnosis and treatment of cancer.85,86 Thus, 
these scaffolds may serve as a future platform for the development of more potent “pan 
modulators” of the sigma receptors. Additionally, these compounds showed little off-target 
activity, and given the synthetic simplicity, it is also possible that these ligands could be 
used as tool compounds to further advance the understanding of sigma receptors. 
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CHAPTER 2: SYNTHESIS OF SIGMA RECEPTOR LIGAND-
GEMCITABINE CONJUGATES FOR TARGETED DRUG 
DELIEVERY 
2.1 Introduction 
Cancer is a group of diseases characterized by uncontrollable growth of abnormal 
cells, and failure to regulate and prevent the replication and spread of cancerous cells leads 
to patient death. Cancer represents one of the most common causes of death in the United 
States; it is estimated that in 2017, 1,700,000 new cancer cases will be diagnosed, and 
600,900 patients will suffer cancer related deaths.87 Significant advances have been made 
in cancer therapy, and survival rates have increased from 49%-68% over the past 50 years, 
yet current chemotherapies suffer a number of shortcomings.87 The major disadvantage of 
current chemotherapeutic agents is that they are nonspecific. With regular dosing of 
chemotherapeutics, the drug enters cancer and healthy cells, usually with the same kinetics, 
resulting in dose limiting toxic effects. This causes a number of side effects that can lead 
to suboptimal dosing regiments or termination of the chemotherapeutic plan. Tumor cells 
can also develop resistance mechanisms over time, causing the chemotherapy to lose its 
efficacy. To overcome these shortcomings, therapeutic strategies must be developed that 
increase the therapeutic window of these agents while also decreasing toxicity.88 
One strategy that is currently being investigated is targeted drug delivery, in which 
a targeting moiety is chemically conjugated to a potent (and typically nonspecific) 
cytotoxic agent via a spacer that contains a cleavable bond.89,90 This rapidly growing class 
of anticancer therapeutics uses a targeting moiety, such as antibodies, aptamers, peptides, 
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small molecule ligands, etc., to selectively deliver the toxic payload to malignant cells. 
Achieving selective delivery of therapeutic agents to cancer cells will improve the 
therapeutic window by increasing the drug concentration at malignant cells while reducing 
drug concentrations at non-tumor sites, thereby minimizing off-target effects.91 However, 
it is important to remember that the efficacy of these conjugates is predominately controlled 
by the potency of the targeting ligand and the chosen receptor.  The targeted receptor must 
be overexpressed in tumor cells and allow for the internalization of therapeutic quantities 
of the conjugate. Ideally, the receptor will also be located on the cell membrane and recycle 
fast after internalization. The chosen targeting ligand must have high affinity and 
selectivity for the chosen receptor to prevent off target interactions that may cause off target 
selectivity. Through careful selection of target receptor and ligand, this strategy is a 
powerful way to overcome the shortcomings of modern chemotherapies.  
 
Figure 2.1: Design of a typical ligand-drug conjugate 
2.1.1 SIGMA RECEPTORS AND THEIR ROLE IN ONCOLOGY 
Sigma receptors, while extensively studied for their functions in the central nervous 
system, have also been implicated in cancer pathology and are current targets for the 
development of novel cancer therapies and diagnostic tools. As mentioned in the previous 
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chapter, SigRs are widely distributed throughout the body, suggesting it may play 
important roles in peripheral cells, not just neurons.  Overexpression of SigRs in cancer 
cells was first observed in a panel of brain tumors via competition binding assays using 
tritiated DTG. Of the 16 tumors examined, non-specific SigR binding was detected in 15, 
with very high levels found in neuroblastoma and a brain metastasis from a lung 
adenocarcinoma.92 Subsequent research based on the binding of labeled non-subtype 
specific ligands have shown increased levels of SigRs in nonsmall cell lung carcinoma, 
breast, lung, melanoma, leukemia, glioblastoma, neuroblastoma, and prostate tumors.93 
Specifically, Sig1R overexpression has been shown in lung, breast, and prostate cancer cell 
lines.19 Using Sig2R selective ligands, overexpression of Sig2R has been observed in 
breast, colon, lung, melanoma, brain, sarcoma, pancreatic, ovarian, and prostate cancer.94 
Additionally, Sig2R is upregulated 10-fold in proliferating cancer cells compared to 
quiescent cells, and therefore it is considered an excellent biomarker for proliferation.61  
The discovery of the presence of both SigR subtypes in a multitude of cancer cell 
lines has prompted research toward an investigation of their involvement in cancer. Studies 
involving classical Sig1R antagonists like IPAG (2.1), rimcazole (2.2), BD1047 (2.3) 
(Figure 2.2), and reduced haloperidol (RHAL) showed dose-dependent decline in tumor 
cell viability (Figure 2.2).95,96 These ligands mediated caspase activated apoptosis via a 
rapid increase in cytoplasmic Ca2+. Additionally, Sig1R agonists, (+)-SKF-10047 and (+)-
pentazocine, abolished the effects of the antagonists, suggesting Sig1R agonists show 
cytoprotective activity and antagonists show cytotoxic activity. This was further supported 
by a study in an animal model of lung cancer that demonstrated that Sig1R agonist, PRE-
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084 (2.4), promoted tumor growth. The exact biological mechanisms that connect Sig1R 
to apoptotic pathways are currently under investigation; however, it is believed that 
antagonists induce ER stress, activating the unfolded protein response and resulting in 
autophagy and apoptosis. 
 
Figure 2.2: Sig1R ligands and their effects in cancerous cells 
Selective Sig2R ligands have also been found to regulate tumor growth, but the 
exact mechanisms are unknown.  Evidence suggests that activation of Sig2R with selective 
agonists can promote both caspase dependent and caspase independent cell death pathways 
in cancerous cells.40,61 Mach and coworkers reported several highly selective, potent Sig2R 
ligands that induced cytotoxicity in several lines of cancer, including mouse EMT-6 breast 
cancer cells and human MDA-MB-435 melanoma tumor cells. When dosed with the Sig2R 
agonist WC-26 (2.7) (Figure 2.3), caspase-3 activation and apoptosis was observed. 
However, the induced cytotoxicity of WC-26 (2.7) was partially blocked when co-
administered with caspase inhibitor, Z-VAD-FMK, supporting that cell death is caused in 
part by caspase-mediated apoptosis.97 Bowen et al. reported that Sig2R selective ligands 
CB-64D (2.5) and CB-184 (2.6) induced dose dependent apoptotic cell death in MCF-7 
breast tumor cells.98 In SK-N-SH neuroblastoma cells, CB-64D (2.5) produced an 
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immediate and transient rise in Ca2+ ion concentration that was attenuated by the partial 
Sig2R agonist CM572.99,100 This result suggests that Sig2R ligands induce cytotoxicity 
through dysregulating Ca2+ homeostasis.  Together, these studies suggest that the 
cytotoxicity of Sig2R ligands is dependent on ligand and cell type. Interestingly, Sig2R 
agonists show no cytotoxicity in healthy cells. Sig2R ligands WC-26 (2.7) and SV119 both 
induce cell death in cancerous cells, but show nominal toxicity to normal tissue as 
measured by caspase-3 activity.101,102  
 
Figure 2.3: Sig2R ligands and their effects in cancerous cells 
With these findings on the role SigRs play in cancer pathology, much research is 
being directed into the design of selective sigma ligands to improve treatment.40,61 It is also 
known that SigRs are able to rapidly internalize their ligands, in part by endocytosis, which 
has motivated the development of SigR ligands for diagnostic imaging.103 The 
overexpression of SigRs has not only made them an attractive target for cancer diagnosis 
and treatment, but also for anticancer drug delivery using SigR ligands to deliver toxic 
payloads (Figure 2.4). For many years, work by Huang et al. was directed towards 
developing liposome or nanoparticle conjugates tethered to a benzamide analog, based on 
the Sig1R selective derivative [I125]PIMBA (2.8) (Figure 2.4), for targeted delivery to 
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cancer cells.104 Prior to injection, the carriers were loaded with a variety of anticancer 
agents including, doxorubicin, antisense oligonucleotides, and siRNA.105–111 One example 
targeting prostate cancer cells showed that the resulting anisamide-conjugated liposomal 
doxorubicin had significantly higher cytotoxicity compared to nontargeted liposomal 
doxorubicin in vitro. Additionally, the conjugate showed improved accumulation within 
the prostate tumor in vivo.105 In an attempt to target lung cancer, Huang et al. demonstrated 
that anisamide conjugated nanoparticles resulted in significant increases of siRNA uptake 
compared to nontargeted control in vitro. In H460 lung cancer cells, the targeted 
nanoparticles showed a 4-fold increased delivery to tumor cells in mice. Additionally, in 
mice bearing both A549 and H460, repeated injections of the targeted nanoparticle 
significantly inhibited tumor growth up to 4-fold in 31 days.107  
 
Figure 2.4: Sigma ligands used in conjugates for targeted drug delivery  
 Another early example utilized the nonselective sigma ligand, haloperidol. Inspired 
by the work by Huang’s group, Banerjee et al. designed a liposome conjugated to 
haloperidol (2.9) via a PEG linker armed with a payload of plasmid DNA containing either 
a reporter or therapeutic gene.112 In human MCF-7 breast cancer cells, the targeted 
liposome showed >10-fold greater uptake of a reported gene than nontargeted liposomes. 
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The expression of the reporter gene was blocked when the targeted liposome was 
administered in the presence of either DTG or free haloperidol (2.9), suggesting that SigRs 
are responsible for the increased uptake of the targeted liposomes. Lastly, cancer cells lines 
that do not overexpress SigRs (Hela, KB, and HepG2), the targeted liposome showed 5-
10-fold less transfection compared to MCF-7 cells. 
Although these initial targeting attempts showed promising results, the ligands used 
for these complexes were non-selective and have off target affinity for neurotransmitter 
binding sites. More recent attempts by Mach’s group have instead employed the highly 
Sig2R selective ligands SV119 (2.10) and SW43 (2.11) that were developed in their lab. 
SV119 (2.10) has been conjugated to liposomes and gold nanocages and showed increased 
uptake of the conjugate in melanoma, prostate, lung, and breast cancer cells compared to 
controls.113 Mach has also focused his efforts towards designing Sig2R conjugates with 
peptides and second mitochondria-derived activator of caspases (Smac) mimetics.  Initial 
work towards this end began with conjugating SV119 (2.10) with Bim, a peptide of Bcl-2 
antagonist.114 The conjugate not only retained affinity for Sig2R but also elicited dose-
dependent cytotoxicity and apoptosis in pancreatic tumor cell lines.  This work led to the 
development of an optimized conjugate, SW IV-134, which utilized a cytotoxic Sig2R 
ligand SW43 (2.11) and second mitochondria-derived activator of caspases (Smac) protein 
mimetic SW IV-52s (2.12) (Figure 2.5).64,115,116 This conjugate showed high affinity for 
Sig2R (Ki= 22.6 nM) and 250-fold selectivity between subtypes. Against a panel of human 
and mouse pancreatic cancer cells lines, SW IV-134 decreased IC50 8-fold compared to 
both SW43 (2.11) and SW IV-52s (2.12) individually and in combination.115 In addition, 
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the conjugate induced target cell apoptosis. In a panel of ovarian cancer cell lines, SW IV-
134 induced apoptotic cell death at substantially lower concentrations than the Sig2R 
ligand alone. The in vivo efficacy of SW IV-134 was measured in female mice inoculated 
interperitoneally with SKOV3-Luc cells via bioluminescence imaging. These experiments 
showed that SW IV-134 is a potent single agent therapeutic that increased survival of the 
mice when compared to SW43 (2.11)  alone.116 Lastly, SW IV-134 was also effective in 
reducing cell viability in triple negative breast cancer cell lines that overexpress Sig2R, 
and its effects were attenuated when Sig2R was saturated with the Sig2R ligand RHM1.64  
 
Figure 2.5: Smac mimetic used as cytotoxic payload with SW43 ligand 
Together, these studies validate the utility of SigRs binding ligands for the 
development of targeted drug delivery to cancer cells with the potential for dual action 
cytotoxicity. However, to date, no SigR ligand has been conjugated to a chemotherapeutic 
currently used in patients today directly via a cleavable bond. Doxorubicin has been used 
in the above studies; however, the toxic payload was encapsulated in a liposome. While 
large drug carriers have their advantages, such as the enhanced permeability and retention 
effect which allows these liposomes/nanoparticles to accumulate in tumor tissue, the large 
molecule carries also fail to penetrate solid tumors.117,118 Low-molecular-weight drug 
conjugates offer the distinct advantage of passively diffusing to cancer masses more 
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thoroughly. Additionally, these small molecule conjugates will be excreted more readily 
minimizing the risk of off target delivery and toxicity.119  
2.1.2 GEMCITABINE: SHORTCOMINGS AND FUTURE PROSPECTS 
Gemcitabine (2.13) is a nucleoside analog with broad spectrum antitumor activity, 
and it can be used as a single agent or in combination therapy to treat lung, pancreatic, 
breast, colon, bladder and ovarian cancer.120 It is a prodrug that upon entering the cell is 
phosphorylated by deoxycytidine kinase to the monophosphate form (dFdCMP (2.14)). It 
then undergoes two additional phosphorylations to give gemcitabine triphosphate (dFdCTP 
(2.15)), which competes with deoxycytidine triphosphate for incorporation into DNA as 
fraudulent base. Once incorporated at the end of the DNA strand, one deoxynucleotide is 
added, and thereafter DNA polymerases are unable to proceed (Figure 2.6). This action, 
called “masked chain termination”, locks the drug into the DNA because proof reading 
exonucleases are unable to remove gemcitabine.121  
Figure 2.6: Gemcitabine mechanism of action 
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Although gemcitabine is a well-tolerated and potent chemotherapeutic agent, the 
reason for its low systemic toxicity is the fact that it is readily deaminated by cytidine 
deaminase (CDA) to its less effective difluoro-uridine derivative.122 This results in rapid 
renal excretion giving gemcitabine a half-life of approximately 70 min. To combat the 
rapid elimination, higher doses are administered. Unfortunately, major toxicity can be 
observed at these higher doses, such as hematotoxicity, hepatotoxicity, and renal and 
gastrointestinal toxicity.123 Clinical trials have suggested that prolonged infusion times 
with lower doses with longer infusion times can be effective while also lowering 
toxicity;124 unfortunately, another downfall of gemcitabine is that tumors acquire resistance 
over time. A major cause of resistance is due to changes in expression of transports on the 
cell membrane.125 Gemcitabine is transported into the cell by a transporter hENT1 and 
resistance has been correlated to decreased expression of hENT1. Additionally, resistance 
has been correlated to higher levels of CDA, which lowers levels of active gemcitabine. 
These resistance pathways make it necessary for higher doses of gemcitabine that in turn 
leads to toxicity. Lastly, gemcitabine suffers from poor bioavailability due to the 
hydrophilic nature of the drug, and it can only be administered intravenously.  
To date, the major strategy to overcome the shortcomings of gemcitabine is 
modifying the deoxycytidine nitrogen atom by installing a hydrolyzable amide bond.122,123 
These prodrugs facilitate slow release of gemcitabine so long infusion times are 
unnecessary, and lower dose requirements by protecting the deoxycytidine nitrogen atom 
thereby decreasing deamination by CDA. These prodrugs can also increase the 
bioavailability by increasing the lipophilicity of gemcitabine depending on the choice of 
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side chain. Additionally, these conjugates have the potential to bypass transporter 
resistance mechanisms by changing the mechanisms by which the prodrug can enter the 
cell. To date, gemcitabine has been modified with poly(ethylene glycol) (2.16),126 squalene 
(2.18),127–129 and aliphatic acyl derivatives.130,131 Currently, N4-valproyl gemcitabine 
(LY2334737 (2.19)) is an orally available prodrug in phase I clinical trial and shows 
increased systemic stability by avoiding first pass metabolism.132 Some of these 
gemcitabine prodrugs have also been designed to include a targeting group. One conjugate 
(2.17) links gemcitabine to folic acid via a PEG linker. In KB-3-1 cells, which over express 
folate receptors, the targeted PEG conjugate was more cytotoxic than the nontargeted PEG 
conjugate.133 In another study, a peripheral benzodiazepine receptor ligand was used to 
target brain cancer. The conjugate PK11195-GEM (2.20) showed a two-fold increase in 
drug concentration at the tumor site than gemcitabine alone. Although it was not proven 
definitively, it can be inferred that it was the PK11195 receptor ligand that facilitated 
greater tumor selective due to receptor-mediated drug delivery.134  
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Figure 2.7: Gemcitabine prodrugs designed for improved stability or targeted delivery 
To overcome some of the shortcomings associated with gemcitabine, the Martin 
group, in collaboration with the Cui group, became interested in developing a drug 
conjugate where gemcitabine is chemically tethered to a SigR ligand. As reported in the 
previous chapter, the Martin group recently developed a unique set of high affinity (<100 
nM) norbenzomorphan SigR ligands with tunable selectivity (>80-fold) for Sig1R or 
Sig2R. To expand upon the SAR of this new class of sigma ligands, a collection of 
isoindoline (n = 1), tetrahydroisoquinoline (n = 2), and tetrahydro-2-benzazepine (n = 3) 
derivatives have been synthesized. From this new library, several potent and moderately 
selective compounds were identified (Table 2.1).  
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Table 2.1: Binding affinity data for isoindoline and tetrahydroisoquinoline derivatives 
with single digit nM potency for Sig1R or Sig2R 
 
Due to the synthetic simplicity of these new compounds, moderate degree of 
selectivity for the respective sigma receptor subtype and clean off target profile, we were 
interested in attaching both a Sig1R and a Sig2R selective ligand to the exocyclic N4 amine 
of gemcitabine. We hypothesized that our sigma selective ligands will selectively deliver 
gemcitabine to cancer cells, thus increasing the concentration of gemcitabine in cancerous 
cells vs. healthy cells. In addition to targeted delivery, we hypothesized that our conjugate 
could improve systemic stability and prevent gemcitabine resistance, both of which will 
improve the efficacy of gemcitabine. Our conjugate is designed to mask exocyclic nitrogen, 
which will decrease metabolism by CDA. Additionally, sigma ligands are also known to 
be internalized, in part by endocytosis, which can prevent uptake resistance by providing a 
new uptake mechanism independent to gemcitabine transporters. Lastly, while the 
functional activity of our sigma ligands is currently unknown, we recognize the potential 
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for dual action therapy in our design. Taken together, a Sig2R-gemcitabine conjugate offers 
immense therapeutic potential through targeted, dual-action therapy, which would be a 
powerful way to address some of the most resistant cancers of today. 
2.2 Results and Discussion 
With the goal of synthesizing a small molecule conjugate with gemcitabine, our 
library of Sig2R ligands was analyzed for a compound that was potent and selective for 
Sig2R. From the library of tetrahydroisoquinoline compounds, 2.25 is the most potent and 
selective Sig2R ligand, so it was selected as our targeting ligand. Unfortunately, 2.25 does 
not have a functional handle to rapidly install a linker for conjugation to gemcitabine. 
However, it was recognized that aldehyde 2.27 could be extended to a dihalogenated 
tetrahydroisoquinoline scaffold 2.25 (Figure 2.8). With two halogen atoms on the scaffold, 
it was envisioned that a Heck cross-coupling reaction could be performed with methyl 
acrylate to give a functional handle for conjugation via a diamide linker. Subsequent 
Buchwald-Hartwig amination would then give the piperazine functionality required for 
binding Sig2R. This dihalogenated scaffold also enables the installation of a linker off a 
position on the molecule that is distal from positions sensitive to SAR changes. 
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Figure 2.8: Design of Sig2R ligand-gemcitabine conjugate 
A Henry reaction of 2.27 with MeNH3Cl and NaOAc in nitromethane gave 
nitrostyrene 2.30 in 70% yield, and subsequent borane reduction gave phenethylamine 2.31 
in 54% yield (Scheme 2.1). Activation of the amine with trifluoroacetic anhydride, 
followed by a Pictet-Spengler reaction gave tetrahydroisoquinoline 2.32 in 39% yield over 
two steps. Finally, saponification of the trifluroacetamide and installation of the benzyl 
carbamate gave 2.28 in 88% yield over two steps.  
 
Scheme 2.1: Synthesis of dihalogenated tetrahydroisoquinoline scaffold 
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With 2.28 in hand, we needed to install the handle for conjugation due to the 
placement and reactivity of the two halogen atoms. A Heck cross coupling reaction with 
2.28 and methyl acrylate would append an ester functionality that could be used as a means 
of conjugation via a diamide linker. Initial attempts at this Heck reaction using PPh3 as the 
ligand resulted in no conversion of starting material (Equation 2.1). In hopes of promoting 
oxidative addition, we switched to a more electron rich ligand P(o-tol)3. This resulted 20% 
conversion to the desired product 2.33; however, there were still significant amounts of 
starting material after heating at 125 °C for 24 h. Using microwave conditions based on a 
similar system135 did not promote any conversion after 30 min. However, when the solvent 
was changed from MeCN to DMF and tributylammonium chloride, a common additive for 
rate enhancement, was added, the reaction was complete after 1 h, giving 2.33 in 60% 
yield.  
 
(2.1) 
With optimized conditions for the Heck cross coupling reaction, only a Buchwald-
Hartwig cross coupling reaction remained to obtain 2.34. Initial attempts using conditions 
optimized in the Martin lab with JohnPhos and Pd(OAc)2 led to no conversion of starting 
material.  
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(2.2) 
This experiment suggested that oxidative addition did not occur under these reaction 
conditions. A screen of other electron rich phosphine ligands unfortunately led to no 
improvement (Equation 2.2).136 Copper and silver salts, which have been shown to increase 
the rate of reactions by forming a more active palladium species,137 did not facilitate the 
amination reaction either. Switching from toluene to DMSO also led to no reaction. Given 
the lack of success in this cross-coupling, it was hypothesized that the enoate moiety on 
the scaffold was the problem. Fortunately, after reduction of 2.35 with Adam’s catalyst, 
preliminary results showed 2.35 underwent Buchwald-Hartwig amination in 18% yield by 
1H NMR to give 2.36 (Scheme 2.2).  
 
Scheme 2.2: Revised synthetic strategy towards Sig2R ligand conjugate 
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With this promising result, we set off to optimize the reaction conditions. First, we 
chose a weaker base, Cs2CO3 to prevent enolization of 2.35.  Although the reaction 
proceeded in toluene, it is known that tert-BuOH is a better solvent when using inorganic 
bases such as Cs2CO3. Initial attempts using tert-BuOH did lead to full consumption of 
starting material; however, undesired hydrolysis of the methyl ester was a major problem 
making isolation very difficult.  
 In hopes of preventing ester hydrolysis, the synthetic strategy was revised to use a 
more sterically hindered ester instead of a methyl ester. Heck cross-coupling of 2.28 with 
tert-butyl acrylate gave 2.37 in 61% yield (Scheme 2.3). Subsequent reduction of 2.37 with 
Adam’s catalyst gave 2.38 in 71% yield. Unfortunately, the Buchwald-Hartwig cross-
coupling reaction was still inconsistent. While hydrolysis was suppressed, keeping the 
reaction dry was very challenging. Due to the scale, the presence of any amount of water 
caused the Cs2CO3 to clump, decreasing the surface area of the base needed to facilitate the 
reaction. Despite the best efforts to dry the solvent, base, and remaining reagents, the 
presence of water was unavoidable and the reaction would not consistently proceed to give 
2.39. At this point, we had run out of material and this conjugate was put on hold.  
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Scheme 2.3: Revised synthetic strategy to prevent hydrolysis during Buchwald-Hartwig 
cross-coupling 
For the Sig1R/gemcitabine conjugate, Sig1R selective ligand 2.21 was selected 
because the respective norbenzomorphan ligand had shown promising preliminary results. 
This study showed that conjugation of a liposome at the position of the -OMe group of the 
norbenzomorphan ligand resulted in increased cellular uptake compared to the free 
liposome.138 Compound 2.21 was selected rather than the norbenzomorphan for this project 
because it has a comparable binding profile to the norbenzomorphan and is easier to 
synthesize. It was envisioned that converting the -OMe group to a phenol would enable 
conjugation of gemcitabine via an ether/amide linker (2.42) (Figure 2.9). To do so in the 
most synthetically efficient fashion, a gemcitabine derivative like 2.41 will be prepared 
and coupled to ligand 2.40 via a substitution reaction.  
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Figure 2.9: Proposed Sig1R ligand-gemcitabine conjugate 
Deoxycytidine (2.43) was chosen as an initial model system to reduce cost. TBS 
protection of 2.43 under standard conditions gave 2.44 in 83% yield (Scheme 2.4). Initially 
6-bromohexanoyl chloride was chosen for the linker. While attempts to acylate 
deoxycytidine with 6-bromohexanoyl chloride produced the desired product 2.45 in 43% 
yield as a mixture of chloride and bromide, optimization of the reaction was a problem. 
With only one equivalent of acyl chloride, the reaction did not go to completion and 
increasing the number of equivalents of acylating agent led to a diacylated product. 
Attempts to overcome this problem were investigated using 6-bromohexanoic acid, DCC, 
and DMAP. These conditions gave 2.46 in an improved 60% yield; however, complete 
consumption of deoxycytidine was still problematic.  
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Scheme 2.4: Acylation of deoxycytidine to use in conjugation model system 
To synthesize 2.40, intermediate 2.47 was deprotected with boron tribromide, 
followed by reductive amination to give 2.40 in 34% yield over two steps (Scheme 2.5). 
We then attempted to alkylate 2.40 with 2.46.  Initial attempts using K2CO3 as the base led 
to no conversion to 2.48. Switching to a NaH as the base in an attempt to quantitatively 
deprotonate the phenol and increase its nucleophilicity, also led to no alkylation. We 
hypothesized that increasing the electrophilicity of the alkylating agent might facilitate the 
reaction. However, an in situ Finkelstein reaction with KI and K2CO3 did not lead to the 
desired product. Instead, 2.46 underwent intramolecular cyclization to give 2.49. 
Increasing the concentration of the reactants did not facilitate the intermolecular 
substitution reaction.  
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Scheme 2.5: Efforts towards alkylating phenol 
Due to the difficulty alkylating compound 2.40, a new conjugation strategy was 
desired. Rather than use an ether/amide linker, it was envisioned that the Sig1R 
ligand/gemcitabine conjugate could also arise via a diamide linker using ligand 2.50 
(Figure 2.10).   
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Figure 2.10: Revised Sig1R ligand-gemcitabine conjugate 
We recognized that alkylation of 2.40 with a bromoacetic acid derivative would 
give an appropriate functional handle for a diamide linkage. Unfortunately, alkylation of 
2.40 with K2CO3 and ethyl bromoacetate led to low conversion to the desired product 2.53 
(Equation 2.3). When two equivalents of alkylating agent were used, the dialkylated 
product 2.54 was formed due to the high electrophilicity of the alkylating agent. When 
reduced to one equivalent of the alkylating agent, a mixture of desired product and 
quaternary ammonium salt and starting material was obtained.  
 
(2.3) 
Given the nucleophilic nature of the nitrogen atom, we designed a new synthetic 
strategy to circumvent this problem. Starting from 2.55, a Suzuki cross-coupling with 3-
hydroxyphenyl boronic acid, gave compound 2.56 in 75% yield (Scheme 2.6). Alkylation 
of 2.57 with methyl bromoacetate gave 2.58 in 77% yield. Hydrogenolysis and subsequent 
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reductive amination with benzaldehyde gave compound 2.58 in 47% yield over two steps. 
Finally, saponification of 2.58 with LiOH gave the desired acid 2.50.  
 
Scheme 2.6: Revised synthesis of compound 2.47 
We then turned our attention to the deoxycytidine model system to obtain the 
requisite substrate for conjugation. Starting from 6-aminohexanoic acid (2.59), the -Boc 
(2.60), -TFA (2.62), and -Cbz (2.63) protected acids were synthesized (Scheme 2.7).  
 
Scheme 2.7: Preparation of amino acid derivatives 
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Compound 2.43 and acid 2.60 were coupled with DCC and DMAP to give 2.63 in 47% 
yield by 1H NMR (Scheme 2.8). Using pyBOP with TEA gave 2.63 in 71% yield by 1H 
NMR. With compound 2.63 in hand, the -Boc group was removed under standard 
deprotection conditions, unfortunately the -TBS groups were also removed to give 2.64. 
Silyl groups tend to be labile under highly acidic conditions, so the -TFA protected amino 
acid, 2.61 was chosen next, because -TFA groups are base labile. Treatment of 2.43 and 
acid 2.61 with pyBOP and TEA gave 2.65 in 69% yield (Scheme 2.9). Subjection of 2.65 
to K2CO3 in methanol, unfortunately gave exclusively 2.66. Lastly, the -Cbz protected 
amino acid, 2.62 was selected, because benzyl carbamates can be removed under neutral 
conditions. Amide coupling gave 2.67 in 68% yield and subsequent hydrogenation with 
Pd/C in ethanol gave 2.68 in 61% yield (Scheme 2.10). 
 
Scheme 2.8: Deoxycytidine model system using -Boc as a protecting group 
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Scheme 2.9: Deoxycytidine model system using -TFA as a protecting group 
 
Scheme 2.10: Deoxycytidine model system using -Cbz as a protecting group 
 However, upon scale-up, under the same reaction conditions, a mixture (1:1) of 
2.68 and 2.43 was obtained (Equation 2.4) suggesting the amide bond is highly labile. 
Because ethanol is a nucleophilic solvent, it is possible that ethanol cleaved the amide of 
2.67 and released 2.43. It is also possible that once the amine is deprotected, it can cyclize 
to an ε-lactam and release 2.43. Accordingly, isopropanol was chosen as solvent because 
of its steric bulk. When 50 mg of 2.67 was subjected to catalytic hydrogenation, the 
deprotection was complete in 3 h, giving 2.68 in 60% yield. With this promising result, the 
reaction was scaled up to 100 mg, but unfortunately after two hours a mixture (1:1) of 2.68 
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to 2.43 was again obtained. Additionally, coupling 2.50 with 2.68 was unsuccessful and a 
new strategy was needed. 
 
(2.4) 
At this point, we turned out attention to aminotetralin Sig2R ligands that were being 
developed in our lab. Based on 2.69, these ligands showed that the aminotetralin scaffold 
tolerates a long aliphatic chain off the exocyclic nitrogen of the scaffold, with 2.70 
exhibiting high affinity for Sig2R (Figure 2.11). Until this point, it was unclear which 
position any of our SigR ligands would tolerate a linker. Given the synthetic difficulties in 
preparing 2.39 and 2.50, we decided to utilize the aminotetralin scaffold in our efforts. It 
was envisioned that an aminotetralin ligand could be conjugated to gemcitabine via an 
amide linkage. To prepare 2.73, tetralone 2.71 will undergo reductive amination with an 
amino acid derivative like 2.72. This intermediate will have a terminal acid functionality 
which can be used to chemically link gemcitabine to the Sig2R ligand (2.73).  
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Figure 2.11: Proposed conjugate between aminotetralin Sig2R ligand and gemcitabine 
The synthetic route to 2.73 was based on the reported synthesis of 2.70. Starting 
from 2.74, Buchwald-Hartwig cross-coupling with piperazine gave 2.75 in 78% yield, and 
reductive amination then gave 2.71 in 58% yield (Scheme 2.11). To install the linker, we 
envisioned that 2.71 would undergo reductive amination with an aliphatic amine with a 
terminal functional handle. A tert-butyl ester was chosen with an aliphatic chain of both 5 
and 10 methylene units to probe the effects of chain length between the ligand and 
gemcitabine. Compound 2.71 was thus subjected to reductive amination with tert-butyl 6-
aminohexanoate and tert-butyl 11-undecanoate in the presence of Ti(OiPr)4 to give 2.76 
and 2.77. It was necessary to heat the reaction to 70-80 °C and 20 equivalents of Ti(OiPr)4 
was required; any less would not promote complete conversion to the imine. Unfortunately, 
Ti(OiPr)4 is also known to facilitate transesterification,
139 even with bulky esters, and a 
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mixture of tert-butyl, iso-propyl, and ethyl esters was obtained. Subsequent -Cbz protection 
gave an inseparable mixture of the three esters. Fortunately, all three esters were 
hydrolyzed with LiOH in methanol to give 2.78 in 45% yield and 2.79 in 49% yield, over 
three steps.  
 
Scheme 2.11:  Synthesis of aminotetralin derivative with conjugate linker 
While sufficient quantities were able to be prepared via the above synthesis, the 
transesterification is a major problem. Ideally, conditions needed to be developed to 
prevent transesterification so only one product is obtained. One change that could be made 
would be to choose an aprotic solvent. Using two equivalents of Ti(OiPr)4, toluene at 80 
°C led to full conversion to the imine; however, upon reduction there was still a mixture of 
the iso-propyl and tert-butyl esters. Another strategy to overcome the transesterification is 
to have only one alcohol present by matching the titanium alkoxide with the ester and 
solvent. Fortunately, Ti(OtBu)4 is a commercially available reagent and was chosen to 
prevent the use of the ethyl or iso-propyl amino esters which may be less stable. In addition, 
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toluene was chosen as the solvent because fewer equivalents of titanium were needed to 
facilitate imine formation. Treatment of 2.71 with the required amine and Ti(OtBu)4 in 
toluene followed by reduction with NaBH4 in tert-BuOH gave solely 2.80 and 2.81 in 46% 
yield and 50% yield respectively. In order to get >90% conversion it was necessary to use 
three equivalents of the amine and four equivalents of Ti(OtBu)4 and heat for 24 h. Tert-
BuOH did facilitate reduction of the imine, but when diglyme was used instead, compound 
2.80 was obtained in 64% yield.  
 
(2.5) 
 Despite eliminating the transesterification side reaction, the solvent swap that was 
necessary for the use of NaBH4 was not ideal, so the use of NaBH(OAc)3 was investigated. 
Treatment of 2.71 and amine in DCE with Ti(OtBu)4 at 80 °C for 18 h led to full conversion 
of the imine (Scheme 2.12). The imine could be reduced with NaBH(OAc)3 and AcOH, 
but a significant rate enhancement was observed when TFA was used as the acid, giving 
2.80 in 79% yield and 2.81 in 65% yield. For the full consumption of the ketone, four and 
six equivalents of amine were required when n=4 and n=9 respectively. Both 2.80 and 2.81 
were then acylated with Cbz-Cl to give 2.82 and 2.83 in 76% and 83% yields, respectively. 
Lastly treatment of 2.82 and 2.83 with TFA gave 2.84 and 2.85 in nearly quantitative yield.  
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Scheme 2.12: Optimized synthetic route for preparation of aminotetralin derivative with 
functional handle for conjugation 
With significant quantities of 2.84 and 2.85, a series of conditions were screened 
for the coupling of compound 2.43 and ligands 2.84 and 2.85 (Equation 2.6). The results 
were monitored by 1H NMR by comparing the integration of the C6-H peak, which shifts 
upon acylation of the exocyclic nitrogen atom. After a screen of several peptide coupling 
reagents, we found that EDCI·HCl and HOBt led to full conversion to 2.86.  
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(2.6) 
With optimized conditions for the peptide coupling reaction, the stage was set to 
prepare the gemcitabine analog. Ligand 2.84 and TBS-gemcitabine were coupled using 
EDCI·HCl and HOBt to give 2.88 in 72% isolated yield. Similarly, 2.87 was prepared in 
74% isolated yield. Subsequent TBS deprotection using TBAF gave the target conjugates 
2.90 and 2.91 (Scheme 2.13). It is important to note that these conjugates are not stable as 
the amine salts. Both conjugates were purified by HPLC using a buffered MeCN/H2O 
(0.1% TFA) solvent system. Upon lyophilization of the desired fractions, the product was 
isolated as the TFA salt, which decomposed over time. Therefore, it was necessary to basify 
the fractions and isolate the free base of the conjugates.  
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Scheme 2.13: Preparation of Sig2R ligand-gemcitabine conjugate 
In conclusion, we have successfully conjugated a Sig2R selective ligands to the 
anticancer agent, gemcitabine, which represent the first examples of gemcitabine 
conjugated to a Sig2R ligand. The two conjugates were prepared with varying linker 
lengths between the ligand and gemcitabine to ensure that the Sig2R ligand will be 
recognized by the receptor. Currently these conjugates are undergoing biological assays in 
human (Panc01) and mouse (Panc02) pancreatic cancer cell lines known to overexpress 
Sig2R. The cellular uptake of both the conjugate and free gemcitabine will be evaluated in 
both Panc01/Panc02 and a control cell line, BXPC3 (human pancreatic adenocarcinoma 
cells that do not overexpress Sig2R), to probe whether the conjugate shows improved 
uptake and if this increase is mediated by Sig2R. Additionally, the cytotoxicity of the 
conjugate, the Sig2R ligand, gemcitabine, and the ligand/gemcitabine in combination will 
be evaluated in both cell lines. Based on the results of these two studies, we hope to show 
that our conjugate is the most cytotoxic, mediated by not only increased uptake through 
Sig2R uptake mechanisms, but also through dual action cytotoxicity through use of a Sig2R 
agonist. If our conjugates meet these criteria, they will represent a potential gemcitabine 
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prodrug with a unique mechanism of action. Such a discovery would open the door to new 
therapeutic strategies for treating some of the most resistant lines of cancer.  
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CHAPTER 3: EXPERIMENTAL METHODS 
General. All solvents were determined to have less than 50 ppm H2O by Karl 
Fischer coulometric moisture analysis. All reagents were reagent grade and used without 
purification unless otherwise noted. Methylene chloride (CH2Cl2), triethylamine (Et3N) 
and diisopropylethylamine (i-Pr2NEt) were distilled from calcium hydride immediately 
prior to use. Where required, solvents were degassed by sparging with argon prior to use. 
Reactions involving air or moisture sensitive reagents or intermediates were performed 
under an inert atmosphere of nitrogen or argon in glassware that was flame dried. Reaction 
temperatures refer to the temperature of the cooling/heating bath. Volatile solvents were 
removed under reduced pressure using a Büchi rotary evaporator. Thin-layer 
chromatography (TLC) was performed on EMD 60 F254 glass-backed pre-coated silica 
gel plates and were visualized using one or more of the following methods: UV light (254 
nm) and staining with basic potassium permanganate (KMnO4) or acidic p-anisaldehyde 
(PAA). Infrared (IR) spectra were obtained with a Thermo Scientific Nicolet IR-100 FT-
IR series spectrometer as thin films on sodium chloride plates and reported in wavenumbers 
(cm-1). Proton nuclear magnetic resonance (1H NMR) and carbon nuclear magnetic 
resonance (13C NMR) spectra were obtained at the indicated field as solutions in 
CDCl3 unless otherwise indicated. Chemical shifts are referenced to the deuterated solvent 
and are reported in parts per million (ppm, δ) downfield from tetramethylsilane (TMS, δ = 
0.00 ppm). Coupling constants (J) are reported in Hz and the splitting abbreviations used 
are: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; comp, overlapping multiplets 
of magnetically nonequivalent protons; br, broad; app, apparent. 
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Preparation of tetrahydroisoquinoline scaffolds 
 
Benzyl 7-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate (1.47). KTL-01-221. A 
solution of H2SO4 (3 ml) and AcOH (6 mL) was cooled in an ice bath for 10 min. 
Paraformaldehyde (1.00 g, 33.3 mmol) and benzyl (4-bromophenethyl)carbamate (0.92 g, 
2.75 mmol) were added to the cooled solution and the reaction was stirred for 10 min at 0 
°C, where upon the reaction was poured onto ice (ca. 50 g). When the ice melted, the 
aqueous solution was extracted with EtOAc (3 x 50 mL). The combined organic layers 
were washed with a saturated aqueous solution of NaHCO3 (1 x 50 mL), water (1 x 50 mL), 
and brine (1 x 50 mL). The organic layer was dried (Na2SO4) and concentrated under 
reduced pressure. The crude material was purified via flash column chromatography 
eluting with EtOAc:hexanes (5:95) to give 720 mg (76%) of 1.47 as a clear oil. 1H NMR 
was consistent with literature. 
 
Benzyl 6-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate (1.45). KTL-01-202. A 
solution of 6-bromo-dihydroisoquinoline (300 mg, 1.42 mmol) in CH2Cl2 (8 mL) was 
cooled to 0 °C and iPr2NEt (243 mg, 1.88 mmol) and CbzCl (322 mg, 1.88 mmol) were 
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added. The reaction was stirred at room temperature for16 h. The reaction was diluted with 
CH2Cl2 (10 mL) and poured into water (20 mL). The layers were separated and the aqueous 
layer was extracted with CH2Cl2 (3 x 20 mL). The combined organic layers were dried 
(Na2SO4) and concentrated under reduced pressure. The crude mixture was purified via 
flash column chromatography eluting with EtOAc:hexanes (5:95) to give 400 mg (81%) of 
1.45 as a clear oil: 1H NMR (400 MHz) δ 7.41 – 7.27 (comp, 7 H), 6.97 (d, J =  10.3 Hz, 
1 H), 5.18 (s, 2 H), 4.59 (s, 2 H), 3.70 (br s, 2 H), 2.82 (br s, 2 H); HRMS (ESI) m/z 
C17H16BrNO2 (M+Na)
+ calcd for 368.0257 and 370.0238; found 368.0257 and 370.0238. 
NMR Assignment. 1H NMR (400 MHz) δ 7.41 – 7.27 (comp, 7 H, C2-H, C6-H, 
and C16-H thru C20-H), 6.97 (d, J = 10.3 Hz, 1 H, C3-H), 5.18 (s, 2 H, C14-H), 4.59 (s, 2 
H, C7-H), 3.70 (br s, 2 H, C9-H), 2.82 (br s, 2 H, C10-H).  
 
Benzyl 6-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate (1.43a). KTL-02-108. A 
solution of 8-bromo-dihydroisoquinoline (300 mg, 1.42 mmol) in CH2Cl2 (14 mL) was 
cooled to 0 °C and iPr2NEt (370 mg, 2.8 mmol) and CbzCl (480 mg, 2.8 mmol) were added. 
The reaction was stirred at room temperature for16 h. The reaction was diluted with CH2Cl2 
(10 mL) and poured into water (20 mL). The layers were separated and the aqueous layer 
was extracted with CH2Cl2 (3 x 20 mL). The combined organic layers were dried (Na2SO4) 
and concentrated under reduced pressure. The crude mixture was purified via flash column 
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chromatography eluting with EtOAc:hexanes (5:95) to give 401 mg (83%) of 1.43a as a 
clear oil: 1H NMR (400 MHz) δ 7.44 – 7.29 (comp, 6 H), 7.11 – 7.01 (comp, 2 H), 5.21 (s, 
2 H), 4.62 (s, 2 H), 3.71 (t, J = 5.8 Hz, 2 H), 2.85 (br s, 2 H). 
NMR Assignment. 1H NMR (400 MHz) δ 7.44 – 7.29 (comp, 6 H, C2-H, C16-H thru C20-
H), 7.11 – 7.01 (comp, 2 H, C1-H and C6-H), 5.21 (s, 2 H, C14-H), 4.62 (s, 2 H, C7-H), 
3.71 (t, J = 5.8 Hz, 2 H, C9-H), 2.85 (br s, 2 H, C10-H). 
Representative procedure for reductive amination/-Cbz protection of benzaldehydes 
 
Benzyl allyl(5-chloro-2-vinylbenzyl)carbamate (1.59). KTL-02-076. A solution of 1.52 
(815 mg, 4.9 mmol) and allyl amine (750 ul, 9.8 mmol) in CH2Cl2 (30 mL) with MgSO4 
(2.6 g) was stirred overnight. The reaction was filtered and the filtrate was concentrated 
under reduced pressure. The resulting residue was dissolved in MeOH (24 mL), and NaBH4 
(400 mg) was added. The reaction was stirred for 20 min and then concentrated to half 
volume. Aqueous NaOH (1 M, 60 mL) was added and the aqueous layer was extracted 
with Et2O (3 x 60 mL). The combined organic layers were dried (MgSO4) and concentrated 
under reduced pressure to give 1.1 g (70%) of the secondary amine intermediate as a clear 
oil of sufficient purity for use in subsequent reactions As solution of the secondary amine 
(700 mg, 3.36 mmol) in CH2Cl2 (34 mL) was cooled to 0 °C and iPr2NEt (0.87 g, 6.73 
mmol) and CbzCl (1.15 g, 6.73  mmol) were added. The bath was removed, and the reaction 
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was stirred at room temperature for 16 h. The reaction was diluted with CH2Cl2 (30 mL) 
and poured into water (60 mL). The layers were separated and the aqueous layer was 
extracted with CH2Cl2 (3 x 30 mL). The combined organic layers were dried (Na2SO4) and 
concentrated under reduced pressure. The crude material was purified via flash column 
chromatography eluting with EtOAc:hexanes (5:95) to give 950 mg (83%) of 1.59 as a 
clear oil: 1H NMR (400 MHz, rotamers) δ 7.35 (comp, 6 H), 7.23 (dd, J = 8.3, 1.9 Hz, 1 
H), 7.14 (d, J = 12.9 Hz, 1 H), 6.86 (m, 1 H), 5.74 (s, 1 H), 5.59 (d, J = 17.1 Hz, 1 H), 5.34 
– 5.01 (comp, 5 H), 4.54 (comp, 2 H), 3.83 (comp, 2 H); HRMS (ESI) m/z  C20H20ClNO2 
(M+Na)+ calcd for 364.1075 and 366.1053; found 364.1079 and 366.1051. 
 
Benzyl allyl(4-chloro-2-vinylbenzyl)carbamate (1.60). KTL-02-084. Prepared 
according to the representative procedure outlined for reductive amination/-Cbz protection 
of benzaldehydes. The crude material was purified via flash column chromatography 
eluting with EtOAc:hexanes (5:95) to give 1.61 g (80% over two steps) of 1.60 as a clear 
oil: 1H NMR (400 MHz, rotamers) δ 7.52 – 7.28 (comp, 7 H), 7.22 – 7.15 (m, 1 H), 7.08 
(d, J = 25.3 Hz, 1 H), 6.84 (dt, J = 45.8, 16.0 Hz, 1 H), 5.76 (d, J = 26.2 Hz, 1 H), 5.62 (d, 
J = 17.7 Hz, 1 H), 5.37 – 5.24 (m, 1 H), 5.22 – 4.98 (comp, 5 H), 4.55 (s, 1.13 H), 4.51 (s, 
0.84 H), 3.83 (s, 0.83 H), 3.74 (s, 1.26 H). 
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Representative procedure for RCM 
 
Benzyl 8-chloro-1,3-dihydro-2H-benzo[c]azepine-2-carboxylate (1.61). KTL-02-077. 
Grubbs second generation catalyst (118 mg, 0.14 mmol) was added to a solution of 
intermediate 1.59 (950 mg, 2.78 mmol) in CH2Cl2 (56 mL) and the reaction was stirred at 
room temperature overnight. The reaction was concentrated under reduced pressure and 
DMSO (1 mL) was added to the crude material and the solution was stirred overnight. The 
crude material was purified via flash column chromatography eluting EtOAc:hexanes (1:9) 
to give 650 mg (75%) of 1.61 as a white solid:  1H NMR (400 MHz, rotamers) δ 7.34-7.30 
(comp, 4 H), 7.26-7.19 (comp, 2 H), 7.11-7.09 (comp, 2 H), 6.45-6.39 (comp, 1 H), 5.85-
5.75 (comp, 1 H), 5.09 (s, 0.70 H), 5.07 (s, 1.30 H), 4.48 – 4.30 (comp, 4 H); 13C NMR 
(101 MHz, rotamers) δ 155.7, 155.4, 139.5, 139.3, 136.7, 136.6, 134.2, 133.9, 133.0, 132.5, 
132.4, 132.2, 130.9, 130.2, 129.0, 128.8, 128.4, 128.33, 128.29, 128.26, 128.18, 127.82, 
127.7, 67.7, 67.6, 51.4, 50.9, 50.8, 50.5. 
NMR Assignment. :  1H NMR (400 MHz, rotamers) δ 7.34-7.30 (comp, 4 H, C14-
H, C15-H, C17-H, and C18-H), 7.26-7.19 (comp, 2 H, C3-H and C16-H), 7.11-7.09 (comp, 
2 H, C2-H and C6-H), 6.45-6.39 (comp, 1 H, C7-H), 5.85-5.75 (comp, 1 H, C8-H), 5.09 
(s, 0.70 H, C12-H), 5.07 (s, 1.30 H, C12-H), 4.48 – 4.30 (comp, 4 H, C9-H and C10-H); 
13C NMR (101 MHz, rotamers) δ 155.7 (C11), 155.4 (C11), 139.5 (C5), 139.3 (C5), 136.7 
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(C13), 136.6 (C13), 134.2 (C4), 133.9 (C4), 133.0 (C7), 132.5 (C1), 132.4 (C7), 132.2 
(C1), 130.9 (C8), 130.2 (C8), 128.9 (C6), 128.8 (C15 and C17), 128.37 (C6), 128.33 (C3), 
128.29 (C3), 128.26 (C16), 128.18 (C14 and C18), 127.8 (C2), 127.7 (C2), 67.7 (C12), 
67.6 (C12), 51.4 (C9), 50.9 (C9), 50.8 (C10), 50.5 (C10).  
 
Benzyl 7-chloro-1,3-dihydro-2H-benzo[c]azepine-2-carboxylate (1.62). KTL-02-085. 
Prepared according to the representative procedure outlined for RCM. The crude material 
was purified via flash column chromatography eluting EtOAc:hexanes (5:95) to give 661 
mg (72%) of 1.62 as a yellow oil: 1H NMR (400 MHz) δ 7.33 – 7.28 (comp, 4 H), 7.21 – 
7.13 (comp, 3 H), 7.05 (dd, J = 8.0, 2.1 Hz, 0.80 H), 6.99 (d, J = 8.0 Hz, 0.80 H), 6.43 – 
6.38 (m, 1 H), 5.92 – 5.80 (m, 1 H), 5.06 (s, 0.80 H), 5.04 (s, 1.20 H), 4.45 (t, J = 2.9 Hz, 
1.20 H), 4.41 – 4.40 (comp, 1.60 H), 4.37 (s, 1.20 H); 13C NMR (101 MHz, rotamers) δ 
155.5, 155.2, 137.1, 136.9, 136.5, 136.0, 135.9, 133.2, 131.7, 131.1, 130.5, 130.4, 130.1, 
129.7, 128.5, 128.4, 128.03, 127.97, 127.8, 127.0, 126.5, 67.3, 50.9, 50.51, 50.48, 50.2. 
NMR Assignment. 1H NMR (400 MHz) δ 7.33 – 7.28 (comp, 4 H, C14-H, C15-
H, C17-H, and C18-H), 7.21 – 7.13 (comp, 2.8 H, C1-H, C3-H, C6-H, and C16-H), 7.05 
(dd, J = 8.0, 2.1 Hz, 0.80 H, C1-H), 6.99 (d, J = 8.0 Hz, 0.80 H, C6-H), 6.43 – 6.38 (m, 1 
H, C7-H), 5.92 – 5.80 (m, 1 H, C8-H), 5.06 (s, 0.80 H, C12-H), 5.04 (s, 1.20 H, C12-H), 
4.45 (t, J = 2.9 Hz, 1.20 H, C9-H), 4.41 – 4.40 (comp, 1.60 H, C9-H and C10-H), 4.37 (s, 
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1.20 H, C10-H); 13C NMR (101 MHz, rotamers) δ 155.5 (C11), 155.2 (C11), 137.1 (C4), 
136.9 (C4), 136.5 (C13), 136.0 (C5), 135.9 (C5), 133.2 (C7), 131.7 (C7), 131.1 (C3), 130.5 
(C8), 130.4 (C8), 130.1 (C2), 129.7 (C2), 128.5 (C15 and C17), 128.4 (C15 and C17), 
128.03 (C14 and C18), 127.97  (C14 and C18), 127.8 (C16), 127.0 (C1), 126.5 (C1), 67.3 
(C12), 50.9 (C10), 50.51 (C10), 50.48 (C9), 50.2 (C9).  
Representative procedure for hydrogenation with Adam’s catalyst  
 
Benzyl 8-chloro-1,3,4,5-tetrahydro-2H-benzo[c]azepine-2-carboxylate (1.63). KTL-
02-078. A solution of carbamate 1.61 (650 mg, 2.07 mmol) in EtOH (24 mL) and Pt2O (30 
mg, 0.13 mmol) was stirred under an atmosphere of H2 until consumption of starting 
material was observed. The reaction was filtered through a pad of celite, and the filtrate 
was concentrated under reduced pressure to provide 550 mg (84%) of 1.63 as a brown solid 
that was of sufficient purity for use in subsequent reactions: 1H NMR (400 MHz, rotamers) 
δ 7.40-7.27 (comp, 5.5 H), 7.13 (d, J = 8.0 Hz, 1 H), 7.08 (s, 1.5 H), 5.07 (s, 0.70 H), 5.04 
(s, 1.30 H), 4.43 (s, 0.70 H), 4.37 (s, 1.30 H), 3.77-3.70 (comp, 2 H), 2.94-2.91 (comp, 2 
H), 1.83-1.72 (comp, 2 H); 13C NMR (126 MHz, rotamers) δ 155.5, 155.3, 140.4, 140.2, 
140.1, 140.0, 136.8, 136.5, 131.8, 131.5, 131.0, 130.9, 129.6, 129.4, 128.65, 128.56, 128.2, 
128.2, 128.1, 128.0, 127.53, 127.46, 67.6, 67.2, 52.2, 51.7, 51.1, 50.6, 34.8, 28.6, 28.0;  
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HRMS (ESI) m/z C18H18ClNO2 (M+Na)
+ calcd for 338.0918 and 340.0895; found 
338.0920 and 340.0895. 
NMR Assignment. 1H NMR (400 MHz, rotamers) δ 7.40-7.27 (comp, 5.5 H, C6-
H and C14-H thru C18-H), 7.13 (d, J = 8.0 Hz, 1 H, C2-H), 7.08 (s, 1.5 H, C3-H and C6-
H), 5.07 (s, 0.70 H, C12-H), 5.04 (s, 1.30 H, C12-H), 4.43 (s, 0.70 H, C10-H), 4.37 (s, 1.30 
H, C10-H), 3.77-3.70 (comp, 2 H, C9-H), 2.94-2.91 (comp, 2 H, C7-H), 1.83-1.72 (comp, 
2 H, C8-H); 13C NMR (126 MHz, rotamers) δ 155.5 (C11), 155.3 (C11), 140.4 (C4 or C5), 
140.2 (C4 or C5), 140.1 (C4 or C5), 140.0 (C4 or C5), 136.8 (C13), 136.5 (C13), 131.8 
(C1), 131.5 (C1), 131.0 (C3), 130.9 (C3), 129.6 (C6), 129.4 (C6), 128.65 (C15 and C17), 
128.56 (C15 and C17), 128.2 (C14 and C18), 128.2 (C14 and C18), 128.1 (C16), 128.0 
(C16), 127.53 (C2), 127.46 (C2), 67.6 (C12), 67.2 (C12), 52.2 (C10), 51.7 (C10), 51.1 
(C9), 50.6 (C9), 34.8 (C7), 28.6 (C8), 28.0 (C8).  
 
Benzyl 7-chloro-1,3,4,5-tetrahydro-2H-benzo[c]azepine-2-carboxylate (1.64). KTL-
02-086. Prepared according to the representative procedure outlined for hydrogenation 
with Adam’s catalyst. The reaction was filtered through a pad of celite, and the filtrate was 
concentrated under reduced pressure to provide 620 mg (94%) of 1.64 as a brown oil that 
was of sufficient purity for use in subsequent reactions: 1H NMR (400 MHz, rotamers) δ 
7.37 – 7.26 (m, 5 H), 7.16 – 7.11 (comp, 1.40 H), 7.03 (dd, J = 8.0, 2.2 Hz, 0.60 H), 6.98 
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(d, J = 8.0 Hz, 0.60 H), 5.05 (s, 0.70 H), 5.04 (s, 1.30 H), 4.43 (s, 0.70 H), 4.40 (s, 1.30 H), 
3.75 (br s, 2 H), 2.95 – 2.87 (comp, 2 H), 1.85 – 1.70 (comp, 2 H); 13C NMR (101 MHz, 
rotamers) δ 155.4, 155.2, 143.8, 143.5, 136.9, 136.7, 136.6, 133.0, 130.9, 130.6, 129.6, 
129.5, 128.5, 128.4, 128.0, 127.9, 127.8, 126.1, 125.8, 67.2, 67.1, 51.9, 51.3, 50.8, 50.5, 
35.1, 28.4, 27.8; LRMS (ESI+APCI) m/z  C18H18ClNO2 (M+H)
+ calcd for 316.11; found 
316.2. 
 NMR Assignment. 1H NMR (400 MHz, rotamers) δ 7.37 – 7.26 (m, 5 H, C14-H 
thru C18-H), 7.16 – 7.11 (comp, 1.40 H, C1-H, C3-H, and C6-H), 7.03 (dd, J = 8.0, 2.2 
Hz, 0.60 H, C1-H), 6.98 (d, J = 8.0 Hz, 0.60 H, C6-H), 5.05 (s, 0.70 H, C12-H), 5.04 (s, 
1.30 H, C12-H), 4.43 (s, 0.70 H, C10-H), 4.40 (s, 1.30 H, C10-H), 3.75 (br s, 2 H, C9-H), 
2.95 – 2.87 (comp, 2 H, C7-H), 1.85 – 1.70 (comp, 2 H, C8-H); 13C NMR (101 MHz, 
rotamers) δ 155.4 (C11), 155.2 (C11), 143.8 (C4), 143.5 (C4), 136.9 (C5), 136.7 (C13), 
136.6 (C5), 133.0 (C3), 130.9 (C2), 130.6 (C2), 129.6 (C6), 129.5 (C6), 128.5 (C15 and 
C17), 128.4 (C15 and C17), 128.0 (C14 and C18), 127.9 (C14 and C18), 127.8 (C16), 
126.1 (C1), 125.8 (C1), 67.2 (C12), 67.1 (C12), 51.9 (C10), 51.3 (C10), 50.8 (C9), 50.5 
(C9), 35.1 (C7), 28.4 (C8), 27.8 (C8). 
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Representative procedure for Buchwald-Hartwig cross-coupling 
 
Benzyl 7-morpholino-3,4-dihydroisoquinoline-2(1H)-carboxylate (1.73). KTL-01-
215. A solution of carbamate 1.47 (100 mg 0.29 mmol), NaO-t-Bu (38 mg 0.40 mmol), 
morpholine (35 mg 0.40 mmol) in degassed toluene was stirred for 5 min. A freshly 
prepared solution of Pd(OAc)2 and JohnPhos (1:1, 0.19 mL, 0.1 M) that had been stirred 
for 30 min, was added via syringe. The solution was heated at 100 °C for 5 h, where upon 
the reaction was cooled to room temperature, poured into 2 mL of water, and extracted 
with CH2Cl2 (3 x 10 mL). The combined organic extracts were dried (K2CO3) and 
concentrated under reduced pressure. The crude material was purified via flash column 
chromatography eluting with EtOAc:hexanes (25:75) to give 78 mg (76%) of 1.73 as a 
clear oil:  1H NMR (400 MHz) δ 7.42-7.29 (comp, 5 H), 7.03 (dd, J = 18.8, 7.6 Hz, 1 H), 
6.78 (dd, J = 8.4, 2.4 Hz, 1 H), 6.67 (s, 1 H), 5.18 (s, 2 H), 4.58 (s, 2 H), 3.84 (t, J = 4.8 
Hz, 4 H), 3.71 (br s, 2 H), 3.13 (t, J = 4.8 Hz, 4 H), 2.82 (br s, 2 H); 13C NMR (100 MHz, 
rotamers) δ 155.5, 155.4, 149.9, 136.8, 135.4, 135.2, 128.5, 128.0, 127.9, 127.1, 126.9, 
125.1, 124.6, 115.6, 115.4, 114.4, 67.1, 66.9, 49.5, 45.2, 41.6, 41.4, 29.4, 29.2; HRMS 
(ESI) m/z C21H24N2O3 (M+Na)
+ calcd for 375.1679; found 375.1684. 
NMR Assignments. 1H NMR (400 MHz) δ 7.42-7.29 (comp, 5 H, C12-H thru C17-
H ), 7.03 (dd, J = 18.8 Hz, 7.6 Hz, 1 H, C8-H), 6.78 (dd, J = 8.4 Hz, 2.4 Hz, 1 H, C7-H), 
25 
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6.67 (s, 1 H, C5-H), 5.18 (s, 2 H, C11-H), 4.58 (s, 2 H, C1-H), 3.84 (t, J = 4.8 Hz, 4 H, 
C18-H and C19-H), 3.71 (br s, 2 H, C2-H), 3.13 (t, J = 4.8 Hz, 4 H, C20-H and C21-H), 
2.82 (br s, 2 H, C3-H); 13C NMR (100 MHz, rotomers) δ 155.5 (C10), 155.4 (C10), 149.9 
(C6), 136.8 (C12), 135.4 (C4), 135.2 (C4), 128.5 (C13 and C17), 128.0 (C14 and C16), 
127.9 (C15), 127.1 (C8), 126.9 (C8), 125.1 (C9), 124.6 (C9), 115.6 (C5), 115.4 (C5), 114.4 
(C7), 67.1 (C11), 66.9 (C20 and C21), 49.5 (C18 and C19), 45.2 (C1), 41.6 (C2), 41.4 (C2), 
29.4 (C3), 29.2 (C3). 
 
Benzyl 7-morpholino-3,4-dihydroisoquinoline-2(1H)-carboxylate (1.72). KTL-03-
138. Prepared according to the representative procedure outlined for Buchwald-Hartwig 
cross-coupling The crude material was purified via flash column chromatography eluting 
with EtOAc:hexanes (20:80) to give 30 mg (55%) of 1.72 as an off white solid: 1H NMR 
(499 MHz) δ 7.44 – 7.29  (comp, 5 H), 7.05 (d, J = 8.4 Hz, 1 H), 6.77 (dd, J = 8.4, 2.6 Hz, 
1 H), 6.64 (d, J = 25.5 Hz, 1 H), 5.18 (s, 2 H), 4.62 (s, 2 H), 3.86 (t, J = 4.7 Hz, 4 H), 3.76 
– 3.63 (comp, 2 H), 3.11 (t, J = 4.7 Hz, 4 H), 2.83 – 2.72 (comp, 2 H); 13C NMR (126 MHz, 
rotamers) δ 155.5, 149.9, 136.8, 134.2, 133.7, 129.5, 129.3, 128.5, 128.0, 127.9, 126.2, 
126.1, 114.8, 114.7, 113.3, 113.1, 67.23, 67.15, 66.9, 49.6, 46.1, 46.0, 42.0, 41.7, 28.1, 
27.9; LRMS (ESI+APCI) m/z  C21H24N2O3 (M+H)
+ calcd for 353.19; found 353.2. 
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 NMR Assignment. 1H NMR (499 MHz) δ 7.44 – 7.29  (comp, 5 H, C13-H thru 
C17-H), 7.05 (d, J = 8.4 Hz, 1 H, C5-H), 6.77 (dd, J = 8.4, 2.6 Hz, 1 H, C6-H), 6.64 (d, J 
= 25.5 Hz, 1 H, C8-H), 5.18 (s, 2 H, C11-H), 4.62 (s, 2 H, C1-H), 3.86 (t, J = 4.7 Hz, 4 H, 
C19-H and C21-H), 3.76 – 3.63 (comp, 2 H, C2-H), 3.11 (t, J = 4.7 Hz, 4 H, C18-H and 
C22-H), 2.83 – 2.72 (comp, 2 H, C3-H); 13C NMR (126 MHz, rotamers) δ 155.5 (C10), 
149.9 (C7), 136.8 (C12), 134.2 (C9), 133.7 (C9), 129.5 (C5), 129.3 (C5), 128.5 (C14 and 
C16), 128.0 (C13 and C17), 127.9 (C15), 126.2 (C4), 126.1 (C4), 114.8 (C6), 114.7 (C6), 
113.3 (C8), 113.1 (C8), 67.23 (C11), 67.15 (C11), 66.9 (C19 and C21), 49.6 (C18 and 
C22), 46.1 (C1), 46.0 (C1), 42.0 (C2), 41.7 (C2), 28.1 (C3), 27.9 (C3).  
 
Benzyl 7-(piperazin-1-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (1.71). KTL-01-
226. Prepared according to the representative procedure outlined for Buchwald-Hartwig 
cross-coupling. The crude material was purified via flash column chromatography eluting 
with MeOH:TEA:CH2Cl2 (1:1:98) to give 170 mg (85%) of 1.71 as a yellow oil: 
1H NMR 
(400 MHz) δ 7.40-7.29 (comp, 5 H), 7.03 (d, J = 8.0 Hz, 1 H), 6.78 (dd, J = 8.4, 2.4 Hz, 1 
H), 6.65 (d, J = 20.8 Hz, 1 H), 5.18 (s, 2 H), 4.61 (s, 2 H), 3.70 (br s, 2 H), 3.12 – 3.05 
(comp, 4 H), 3.05 – 2.97 (comp, 4 H), 2.76 (br s, 2 H), 1.84 (s, 1 H); 13C NMR (126 MHz, 
rotamers) δ 155.5, 150.1, 136.8, 134.1, 133.7, 129.5, 129.2, 128.5, 128.0, 127.9, 126.3, 
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126.1, 115.4, 115.3, 115.1, 114.0, 113.7, 67.2, 50.0, 46.0, 45.6, 42.0, 41.7, 28.1, 27.9; 
LRMS (ESI+APCI) m/z  C21H25N3O2 (M+H)
+ calcd for 352.20; found 352.3. 
NMR Assignment. 1H NMR (400 MHz) δ 7.40-7.29 (comp, 5 H, C13-H thru C17-
H), 7.03 (d, J = 8.0 Hz, 1 H, C5-H), 6.78 (dd, J = 8.4, 2.4 Hz, 1 H, C6-H), 6.65 (d, J = 20.8 
Hz, 1 H, C8-H), 5.18 (s, 2H, C11-H), 4.61 (s, 2H, C1-H), 3.70 (br s, 2H, C2-H), 3.12 – 
3.05 (comp, 4 H, C19-H and C21-H), 3.05 – 2.97 (comp, 4 H, C18-H and C22-H), 2.76 (br 
s, 2 H, C2-H), 1.84 (s, 1 H, 20-H). 13C NMR (126 MHz, rotamers) δ 155.5 (C10), 150.1 
(C7), 136.8 (C12), 134.1 (C9), 133.7 (C9), 129.5 (C5), 129.2 (C5), 128.5 (C14 and C16), 
128.0 (C13 and C17), 127.9 (C15), 126.3 (C4), 126.1 (C4), 115.4 (C6), 115.1 (C6), 114.0 
(C8), 113.7 (C8), 67.2 (C11), 50.0 (C18 and C22), 46.0 (C1), 45.6 (C19 and C21)), 42.0 
(C2), 41.7 (C2), 28.1 (C3), 27.9 (C3).  
 
Benzyl 6-(piperazin-1-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (1.109). KTL-
02-069. Prepared according to the representative procedure outlined for Buchwald-Hartwig 
cross-coupling. The crude material was purified via flash column chromatography eluting 
with MeOH:TEA:CH2Cl2 (1:1:98) to give 163 mg (80%) of 1.109 as a yellow oil: 
1H NMR 
(400 MHz) δ 7.42 – 7.29 (comp, 5 H), 7.06 – 6.94 (m, 1 H), 6.79 (dd, J = 8.4, 2.6 Hz, 1 H), 
6.68 (s, 1 H), 5.17 (s, 2 H), 4.57 (s, 2 H), 3.70 (br s, 2 H), 3.18 – 3.10 (comp, 4 H), 3.09 – 
3.01 (comp, 4 H), 2.81 (br s, 2 H); 13C NMR (101 MHz, rotamers) δ 155.5, 150.1, 149.6, 
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136.8, 135.4, 135.3, 128.5, 128.0, 127.0, 116.5, 115.8, 115.3, 114.8, 67.1, 51.5, 49.3, 48.9, 
48.6, 45.2, 44.8, 41.5, 29.4, 29.2. 
 
Benzyl 8-(piperazin-1-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (1.119). KTL-
02-111. Prepared according to the representative procedure outlined for Buchwald-Hartwig 
cross-coupling.  The crude material was purified via flash column chromatography eluting 
with MeOH:TEA:CH2Cl2 (1:1:98) to give 35 mg (69%) of 1.119 as a yellow oil: 
1H NMR 
(400 MHz) δ 7.43 – 7.28 (comp, 5 H), 7.18 (t, J = 7.7 Hz, 1 H), 6.98 (d, J = 8.0 Hz, 1 H), 
6.91 (s, 1 H), 5.18 (s, 2 H), 4.67 (s, 2 H), 3.68 (t, J = 6.1 Hz, 2 H), 3.12 – 2.96 (comp, 4 H), 
2.86 (s, 6 H), 2.42 (s, 1 H); LRMS (ESI+APCI) m/z  C21H24N2O3 (M+H)
+ calcd for 353.19; 
found 353.3. 
 NMR Assignment. 1H NMR (400 MHz) δ 7.43 – 7.28 (comp, 5 H, C16-H thru 
C20-H), 7.18 (t, J = 7.7 Hz, 1 H, C1-H), 6.98 (d, J = 8.0 Hz, 1 H, C6-H), 6.91 (s, 1 H, 
C2-H), 5.18 (s, 2 H, C14-H), 4.67 (s, 2 H, C7-H), 3.68 (t, J = 6.1 Hz, 2 H, C9-H), 3.12 – 
2.96 (comp, 4 H, C22-H and C26-H), 2.86 (s, 6 H, C10-H, C23-H, and C25-H), 2.42 (s, 1 
H, N24-H). 
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Benzyl 7-(4-methylpiperazin-1-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (1.70). 
KTL-01-229. Prepared according to the representative procedure outlined for Buchwald-
Hartwig cross-coupling. The crude material was purified via flash column chromatography 
eluting with EtOAc:TEA:hexanes (50:1:49) to give 129 mg (82%) of 1.70 as a yellow oil: 
1H NMR (499 MHz) δ 7.41 – 7.29 (m, 5 H), 7.03 (d, J = 8.3 Hz, 1 H), 6.78 (dd, J = 8.5, 
2.6 Hz, 1 H), 6.65 (d, J = 26.7 Hz, 1 H), 5.17 (s, 2 H), 4.61 (s, 2 H), 3.75 – 3.65 (comp, 2 
H), 3.17 (t, J = 4.9 Hz, 4 H), 2.80 – 2.70 (comp, 2 H), 2.58 (t, J = 5.0 Hz, 4 H), 2.36 (s, 3 
H); 13C NMR (126 MHz, rotamers) δ 155.5, 149.9, 136.8, 134.1, 133.6, 129.5, 129.2, 
128.6, 128.5, 128.0, 127.9, 125.9, 125.7, 115.1, 115.0, 113.7, 113.4, 67.2, 67.1, 55.1, 49.3, 
46.1, 42.0, 41.8, 28.1, 27.9; LRMS (ESI+APCI) m/z  C22H27N3O2 (M+H)
+ calcd for 366.22; 
found 366.3. 
 NMR Assignment. 1H NMR (499 MHz) δ 7.41 – 7.29 (m, 5 H, C13-H thru C17-
H), 7.03 (d, J = 8.3 Hz, 1 H, C5-H), 6.78 (dd, J = 8.5, 2.6 Hz, 1 H, C6-H), 6.65 (d, J = 26.7 
Hz, 1 H, C8-H), 5.17 (s, 2 H, C11-H), 4.61 (s, 2 H, C1-H), 3.75 – 3.65 (comp, 2 H, C2-H), 
3.17 (t, J = 4.9 Hz, 4 H, C18-H and C22-H), 2.80 – 2.70 (comp, 2 H, C3-H), 2.58 (t, J = 
5.0 Hz, 4 H, C19-H and C21-H), 2.36 (s, 3 H, C20-H); 13C NMR (126 MHz, rotamers) δ 
155.5 (C10), 149.9 (C7), 136.8 (C12), 134.1 (C9), 133.6 (C9), 129.5 (C5), 129.2 (C5), 
128.6 (C14 and C16), 128.5 (C14 and C16), 128.0 (C13 and C17), 127.9 (C15), 125.9 (C4), 
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125.7 (C4), 115.1 (C6), 115.0 (C6), 113.7 (C8), 113.4 (C8), 67.2 (C11), 67.1 (C11), 55.1 
(C18 and C22), 49.3 (C19 and C22), 46.1 (C9 and C20), 42.0 (C2), 41.8 (C2), 28.1 (C3), 
27.9 (C3).  
 
Benzyl 6-(4-methylpiperazin-1-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
(1.110). KTL-02-061. Prepared according to the representative procedure outlined for 
Buchwald-Hartwig cross-coupling. The crude material was purified via flash column 
chromatography eluting with EtOAc:TEA:hexanes (50:1:49) to give 12 mg (11%) of 1.110 
as a yellow oil: 1H NMR (400 MHz) δ 7.40-7.29 (comp, 5 H), 7.00 (dd, J = 19.8, 8.0 Hz, 
1 H), 6.79 (dd, J = 8.5, 2.1 Hz, 1 H), 6.68 (s, 1 H), 5.17 (s, 2 H), 4.57 (s, 2 H), 3.69 (s, 2 
H), 3.25 – 3.15 (comp, 4 H), 2.80 (s, 2 H), 2.65 – 2.58 (comp, 4 H), 2.38 (s, 3 H); 13C NMR 
(101 MHz, rotamers) δ 155.5, 149.8, 136.8, 135.3, 135.2, 128.5, 128.0, 127.9, 127.0, 124.9, 
124.5, 116.0, 115.8, 114.8, 67.1, 55.0, 49.1, 46.0, 45.2, 41.6, 41.5, 29.5, 29.2; HRMS (ESI) 
m/z  C22H27N3O2 (M+H)
+ calcd for 366.2176; found 366.2176. 
NMR Assignment. : 1H NMR (400 MHz) δ 7.40-7.29 (comp, 5 H, C13-H thru 
C17-H), 7.00 (dd, J = 19.8, 8.0 Hz, 1 H, C6-H), 6.79 (dd, J = 8.5, 2.1 Hz, 1 H, C1-H), 6.68 
(s, 1 H, C3-H), 5.17 (s, 2 H, C11-H), 4.57 (s, 2 H, C9-H), 3.69 (s, 2 H, C8-H), 3.25 – 3.15 
(comp, 4 H, C18-H and C21-H), 2.80 (s, 2 H, C7-H), 2.65 – 2.58 (comp, 4 H, C19-H and 
C20-H), 2.38 (s, 3 H, C22-H); 13C NMR (101 MHz, rotamers) δ 155.5 (C10), 149.8 (C2), 
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136.8 (C12), 135.3 (C5), 135.2 (C5), 128.5 (C14 and C16), 128.0 (C13 and C17), 127.9 
(C15), 127.0 (C3), 126.9 (C3), 124.9 (C4), 124.5 (C4), 11.6 (C1), 115.8 (C1), 114.8 (C3), 
67.1 (C11), 55.0 (C18 and C22), 49.1 (C19 and C20), 46.0 (C22), 45.2 (C9), 41.4 (C8), 
41.4 (C8), 29.5 (C7), 29.2 (C7). 
 
Benzyl 5-(3-methoxyphenyl)isoindoline-2-carboxylate (1.68). KTL-01-174.  Prepared 
according to the representative procedure outlined Buchwald-Hartwig cross-coupling. The 
crude material was purified by flash column chromatography using EtOAc:Hexanes 
(25:75) to give 73 mg (70%) of 1.68  as a white solid:  1H NMR (400 MHz) δ 7.41-7.29 
(comp, 5 H), 7.14 (dd, J = 22.6, 8.4 Hz, 1 H), 6.85 (q, J = 7.9 Hz, 1 H), 6.83 – 6.74 (m, 1 
H), 5.22 (s, 2 H), 4.70 (comp, 4 H), 3.86 (comp, 4 H), 3.13 (comp, 4 H);  13C NMR (101 
MHz, rotomers) δ 156.1, 154.8, 154.8, 151.3, 138.0, 137.7, 136.8, 128.5, 128.3, 128.1, 
128.0, 127.8, 123.2, 123.1, 115.7, 115.6, 109.8, 109.7, 66.9, 66.8, 52.7, 52.3, 52.1, 51.6, 
49.8, 49.7; HRMS (ESI) m/z C21H24N2O3 (M+Na)
+ calcd for 361.1423; found 361.1526. 
NMR Assignment.  1H NMR (400 MHz) δ 7.41-7.29 (comp, 5 H, C12-H thru C-
16-H), 7.14 (dd, J = 22.6, 8.4 Hz, 1 H, C4-H), 6.85 (q, J = 7.9 Hz, 1 H, C5-H), 6.83 – 6.74 
(m, 1 H, C7-H), 5.22 (s, 2 H, C10-H), 4.70 (comp, 4 H, C1-H and C2-H), 3.86 (comp, 4 H, 
C19-H and C20-H), 3.13 (comp, 4 H, C17-H and C18-H);  13C NMR (101 MHz, rotomers 
) δ 154.8 (C9), 154.8 (C9), 151.3 (C6), 138.0 (C8), 137.7 (C8), 136.8 (C11), 128.5 (C13 
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and C15), 128.3 (C4), 128.1 (C4), 128.0 (C14), 127.8 (C12 and C16), 123.2 (C3), 123.1 
(C3), 115.7 (C5), 115.6 (C5), 109.8 (C7), 109.7 (C7), 66.9 (C10), 66.8 (C19 and C20), 52.7 
(C1 or C2), 52.3 (C1 or C2), 52.1 (C1 or C2), 51.6 (C1 or C2), 49.8 (C17 and C18), 49.7 
(C17 and C18). 
 
Benzyl 5-(piperazin-1-yl)isoindoline-2-carboxylate (1.67). KTL-01-268. Prepared 
according to the representative procedure outlined Buchwald-Hartwig cross-coupling. The 
crude material was purified via flash column chromatography eluting MeOH:TEA:CH2Cl2 
(1:1:98) to give 150 mg (73%) of 1.67 as a yellow solid: 1H NMR (400 MHz, rotamers) δ 
7.41-7.30 (comp, 5 H), 7.13 (dd, J = 23.3, 8.4 Hz, 1 H), 6.86 (ddd, J = 8.0, 5.6, 2.1 Hz, 1 
H), 6.79 (d, J = 24.0 Hz, 1 H), 5.20 (s, 2 H), 4.69 (t, J = 10.3 Hz, 4 H), 3.15-3.11 (dd, J = 
9.9, 5.2 Hz, 4 H), 3.09 – 3.01 (comp, 3 H), 2.31 (s, 1 H); 13C NMR (126 MHz) δ 154.9, 
154.9, 151.9, 138.0, 137.7, 136.9, 136.9, 128.5, 128.1, 128.0, 127.9, 127.8, 123.2, 123.0, 
116.2, 116.1, 110.3, 110.1, 66.9, 52.8, 52.3, 52.1, 51.7, 50.94, 50.91, 46.2; LRMS 
(ESI+APCI) m/z  C20H23N3O2 (M+H)
+ calcd for 338.19; found 338.2. 
 NMR Assignment. 1H NMR (400 MHz,) δ 7.41-7.30 (comp, 5 H, C12-H thru C16-
H), 7.13 (dd, J = 23.3, 8.4 Hz, 1 H, C3-H), 6.86 (ddd, J = 8.0, 5.6, 2.1 Hz, 1 H, C2-H), 6.79 
(d, J = 24.0 Hz, 1 H, C6-H), 5.20 (s, 2 H, C10-H), 4.69 (t, J = 10.3 Hz, 4 H, C7-H and C8-
H), 3.15-3.11 (comp, 4 H C17-H and C20-H), 3.09 – 3.01 (comp, 4 H, C18-H and C19-H), 
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2.31 (s, 1 H, N21-H). 13C NMR (126 MHz) δ 154.9 (C9), 154.9 (C9), 151.9 (C1), 138.0 
(C5), 137.7 (C5), 136.9 (C11), 136.9 (C11), 128.5 (C13 and C15), 128.1 (C3), 128.0 (C14), 
127.9 (C12 and C16), 127.8 (C3), 123.2 (C4), 123.0 (C4), 116.2 (C2), 116.1 (C2), 110.3 
(C6), 110.1 (C6), 66.9 (C10), 52.8 (C7 or C8), 52.3 (C7 or C8), 52.1 (C7 or C8), 51.7 (C7 
or C8), 50.94 (C17 and C20), 50.91 (C17 and C20), 46.2 (C18 and C19).  
 
Benzyl 5-(4-methylpiperazin-1-yl)isoindoline-2-carboxylate (1.66). KTL-01-140.  
Prepared according to the representative procedure outlined Buchwald-Hartwig cross-
coupling. The crude material was purified via flash column chromatography using 
EtOAc:TEA:hexanes (75:1:24) to give 65 mg (62%) of 1.66 as a pale yellow solid:  1H 
NMR (400 MHz) δ 7.43-7.29 (comp, 5 H), 7.16 (dd, J = 23.4, 8.3 Hz, 1 H), 6.87 (dd, J = 
11.3, 4.9 Hz, 1 H), 6.80 (d, J = 24.1 Hz, 1 H), 5.21 (s, 2 H), 4.69 (t, J = 10.5 Hz, 4 H), 3.19 
(comp, 4 H), 2.58 (comp, 4 H), 2.35 (s, 3 H); 13C NMR (100 MHz, rotomers) δ 154.9, 
154.8, 151.3, 137.9, 137.6, 136.8, 128.4, 127.9, 127.8, 127.7, 123.1, 123.0, 116.1, 115.9, 
110.2, 110.0, 66.9, 55.0, 52.7, 52.3, 52.0, 51.6, 49.5, 49.5, 46.1; HRMS (ESI) m/z 
C21H24N2O3 (M+H)
+ calcd for 352.2020; found 352.2038; IR (neat) 2938, 2858, 2798, 
1706, 1453, 1416, 1361, 1247, 1104 cm-1 
NMR Assignment. 1H NMR (400 MHz) δ 7.43-7.29 (comp, 5 H, C12-H thru C16-
H), 7.13 (dd, J = 23.4, 8.3 Hz, 1 H, C4-H), 6.87 (dd, J = 11.3, 4.9 Hz, 1 H, C5-H), 6.80 (d, 
23 
 98 
J = 24.1 Hz, 1 H, C7-H), 5.21 (s, 2 H, C10-H), 4.69 (t, J = 10.5 Hz, 4 H, C1-H and C2-H), 
3.19 (comp, 4 H, C19-H and C20-H), 2.58 (comp, 4 H, C17-H and C18-H), 2.35 (s, 3 H, 
C21-H);  13C NMR (100 MHz, rotomers) δ 154.9 (C9), 154.8 (C9), 151.3 (C6), 137.9 (C8), 
137.6 (C8), 136.8 (C11), 128.4 (C13 and C15), 127.9 (C14), 127.8 (C12 and C16), 127.7 
(C4), 123.1 (C3), 123.0 (C3), 116.1 (C5), 115.9 (C5), 110.2 (C7), 110.0 (C7), 66.9 (C10), 
55.0 (C17 and C18), 52.7 (C1 or C2), 52.3 (C1 or C2), 52.0 (C1 or C2), 51.6 (C1 or C2), 
49.5 (C19 and C 20), 49.5 (C19 and C 20), 46.1 (C21). 
 
Benzyl 8-morpholino-1,3,4,5-tetrahydro-2H-benzo[c]azepine-2-carboxylate (1.77). 
KTL-02-057. Prepared according to the representative procedure outlined Buchwald-
Hartwig cross-coupling. The crude material was purified via flash column chromatography 
eluting with EtOAc:hexanes (25:75) to give 53 mg (91%) of 1.77 as a white solid:  1H 
NMR (400 MHz, rotamers) δ 7.40-7.28 (comp, 5 H), 7.04 (d, J = 8.2 Hz, 1 H), 6.93 (d, J 
= 2.4 Hz, 0.35 H), 6.68 (td, J = 8.5, 2.6 Hz, 1 H), 6.61 (d, J = 2.5 Hz, 0.65 H), 5.06 (s, 0.70 
H), 5.04 (s, 1.30 H), 4.45 (s, 0.70 H), 4.40 (s, 1.30 H), 3.87 – 3.81 (comp, 1.50 H), 3.81 – 
3.70 (comp, 4.50 H), 3.19 – 3.10 (comp, 1.50 H), 2.94 – 2.85 (comp, 4.50 H), 1.81-1.71 
(comp, 2 H); 13C NMR (101 MHz, rotamers) δ 155.4, 155.2, 149.6, 149.4, 139.0, 138.9, 
136.9, 136.7, 133.3, 132.9, 130.2, 130.2, 128.4, 128.0, 127.9, 127.8, 117.5, 117.2, 114.2, 
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113.9, 67.3, 66.9, 66.9, 53.0, 52.5, 51.0, 50.5, 49.4, 49.3, 34.4, 34.3, 28.9, 28.4; HRMS 
(ESI) m/z  C22H26N3O2 (M+Na)
+ calcd for 389.1836; found 389.1845. 
NMR Assignemnt. 1H NMR (400 MHz, rotamers) δ 7.40-7.28 (comp, 5 H, C14-
H thru C18-H), 7.04 (d, J = 8.2 Hz, 1 H, C3-H), 6.93 (d, J = 2.4 Hz, 0.35 H, C6-H), 6.68 
(td, J = 8.5, 2.6 Hz, 1 H, C2-H), 6.61 (d, J = 2.5 Hz, 0.65 H, C6-H), 5.06 (s, 0.70 H, C12-
H), 5.04 (s, 1.30 H, C12-H), 4.45 (s, 0.70 H, C10-H), 4.40 (s, 1.30 H, C10-H), 3.87 – 3.81 
(comp, 1.5 H, C19-H and C22-H), 3.81 – 3.70 (comp, 4.5 H, C9-H, C19-H and C22-H), 
3.19 – 3.10 (comp, 1.5 H, C20-H and C21-H), 2.94 – 2.85 (comp, 4.5 H, C7-H, C20-H and 
C21-H), 1.81-1.71 (comp, 2 H, C8-H); 13C NMR (101 MHz, rotamers) δ 155.42 (C11), 
155.22 (C11), 149.58 (C1), 149.44 (C1), 139.01 (C5), 138.87 (C5), 136.87 (C13), 136.73 
(C13), 133.31 (C4), 132.88 (C4), 130.23 (C3), 130.15 (C3), 128.40 (C15 and C17), 128.00 
(C14 and C18), 127.86 (C14 and C18), 127.80 (C16), 117.46 (C2), 117.15 (C2), 114.21 
(C6), 113.94 (C6), 67.26 (C12), 66.94 (C20 and C21), 66.89 (C20 and C21), 53.04 (C10), 
52.49 (C10), 51.03 (C9), 50.48 (C9), 49.39(C19 and C22), 49.30 (C19 and C22), 34.38 
(C7), 34.34 (C7), 28.91 (C8), 28.42 (C8). 
 
Benzyl 7-morpholino-1,3,4,5-tetrahydro-2H-benzo[c]azepine-2-carboxylate (1.78). 
KTL-02-087. Prepared according to the representative procedure outlined for Buchwald-
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Hartwig cross-coupling. The crude material was purified via flash column chromatography 
eluting EtOAc:hexanes (25:75) to give 45 mg (38%) of 1.78 as a clear oil: 1H NMR (400 
MHz, rotamers) δ 7.33 (comp, 5 H), 7.24 (s, 0.45 H), 7.01 (d, J = 8.2 Hz, 0.55 H), 6.73 (s,1 
H), 6.68 (dd, J = 8.2, 2.4 Hz, 0.45 H), 6.61 (dd, J = 8.2, 2.5 Hz, 0.55 H), 5.06 (s, 2 H), 4.42 
(s, 0.87 H), 4.39 (s, 1.13 H), 3.87-3.84 (comp, 4 H), 3.78-3.66 (comp, 2 H), 3.20 – 3.10 
(comp, 4 H), 2.93-2.89 (comp, 2 H), 1.85-1.71 (comp, 2 H); 13C NMR (101 MHz, rotamers) 
δ 155.5, 155.2, 150.7, 142.8, 142.4, 136.9, 130.4, 130.1, 130.0, 129.8, 128.4, 128.3, 127.84, 
127.82, 127.80, 117.1, 112.8, 112.5, 67.0, 66.9, 66.89, 51.9, 51.3, 50.7, 50.2, 49.4, 35.8, 
28.8, 28.2; LRMS (ESI+APCI) m/z  C22H26N2O3 (M+H)
+ calcd for 367.20; found 367.2. 
NMR Assignment. 1H NMR (400 MHz, rotamers) δ 7.33 (comp, 5 H, C14-H thru 
C18-H), 7.24 (s, 0.45 H, C6-H), 7.01 (d, J = 8.2 Hz, 0.55 H, C6-H), 6.73 (s,1 H, C3-H), 
6.68 (dd, J = 8.2, 2.4 Hz, 0.45 H, C1-H), 6.61 (dd, J = 8.2, 2.5 Hz, 0.55 H, C1-H), 5.06 (s, 
2 H, C12-H), 4.42 (s, 0.87 H, C10-H), 4.39 (s, 1.13 H, C10-H), 3.87-3.84 (comp, 4 H, C20-
H and C21-H), 3.78-3.66 (comp, 2 H, C9-H), 3.20 – 3.10 (comp, 4 H, C19-H and C22-H), 
2.93-2.89 (comp, 2 H, C7-H), 1.85-1.71 (comp, 2 H, C8-H); 13C NMR (101 MHz, 
rotamers) δ 155.5 (C11), 155.2 (C11), 150.7 (C2), 142.8 (C4), 142.4 (C4), 136.9 (C13), 
130.4 (C6), 130.1 (C6), 130.0 (C5), 129.8 (C5), 128.4 (C15 and C17), 128.3 (C15 and 
C17), 127.84 (C16), 127.82 (C14 and C18), 128.80 (C14 and C18), 117.1 (C3), 112.8 (C1), 
112.5 (C1), 67.0 (C12), 66.9 (C20 and C21), 66.89 (C12), 51.9 (C10), 51.3 (C10), 50.7 
(C9), 50.2 (C9), 49.4 (C19 and C22), 35.8 (C7), 28.8 (C8), 28.2 (C8). 
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Benzyl 8-(piperazin-1-yl)-1,3,4,5-tetrahydro-2H-benzo[c]azepine-2-carboxylate 
(1.76). KTL-02-035. Prepared according to the representative procedure outlined for 
Buchwald-Hartwig cross-coupling. The crude material was purified via flash column 
chromatography eluting with MeOH:TEA:CH2Cl2 (1:1:98) to give 104 mg (60%) of 1.76 
as a yellow oil: 1H NMR (400 MHz, rotamers) δ 7.40-7.27 (s, 5 H), 7.01 (d, J = 8.2 Hz, 1 
H), 6.93 (d, J = 2.5 Hz, 0.35 H), 6.70 – 6.65 (m, 1 H), 6.63 (d, J = 2.6 Hz, 0.65 H), 5.05 (s, 
0.70 H), 5.02 (s, 1.30 H), 4.43 (s, 0.70 H), 4.38 (s, 1.30 H), 3.80-6.69 (comp, 2 H), 3.15 – 
3.07 (comp, 1.5 H), 3.03 – 2.97 (comp, 1.5 H), 2.97 – 2.90 (m, 5 H), 2.86-2.83 (comp, 2 
H), 1.79-1.67 (comp, 2 H); 13C NMR (101 MHz, rotamers) δ 155.4, 155.2, 149.9, 149.8, 
138.9, 138.7, 136.8, 136.7, 133.1, 132.7, 130.2, 130.1, 128.4, 127.8, 118.0, 117.7, 117.6, 
114.6, 114.6, 114.4, 67.2, 66.9, 52.5, 51.0, 50.1, 50.0, 45.9, 45.8, 34.4, 34.3, 28.9, 28.4; 
LRMS (ESI+APCI) m/z  C22H27N3O2 (M+H)
+ calcd for 366.21; found 366.3. 
NMR Assignment. 1H NMR (400 MHz, rotamers) δ 7.40-7.27 (s, 5 H, C14-H thru 
C18-H), 7.01 (d, J = 8.2 Hz, 1 H, C3-H), 6.93 (d, J = 2.5 Hz, 0.35 H, C6-H), 6.70 – 6.65 
(m, 1 H, C2-H), 6.63 (d, J = 2.6 Hz, 0.65 H, C6-H), 5.05 (s, 0.70 H, C12-H), 5.02 (s, 1.30 
H, C12-H), 4.43 (s, 0.70 H, C10-H), 4.38 (s, 1.30 H, C10-H), 3.80-6.69 (comp, 2 H, C9-
H), 3.15 – 3.07 (comp, 1.5 H, C19-H and C22-H), 3.03 – 2.97 (comp, 1.5 H, C20-H and 
C21-H), 2.97 – 2.90 (m, 5 H, C19-H thru C22-H), 2.86-2.83 (comp, 2 H, C7-H), 1.79-1.67 
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(comp, 2 H, C8-H); 13C NMR (101 MHz, rotamers) δ 155.4 (C11), 155.2 (C11), 149.9 
(C1), 149.8 (C1), 138.9 (C5), 138.7 (C5), 136.8 (C13), 136.7 (C13), 133.1 (C4), 132.7 
(C4), 130.2 (C3), 130.1 (C3), 128.4 (C15 and C17), 127.8 (C14, C16, and C18), 118.0 
(C2), 117.7 (C2), 117.6, 114.6 (C6), 114.6 (C6), 114.4 (C6), 67.2 (C12), 66.9 (C12), 53.0 
(C10), 52.5 (C10), 50.1 (C19 and C22), 50.0(C19 and C22), 45.9 (C9, C20, and C21), 
45.8(C9, C20, and C21), 34.4 (C9), 34.3 (C9), 28.9 (C8), 28.4 (C8).  
 
Benzyl 7-(piperazin-1-yl)-1,3,4,5-tetrahydro-2H-benzo[c]azepine-2-carboxylate 
(1.113). KTL-02-096. Prepared according to the representative procedure outlined for 
Buchwald-Hartwig cross-coupling. The crude material was purified via flash column 
chromatography eluting with MeOH:TEA:CH2Cl2 (1:1:98) to give 80 mg (69%) of 1.113 
as a yellow oil:  1H NMR (400 MHz, rotamers) δ 7.39-7.27 (comp, 5 H), 7.23 (d, J = 8.2 
Hz, 0.40 H), 7.00 (d, J = 8.2 Hz, 0.60 H), 6.74 (s, 1 H), 6.69 (dd, J = 8.1, 2.4 Hz, 0.40 H), 
6.62 (dd, J = 8.2, 2.4 Hz, 0.60 H), 5.05 (s, 2 H), 4.41 (s, 0.70 H), 4.38 (s, 1.30 H), 3.73 (s, 
2 H), 3.15-3.08 (comp, 4 H), 3.05-2.97 (comp, 4 H), 2.94-2.89 (comp, 2 H), 1.81-1.74 
(comp, 2 H); 13C NMR (101 MHz, rotamers) δ 155.5, 155.2, 151.2, 142.7, 142.3, 136.93, 
136.91, 130.3, 130.0, 129.6, 129.4, 128.4, 128.4, 127.8, 117.53, 117.51, 113.1, 112.8, 67.0, 
66.9, 51.9, 51.3, 50.7, 50.42, 50.40, 50.2, 46.2, 35.8, 35.6, 28.8, 28.3. 
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NMR Assignment. :  1H NMR (400 MHz, rotamers) δ 7.39-7.27 (comp, 5 H, C14-
H thru C18-H), 7.23 (d, J = 8.2 Hz, 0.40 H, C6-H), 7.00 (d, J = 8.2 Hz, 0.60 H, C6-H), 
6.74 (s, 1 H, C3-H), 6.69 (dd, J = 8.1, 2.4 Hz, 0.40 H, C1-H), 6.62 (dd, J = 8.2, 2.4 Hz, 
0.60 H, C1-H), 5.05 (s, 2 H, C12-H), 4.41 (s, 0.70 H, C10-H), 4.38 (s, 1.30 H, C10-H), 
3.73 (s, 2 H, C9-H), 3.15-3.08 (comp, 4 H, C19-H and C22-H), 3.05-2.97 (comp, 4 H, C20-
H and C21-H), 2.94-2.89 (comp, 2 H, C7-H), 1.81-1.74 (comp, 2 H, C8-H); 13C NMR (101 
MHz, rotamers) δ 155.47 (C11), 155.20 (C11), 151.21 (C2), 142.67 (C4), 142.29 (C4), 
136.93 (C13), 136.91 (C13), 130.31 (C6), 130.04 (C6), 129.58 (C5), 129.38 (C5), 128.40 
(C15 and C17), 128.35 (C15 and C17), 127.80 (C14, C16, and C18), 117.53 (C3), 117.51 
(C3), 113.11 (C1), 112.79 (C1), 67.01 (C12), 66.86 (C12), 51.92 (C10), 51.33 (C10), 50.69 
(C9), 50.42 (C19 and C22), 50.40 (C19 and C22), 50.18 (C9), 46.16 (C20 and C21), 35.81 
(C7), 35.75 (C7), 28.79 (C8), 28.25 (C8). 
 
Benzyl 8-(4-methylpiperazin-1-yl)-1,3,4,5-tetrahydro-2H-benzo[c]azepine-2-
carboxylate (1.75). KTL-02-027. Prepared according to the representative procedure 
outlined for Buchwald-Hartwig cross-coupling. The crude material was purified via flash 
column chromatography eluting EtOAc:TEA:hexanes (25:1:74) to give 38 mg (63%) of 
1.75 as a yellow oil: 1H NMR (400 MHz, rotamers) δ 7.29 (comp, 5 H), 7.02 (d, J =8.2 
Hz, 1 H), 6.95 (d, J =2.5 Hz, 0.33 H), 6.69 (d, J =15.2 Hz, 1 H), 6.65 (d, J =2.6 Hz, 0.67 
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H), 5.06 (s, 0.7 H), 5.03 (s, 1.3 H), 4.44 (s, 0.67 H), 4.39 (s, 1.33 H), 3.80 – 3.70 (m, 2 H), 
3.23 – 3.17 (m, 1.5 H), 3.03 – 2.98 (m, 2.5 H), 2.87 (comp, 2 H), 2.58 – 2.53 (m, 1.5 H), 
2.53 – 2.47 (m, 2.5 H), 2.34 (s, 3 H), 1.76 (comp, 2 H); 13C NMR (101 MHz, rotamers) δ 
155.4, 155.2, 149.6, 149.4, 138.9, 138.7, 136.9, 136.7, 132.8, 132.4, 130.2, 130.0, 128.4, 
127.9, 127.83, 127.80, 127.79, 117.8, 117.4, 114.3, 114.1, 67.2, 66.9, 55.2, 55.1, 53.0, 52.5, 
51.0, 50.4, 49.05, 48.98, 46.2, 34.4, 34.3, 28.9, 28.4; HRMS (ESI) m/z  C23H29N3O2 
(M+H)+ calcd for 380.2333; found 320.2337. 
NMR Assignment. 1H NMR (400 MHz, rotamers) δ 7.29 (comp, 5 H, C14-H thru 
C18-H), 7.02 (d, J =8.2 Hz, 1 H, C3-H), 6.95 (d, J =2.5 Hz, 0.33 H, C6-H), 6.69 (d, J 
=15.2 Hz, 1 H, C2-H), 6.65 (d, J =2.6 Hz, 0.67 H, C6-H), 5.06 (s, 0.7 H, C12-H), 5.03 (s, 
1.3 H, C12-H), 4.44 (s, 0.67 H, C10-H), 4.39 (s, 1.33 H, C10-H), 3.80 – 3.70 (m, 2 H, C9-
H), 3.23 – 3.17 (m, 1.5 H, C19-H and C22-H), 3.03 – 2.98 (m, 2.5 H, C19-H and C22-H), 
2.87 (comp, 2 H, C7-H), 2.58 – 2.53 (m, 1.5 H, C20-H and C21-H), 2.53 – 2.47 (m, 2.5 H, 
C20-H and C21-H), 2.34 (s, 3 H, C23-H), 1.76 (comp, 2 H, C8-H); 13C NMR (101 MHz, 
rotamers) δ 155.4 (C11), 155.2 (C11), 149.6 (C1), 149.4 (C1), 138.9 (5), 138.7 (C5), 136.9 
(C13), 136.7 (C13), 132.8 (C4), 132.4 (C4), 130.2 (C3), 130.0 (C3), 128.4 (C15 and C17) 
, 127.9 (C14 and C18), 127.83 (C16), 127.80 (C14 and C18), 127.79 (C16), 117.8 (C2), 
117.4 (C2), 114.3 (C6), 114.1 (C6), 67.2 (C12), 66.9 (C12), 55.2 (C19 and C22), 55.1 (C19 
and C22), 53.0 (C10), 52.5 (C10), 51.0 (C9), 50.4 (C10), 49.05 (C20 and C21), 48.98 (C20 
and C21), 46.2 (C23), 34.4 (C7), 34.3 (C7), 28.9 (C8), 28.4 (C8). 
 105 
 
Benzyl 7-(4-methylpiperazin-1-yl)-1,3,4,5-tetrahydro-2H-benzo[c]azepine-2-
carboxylate (1.114). KTL-02-089. Prepared according to the representative procedure 
outlined for Buchwald-Hartwig cross-coupling. The crude material was purified via flash 
column chromatography eluting with EtOAc:TEA:hexanes (75:1:24) to give 32 mg (53%) 
of 1.114 as a yellow oil: 1H NMR (400 MHz, rotamers) δ 7.39-7.27 (comp, 5 H), 7.23 (d, 
J = 8.2 Hz, 0.45 H), 6.99 (d, J = 8.2 Hz, 0.55 H), 6.74 (s, 1 H), 6.69 (dd, J = 8.1, 2.4 Hz, 
0.45 H), 6.62 (dd, J = 8.2, 2.5 Hz, 0.55 H), 5.05 (s, 2 H), 4.41 (s, 0.80 H), 4.38 (s, 1.20 H), 
3.79 – 3.66 (comp, 2 H), 3.25 – 3.13 (comp, 4 H), 2.95 – 2.85 (comp, 2 H), 2.61 – 2.50 
(comp, 4 H), 2.36 (s, 1.85 H), 2.35 (s, 1.15 H), 1.85-1.73 (comp, 2 H); 13C NMR (101 
MHz, rotamers) δ 155.5, 155.2, 150.6, 142.7, 142.3, 136.92, 136.90, 130.3, 130.0, 129.6, 
129.4, 128.4, 128.3, 127.82, 127.80, 127.8, 117.5, 113.1, 112.8, 67.0, 66.9, 55.1, 51.9, 51.3, 
50.7, 50.2, 49.0, 46.1, 35.8, 35.7, 28.8, 28.2; LRMS (ESI+APCI) m/z  C23H29N3O2 (M+H)
+ 
calcd for 380.24; found 380.3. 
NMR Assignment. 1H NMR (400 MHz, rotamers) δ 7.39-7.27 (comp, 5 H, C14-
H thru C18-H), 7.23 (d, J = 8.2 Hz, 0.45 H, C6-H), 6.99 (d, J = 8.2 Hz, 0.55 H, C6-H), 
6.74 (s, 1 H, C3-H), 6.69 (dd, J = 8.1, 2.4 Hz, 0.45 H, C1-H), 6.62 (dd, J = 8.2, 2.5 Hz, 
0.55 H, C1-H), 5.05 (s, 2 H, C12-H), 4.41 (s, 0.80 H, C10-H), 4.38 (s, 1.20 H, C10-H), 
3.79 – 3.66 (comp, 2 H, C9-H), 3.25 – 3.13 (comp, 4 H, C19-H and C22-H), 2.95 – 2.85 
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(comp, 2 H, C7-H), 2.61 – 2.50 (comp, 4 H, C20-H and C21-H), 2.36 (s, 1.85 H, C23-H), 
2.35 (s, 1.15 H, C23-H), 1.85-1.73 (comp, 2 H, C8-H); 13C NMR (101 MHz, rotamers) δ 
155.47 (C11), 155.21 (C11), 150.62 (C2), 142.69 (C4), 142.31 (C4), 136.92 (C13), 136.90 
(C13), 130.33 (C6), 130.05 (C6), 129.57 (C5), 129.38 (C5), 128.39 (C15 and C17), 128.34 
(C15 and C17), 127.82 (C16), 127.80 (C14 and C16), 127.77 (C14 and C16), 117.45 (C3), 
113.09 (C1), 112.75 (C1), 67.01 (C12), 66.87 (C12), 55.13 (C19 and C22), 51.91 (C10), 
51.32 (C10), 50.68 (C9), 50.18 (C9), 49.04 (C20 and C21), 46.12 (C23), 35.81 (C7), 35.74 
(C7), 28.77 (C8), 28.23 (C8). 
Representative procedure for Suzuki cross-coupling 
 
Benzyl 7-(3-methoxyphenyl)-1,3,4,5-tetrahydro-2H-benzo[c]azepine-2-carboxylate 
(1.74). KTL-02-090. A solution of 1.64 (50 mg, 0.16 mmol), 3-methoxyphenylboronic 
acid (49 mg, 0.32 mmol), Cs2CO3 (104 mg, 0.32 mmol), and palladium (bis)(t-butyl)3 
phosphine (4 mg, 0.008mmol) in degassed 1,4-dioxane (0.5 mL) was stirred for 24 h at 90 
°C. The reaction was cooled to room temperature and poured into water (1 mL). The 
material was extracted with CH2Cl2 (3 x 10 mL) and the combined organic layers were 
dried (MgSO4) and concentrated under reduced pressure. The crude material was purified 
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via flash column chromatography eluting with EtOAc:hexanes (1:9) to give 51 mg (83%) 
of 1.74 as a clear oil: 1H NMR (400 MHz, rotamers) δ 7.44-7.30 (comp, 9 H), 7.17 (dd, J 
=  8.1, 1.9 Hz, 1 H), 7.12 (t, J =  2.4 Hz, 1 H), 6.95 – 6.87 (m, 1 H), 5.09 (s, 2 H), 4.54 (s, 
0.81 H), 4.50 (s, 1.20 H), 3.88 (s, 1.70 H), 3.87 (s, 1.30 H), 3.80 (s, 2 H), 3.04-3.02 (comp, 
2 H), 1.92-1.79 (s, 2 H); 13C NMR (101 MHz, rotamers) δ 159.9, 155.5, 155.3, 142.5, 
142.4, 142.3, 141.9, 140.4, 140.38, 137.53, 137.35, 136.83, 136.77, 130.00, 129.74, 
129.72, 128.51, 128.44, 128.40, 127.91, 127.4, 125.0, 124.7, 119.6, 112.82, 112.77, 112.7, 
77.4, 77.1, 76.7, 67.2, 67.0, 55.3, 52.3, 51.7, 50.9, 50.5, 35.5, 28.6, 28.1. 
NMR Assignment. 1H NMR (400 MHz, rotamers) δ 7.44-7.30 (comp, 9 H, C1-H, 
C3-H, C6-H, C14-H thru C18-H, and C21-H), 7.17 (dd, J = 8.1, 1.9 Hz, 1 H, C20-H), 7.12 
(t, J = 2.4 Hz, 1 H, C22-H), 6.95 – 6.87 (m, 1 H, C24-H), 5.09 (s, 2 H, C12-H), 4.54 (s, 
0.81 H, C10-H), 4.50 (s, 1.20 H, C10-H), 3.88 (s, 1.70 H, C25-H), 3.87 (s, 1.30 H, C25-
H), 3.80 (s, 2 H, C9-H), 3.04-3.02 (comp, 2 H, C7-H), 1.92-1.79 (s, 2 H, C8-H); 13C NMR 
(101 MHz, rotamers) δ 159.91 (C23), 155.50 (C11), 155.34 (C11), 142.47 (C19), 142.38 
(C19), 142.29 (C4), 141.94 (C4), 140.42 (C5), 140.38 (C5), 137.53 (C2), 137.35 (C2), 
136.83 (C13), 136.77 (C13), 130.00 (C21), 129.74, 129.72, 128.51, 128.44, 128.40 (C15 
and C17), 127.91 (C14 and C18), 127.85 (C1), 125.03 (C1), 124.66 (C6), 119.61 (C20), 
112.82 (C24), 112.77 (C24), 112.66 (C22), 77.37, 77.06, 76.74, 67.19 (C12), 67.02 (C12), 
55.31 (C25), 52.27 (C10), 51.69 (C10), 50.91 (C9), 50.48 (C9), 35.46 (C7), 28.64 (C8), 
28.07 (C8). 
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Benzyl 5-(3-methoxyphenyl)isoindoline-2-carboxylate (1.65). KTL-02-130. Prepared 
according to the representative procedure outlined for Suzuki cross-coupling. The crude 
material was purified by flash column chromatography eluting with EtOAc:hexanes (5:95) 
to give 150 mg (87%) of 1.65 as an orange oil:  1H NMR (400 MHz) δ 7.40-7.29 (comp, 9 
H), 7.16 (s, 1 H), 7.10 (s, 1 H), 6.91 (s, 1 H), 5.25 (s, 2 H), 4.81 (s, 4 H), 3.87 (s, 3 H);  13C 
NMR (101 MHz, cdcl3, rotomers) δ 159.9, 154.8, 142.3, 142.2, 140.8, 140.7, 137.5, 137.25, 
136.7, 136.1, 135.8, 129.8, 128.5, 128.0, 127.9, 126.7, 126.6, 123.0, 122.8, 121.5, 121.3, 
119.6, 119.61, 112.9, 112.8, 112.7, 112.7, 67.0, 55.3, 55.2, 52.5, 52.35, 52.1, 51.9; HRMS 
(ESI) m/z C21H24N2O3 (M+Na)
+ calcd for 382.1414; found 382.1416. 
NMR Assignment. 1H NMR (400 MHz) δ 7.40-7.29 (comp, 9 H,C4-H, C5-H, C7-
H, C12-h thru C16-H and C19-H), 7.16 (m, 1 H, C18-H), 7.10 (m, 1 H, C22-H), 6.91 (ddd, 
1 H, C20-H), 5.25 (s, 2 H, C10-H), 4.81 (comp, 4 H, C1-H and C2-H), 3.87 (s, 3 H, C23-
H);  13C NMR (101 MHz, rotomers) δ 159.9 (C21), 154.88 (C9), 142.3 (C17), 142.2 (C17), 
140.8 (C8), 140.7 (C8), 137.5 (C4), 137.2 (C4), 136.7 (C11), 136.1 (C6), 135.8 (C6), 129.8 
(C19), 128.5 (C13 and C15), 128.0 (C14), 127.9 (C12 and C16), 126.7 (C5), 126.6 (C5), 
123.0 (C7), 122.8 (C7), 121.5 (C4), 121.3 (C4), 119.6 (C18), 119.6 (C18), 112.9 (C22), 
112.8 (C22), 112.7 (C20), 112.7 (C20), 67.0 (C10), 55.3 (C23), 55.2 (C23), 52.5 (C1), 52.3 
(C1), 52.1 (C2), 51.9 (C2). 
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Benzyl 6-(3-methoxyphenyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
(1.69). KTL-02-139.  Prepared according to the representative procedure outlined for 
Suzuki cross-coupling. The crude material was purified by flash column chromatography 
eluting with EtOAc:hexanes (5:95) to give 40 mg (73%)  of 1.69 as a clear oil: 1H NMR 
(400 MHz) δ 7.44-7.35 (comp, 8 H), 7.18 (ddd, 1 H), 7.11 (s, 1 H), 6.90 (s, 1 H), 5.21 (s, 
2 H), 4.71 (s, 2 H), 3.87 (s, 3 H), 3.78 (br s, 2 H), 2.93 (br s, 2 H); 13C NMR (101 MHz, 
rotomers) δ 159.9, 155.5, 142.3, 139.5, 136.7, 135.0, 134.8, 132.7, 132.3, 129.8, 128.5, 
128.1, 127.5, 127.3, 126.8, 126.6, 125.2, 119.54, 112.8, 112.7, 67.3, 55.3, 45.6, 41.7, 41.4, 
29.2, 28.9; HRMS (ESI) m/z C21H24N2O3 (M+Na)
+ calcd for 396.1570; found 396.1574. 
NMR Assignment. 1H NMR (400 MHz) δ 7.44-7.35 (comp, 8 H, C5-H, C7-H, C8-
H, and C13-H thru C17-H), 7.18 (comp, 2 H, C19-H and C20-H), 7.11 (t, J = 2.4 Hz,  1 H, 
C23-H), 6.90 (ddd, 1 H, C21-H), 5.21 (s, 2 H, C11-H), 4.71 (s, 2 H, C1-H), 3.87 (s, 3 H, 
C24-H), 3.78 (br s, 2 H, C2-H), 2.93 (br s, 2 H, C3-H); 13C NMR (101 MHz, rotomers) δ 
159.9 (C22), 155.5 (C10), 142.3 (C18), 139.5 (C6), 136.7 (C12), 135.0 (C4), 134.8 (C4), 
132.7 (C9), 132.3 (C9), 129.8 (C20), 128.5 (C14 and C16), 128.1 (C13 and C17), 127.5 
(C5), 127.3 (C5), 126.8 (C7), 126.6 (C7), 125.2 (C15), 119.5 (C19), 112.8 (C23), 112.7 
(C21), 67.3 (C11), 55.3 (C24), 45.6 (C1), 41.7 (C2), 41.4 (C2), 29.2 (C3), 28.9 (C3). 
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Representative procedure for alkylation of piperazines with alkyl bromides 
 
Benzyl 5-(4-(2-methylallyl)piperazin-1-yl)isoindoline-2-carboxylate (1.79). KTL-01-
228.  NaH (14 mg, 0.30 mmol) and 3-bromo-2-methylpropene (47 mg, 0.35 mmol) were 
added to a solution of intermediate 1.67 (20 mg, 0.06 mmol) in THF (2.5 mL). The 
suspension was stirred at room temperature overnight. The reaction was quenched with 
aqueous NH4Cl
+
 (1 mL), the layers were separated, and the aqueous layer was extracted 
with CH2Cl2 (3 x 5 mL). The combined organic layers were dried (Na2SO4) and 
concentrated under reduced pressure. The crude material was purified via flash column 
chromatography eluting EtOAc:TEA:hexanes (15:1:84) to give 16.5 mg (71%) of 1.79 as 
a white solid: 1H NMR (400 MHz) δ 7.43 – 7.29 (comp, 5 H), 7.12 (dd, J =23.4, 8.4 Hz, 1 
H), 6.86 (t, J =5.3 Hz, 1 H), 6.79 (d, J =26.4 Hz, 1 H), 5.21 (s, 2 H), 4.91 (s, 1 H), 4.88 (s, 
1 H), 4.69 (t, J =10.5 Hz, 4 H), 3.17 (dd, J =10.2, 5.4 Hz, 4 H), 2.92 (s, 2 H), 2.57 – 2.51 
(m, 4 H), 1.77 (s, 3 H); 13C NMR (101 MHz, rotamers) δ 154.92, 154.88, 151.5, 142.5, 
137.9, 137.6, 136.9, 128.0, 127.85, 127.79, 127.6, 123.2, 123.0, 116.0, 115.9, 113.1, 110.1, 
109.9, 66.9, 65.3, 53.1, 52.8, 52.3, 52.1, 51.6, 49.6, 49.6, 20.9; HRMS (ESI) m/z  
C24H29N2O2 (M+H)
+ calcd for 392.2333; found 392.2334. 
NMR Assignment.  1H NMR (400 MHz) δ 7.43 – 7.29 (comp, 5 H, C12-H thru 
C16-H), 7.12 (dd, J =23.4, 8.4 Hz, 1 H, C3-H), 6.86 (t, J =5.3 Hz, 1 H, C2-H), 6.79 (d, J 
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=26.4 Hz, 1 H, C6-H), 5.21 (s, 2 H, C10-H), 4.91 (s, 1 H, C24-H), 4.88 (s, 1 H, C24-H), 
4.69 (comp, 4 H, C7-H and C8-H), 3.17 (dd, J =10.2, 5.4 Hz, 4 H, C17-H and C20-H), 
2.92 (s, 2 H, C21-H), 2.57 – 2.51 (m, 4 H, C18-H and C19-H), 1.77 (s, 3 H, C23-H); 13C 
NMR (101 MHz, rotamers) δ 154.92 (C9), 154.88 (C9), 151.5 (C1), 142.5 (C22), 137.9 
(C5), 137.6 (C5), 136.9 (C11), 128.6 (C13 and C15) 128.0 (C14), 127.85 (C4), 127.79 
(C12 and C16), 127.6 (C4) , 123.2 (C3), 123.0 (C3), 116.0 (C2), 115.9 (C2), 113.1 (C24), 
110.1 (C6), 109.9 (C6), 66.9 (C10), 65.3 (C21), 53.1 (C17 and C20), 52.8 (C7 or C8), 52.3 
(C7 or C8), 52.1 (C7 or C8), 51.6 (C7 or C8), 49.6 (C18 and C19), 49.6 (C18 and C19), 
20.9 (C23). 
 
Benzyl 7-(4-(2-methylallyl)piperazin-1-yl)-3,4-dihydroisoquinoline-2(1H)-
carboxylate (1.80). KTL-01-222.  Prepared according to the representative procedure 
outlined for alkylation of piperazines with alkyl bromides. The crude material was purified 
via column chromatography eluting with EtOAc:TEA:hexanes (5:1:94) to give 30 mg 
(53%) of 1.80 as a yellow oil:  1H NMR (400 MHz) δ 7.43-7.30 (comp, 5 H), 7.03 (d, J = 
8.6 Hz, 1 H), 6.79 (dd, J = 8.4, 2.3 Hz, 1 H), 6.65 (d, J = 20.9 Hz, 1 H), 5.18 (s, 2 H), 4.91 
(s, 1 H), 4.89 (s, 1 H), 4.61 (s, 2 H), 3.72 (br s, 2 H), 3.15 (t, J = 4.8 Hz, 4 H), 2.93 (s, 2 
H), 2.77 (br s, 2 H), 2.54 (t, J = 4.8 Hz, 4 H), 1.78 (s, 3 H); 13C NMR (101 MHz, rotomers) 
δ 155.5, 150.1, 142.5, 136.8, 133.9, 133.5, 129.4, 129.1, 128.5, 128.0, 127.9, 125.6, 125.4, 
114.9, 113.5, 113.3, 113.1, 67.1, 65.3, 53.1, 49.4, 46.1, 46.1, 42.0, 41.7, 28.1, 27.9, 20.9; 
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HRMS (ESI) m/z C21H24N2O3 (M+H)
+ calcd for 406.2489; found 406.2493; IR (neat) 2935, 
2816, 1702, 1508, 1431, 1232, 1104 cm-1. 
NMR Assignment. :  1H NMR (400 MHz) δ 7.43-7.30 (comp, 5 H, C13-H-C17-
H), 7.03 (d, J = 8.6 Hz, 1 H, C5-H), 6.79 (dd, J = 8.4, 2.3 Hz, 1 H, C6-H), 6.65 (d, J = 20.9 
Hz, 1 H, C8-H), 5.18 (s, 2 H, C11), 4.91 (s, 1 H, C25-H), 4.89 (s, 1 H, C25-H), 4.61 (s, 2 
H, C1-H), 3.72 (br s, 2 H, C2-H), 3.15 (t, J = 4.8 Hz, 4 H, C18-H and C19-H), 2.93 (s, 2 
H, C22-H), 2.77 (br s, 2 H, C3-H), 2.54 (t, J = 4.8 Hz, 4 H, C20-H and C21-H), 1.78 (s, 3 
H, C24-H); 13C NMR (101 MHz, rotomers) δ 155.5 (C10), 150.1 (C7), 142.5 (C23), 136.8 
(C12), 133.9 (C9), 133.5 (C9), 129.4 (C5), 129.1 (C5), 128.5 (C13 and C17), 128.0 (C14 
and C16), 127.9 (C15), 125.6 (C4), 125.4 (C4), 114.8 (C6), 113.5 (C8), 113.3 (C8), 113.1 
(C25), 67.1 (C11), 65.3 (C22), 53.1 (C20 and C21), 49.4 (C18 and C19), 46.1 (C1), 46.1 
(C1), 42.0 (C2), 41.7 (C2), 28.1 (C3), 27.9 (C3), 20.9 (C24). 
 
Benzyl 6-(4-(2-methylallyl)piperazin-1-yl)-3,4-dihydroisoquinoline-2(1H)-
carboxylate (1.112). KTL-02-071. Prepared according to the representative procedure 
outlined for alkylation of piperazines with alkyl bromides. The crude material was purified 
via flash column chromatography eluting with EtOAc:TEA:hexanes (10:1:89) to give 16 
mg (46%) of 1.112 as a yellow oil: 1H NMR (400 MHz) δ 7.29 (comp, 5 H), 6.99 (dd, J  = 
21.2, 9.3 Hz, 1 H), 6.79 (dd, J  = 8.3, 2.3 Hz, 1 H), 6.68 (s, 1 H), 5.17 (s, 2 H), 4.89 (d, J 
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=10.9 Hz, 2 H), 4.57 (s, 2 H), 3.69 (s, 2 H), 3.20 – 3.12 (comp, 4 H), 2.93 (s, 2 H), 2.80 (s, 
2 H), 2.57 – 2.49 (m, 4 H), 1.77 (s, 3 H); 13C NMR (101 MHz, rotamers) δ 155.5, 155.4, 
150.1, 142.4, 136.8, 135.3, 135.1, 128.5, 128.0, 127.0, 126.80 124.6, 124.1, 115.9, 115.7, 
114.7, 113.3, 113.2, 67.1, 65.3, 53.0, 49.3, 45.2, 41.7, 41.4, 29.4, 29.2, 21.0; HRMS (ESI) 
m/z  C25H31N3O2 (M+H)
+ calcd for 406.2489; found 406.2493. 
NMR Assignment. 1H NMR (400 MHz) δ 7.29 (comp, 5 H, C13-H thru C17-H), 
6.99 (dd, J  = 21.2, 9.3 Hz, 1 H, C3-H), 6.79 (dd, J  = 8.3, 2.3 Hz, 1 H, C2-H), 6.68 (s, 1 
H, C6)), 5.17 (s, 2 H, C11-H), 4.89 (d, J =10.9 Hz, 2 H, C25-H), 4.57 (s, 2 H, C9-H), 3.69 
(s, 2 H, C8-H), 3.20 – 3.12 (comp, 4 H, C18-H and C21-H), 2.93 (s, 2 H, C22-H), 2.80 (s, 
2 H, C8-H), 2.57 – 2.49 (m, 4 H, C19-H and C20-H), 1.77 (s, 3 H, C24-H); 13C NMR (101 
MHz, rotamers) δ 155.5 (C10), 155.4 (C10), 150.1 (C1), 142.4 (C23), 136.8 (C12), 135.3 
(C4), 135.1 (C4), 128.5 (C14 and C16), 128.0 (C13, C15, and C17), 127.0 (C3), 126.8 
(C3), 124.6 (C5), 124.1 (C5), 115.9 (C2), 115.7 (C2), 114.7 (C25), 113.3 (C6), 113.2 (C6), 
67.1 (C11), 65.3 (C22), 53.0 (C18 and C21), 49.3 (C19 and C20), 45.2 (C9), 41.7 (C8), 
41.4 (C8), 29.4 (C7), 29.2 (C7), 21.0 (C24). 
 
Benzyl 8-(4-(2-methylallyl)piperazin-1-yl)-1,3,4,5-tetrahydro-2H-benzo[c]azepine-2-
carboxylate (1.81). KTL-02-099. Prepared according to the representative procedure 
outlined for alkylation of piperazines with alkyl bromides. The crude material was purified 
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via flash column chromatography eluting with EtOAc:TEA:hexanes (10:1:89) to give 21 
mg (62%) of 1.81 as a clear oil: 1H NMR (400 MHz, rotamers) δ 7.27 (s, 5 H), 7.02 (d, J 
= 8.2 Hz, 1 H), 6.94 (d, J = 2.5 Hz, 0.35 H), 6.70 (dt, J = 8.2, 2.9 Hz, 1 H), 6.64 (d, J = 2.6 
Hz, 0.65 H), 5.06 (s, 0.70 H), 5.03 (s, 1.30 H), 4.94 – 4.85 (comp, 2 H), 4.44 (s, 0.70 H), 
4.39 (s, 1.30 H), 3.81 – 3.67 (comp , 2 H), 3.22 – 3.14 (comp, 1.50 H), 3.02 – 2.95 (comp, 
2.50 H), 2.91 (s, 2 H), 2.89-2.85 (comp, 2 H), 2.55 – 2.49 (comp, 1.50 H), 2.49 – 2.43 
(comp, 2.50 H), 1.82 – 1.70 (comp, 5 H); 13C NMR (101 MHz, rotamers) δ 155.5, 155.2, 
149.8, 149.7, 142.6, 138.8, 138.6, 136.9, 136.8, 132.7, 132.2, 130.1, 130.0, 128.4, 128.0, 
127.81, 127.78, 117.7, 117.3, 114.5, 114.2, 113.0, 67.2, 66.9, 65.3, 53.1, 53.1, 52.5, 51.0, 
50.3, 49.2, 34.4, 34.2, 28.9, 28.4, 20.9; HRMS (ESI) m/z  C26H33N3O2 (M+Na)
+ calcd for 
442.2465; found 442.2469. 
NMR Assignment. 1H NMR (400 MHz, rotamers) δ 7.27 (s, 5 H, C14-H thru C18-
H), 7.02 (d, J = 8.2 Hz, 1 H, C3-H), 6.94 (d, J = 2.5 Hz, 0.35 H, C6-H), 6.70 (dt, J = 8.2, 
2.9 Hz, 1 H, C2-H), 6.64 (d, J = 2.6 Hz, 0.65 H, C6-H), 5.06 (s, 0.70 H, C12-H), 5.03 (s, 
1.30 H, C12-H), 4.94 – 4.85 (comp, 2 H, C26-H), 4.44 (s, 0.70 H, C10-H), 4.39 (s, 1.30 H, 
C10-H), 3.81 – 3.67 (comp , 2 H, C9-H), 3.22 – 3.14 (comp, 1.50 H, C19-H and C22-H), 
3.02 – 2.95 (comp, 2.50 H, C19-H and C22-H), 2.91 (s, 2 H, C23-H), 2.89-2.85 (comp, 2 
H, C7-H), 2.55 – 2.49 (comp, 1.50 H, C20-H and C21-H), 2.49 – 2.43 (comp, 2.50 H, C20-
H and C21-H), 1.82 – 1.70 (comp, 5 H, C8-H and C25-H); 13C NMR (101 MHz, rotamers) 
δ 155.45 (C11), 155.21 (C11), 149.78 (C1), 149.66 (C1), 142.60 (C24), 138.84 (C5), 
138.63 (C5), 136.92 (C13), 136.75 (C13), 132.70 (C4), 132.23 (C4), 130.14 (C3), 130.02 
(C3), 128.40 (C17 and C15), 127.95 (C14 and C18), 127.81 (C14 and C18), 127.78 (C16), 
 115 
117.72 (C2), 117.34 (C2), 114.54 (C6), 114.19 (C6), 112.96 (C26), 67.23 (C12), 66.91 
(C12), 65.31 (C23), 53.13 (C10), 53.10 (C19 and C22), 52.54 (C10), 50.97 (C9), 50.32 
(C9), 49.17 (C20 and C21), 34.37 (C7), 34.25 (C7), 28.91 (C8), 28.43 (C8), 20.89 (C25). 
 
Benzyl 7-(4-(2-methylallyl)piperazin-1-yl)-1,3,4,5-tetrahydro-2H-benzo[c]azepine-2-
carboxylate (1.116). KTL-02-101. Prepared according to the representative procedure 
outlined for alkylation of piperazines with alkyl bromides. The crude material was purified 
via flash column chromatography eluting with EtOAc:TEA:hexanes (10:1:89) to give 19 
mg (50%) of 1.116 as a clear oil: 1H NMR (400 MHz, rotamers) δ 7.37-7.29 (comp, 5 H), 
7.22 (d, J = 8.1 Hz, 0.40 H), 6.99 (d, J = 8.2 Hz, 0.60 H), 6.74 (s, 1 H), 6.69 (dd, J = 8.2, 
2.4 Hz, 0.40 H), 6.62 (dd, J = 8.2, 2.5 Hz, 0.60 H), 5.05 (s, 2 H), 4.91 (s, 1 H), 4.88 (s, 1 
H), 4.41 (s, 0.80 H), 4.38 (s, 1.2 H), 3.72 (s, 2 H), 3.24 – 3.13 (comp, 4 H), 2.92-2.89 
(comp, 4 H), 2.56 – 2.46 (comp, 4 H), 1.83-1.72 (comp, 5 H); 13C NMR (101 MHz, 
rotamers) δ 155.5, 155.2, 150.8, 142.61, 142.58, 142.2, 136.9, 130.3, 130.0, 129.3, 129.1, 
128.4, 128.3, 127.80, 127.75, 117.4, 113.03, 112.99, 112.6, 67.0, 66.8, 65.3, 53.1, 51.9, 
51.3, 50.6, 50.1, 49.1, 35.8, 35.7, 28.8, 28.2, 20.9; LRMS (ESI+APCI) m/z  C26H33N3O2 
(M+H)+ calcd for 420.26; found 420.3. 
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NMR Assignment. 1H NMR (400 MHz, rotamers) δ 7.37-7.29 (comp, 5 H, C14-
H thru C18-H), 7.22 (d, J = 8.1 Hz, 0.40 H, C6-H), 6.99 (d, J = 8.2 Hz, 0.60 H, C6-H), 
6.74 (s, 1 H, C3-H), 6.69 (dd, J = 8.2, 2.4 Hz, 0.40 H, C1-H), 6.62 (dd, J = 8.2, 2.5 Hz, 
0.60 H, C1-H), 5.05 (s, 2 H, C12-H), 4.91 (s, 1 H, C25-H), 4.88 (s, 1 H, C25-H), 4.41 (s, 
0.80 H, C10-H), 4.38 (s, 1.2 H, C10-H), 3.72 (s, 2 H, C9-H), 3.24 – 3.13 (comp, 4 H, C19-
H and C22-H), 2.92-2.89 (comp, 4 H, C7-H and C32-H), 2.56 – 2.46 (comp, 4 H, C20-H 
and C21-H), 1.83-1.72 (comp, 5 H, C8-H and C26-H); 13C NMR (101 MHz, rotamers) δ 
155.49 (C11), 155.21 (C11), 150.82 (C2), 142.61 (C4), 142.58 (C24), 142.22 (C4), 136.94 
(C13), 130.30 (C6), 130.01 (C6), 129.34 (C5), 129.12 (C5), 128.38 (C15 and C17), 128.33 
(C15 and C17), 127.80 (C14 and C18), 127.75 (C16), 117.36 (C3), 113.03 (C25), 
112.99(C1), 112.65 (C1), 67.00 (C12), 66.85 (C12), 65.33 (C23), 53.13 (C19 and C22), 
51.92 (C10), 51.34 (C10), 50.65 (C9), 50.11 (C9), 49.14 (C20 and C21), 35.80 (C7), 35.72 
(C7), 28.79 (C8), 28.25 (C8), 20.90 (C26). 
 
Benzyl 5-(4-allylpiperazin-1-yl)isoindoline-2-carboxylate (1.82). KTL-01-270. 
Prepared according to the representative procedure outlined for alkylation of piperazines 
with alkyl bromides. The crude material was purified via flash column chromatography 
eluting EtOAc:TEA:hexanes (15:1:84) to give 60 mg (74%) of 1.82 as a yellow solid: 1H 
NMR (400 MHz, CDCl3) δ 7.36 (d, J =48.7 Hz, 5 H), 7.12 (dd, J =23.4, 8.4 Hz, 1 H), 6.86 
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(d, J =17.0 Hz, 1 H), 6.79 (d, J =25.9 Hz, 1 H), 5.86 (s, 1 H), 5.29 (s, 2 H), 5.27 – 5.17 
(comp, 4 H), 4.69 (t, J =10.4 Hz, 4 H), 3.20 (dd, J =10.1, 5.6 Hz, 4 H), 3.08 (d, J =6.6 Hz, 
2 H), 2.65 – 2.60 (comp, 4 H); LRMS (ESI+APCI) m/z  C23H27N3O2 (M+H)+ calcd for 
378.22; found 378.2. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.36 (d, J =48.7 Hz, 5 H, C12-
H thru C16-H), 7.12 (m, 1 H, C3-H), 6.86 (d, J =17.0 Hz, 1 H, C2-H), 6.79 (d, J =25.9 Hz, 
1 H, C6-H), 5.86 (m, 1 H, C22-H), 5.29 (s, 2 H, C10-H), 5.27 – 5.17 (comp, 2 H, C23-H), 
4.69 (t, J =10.4 Hz, 4 H, C7-H and C8-H), 3.20 (dd, J =10.1, 5.6 Hz, 4 H, C17-H and C20-
H), 3.08 (d, J =6.6 Hz, 2 H, C21-H), 2.65 – 2.60 (comp, 4 H, C18-H and C19-H). 
 
Benzyl 6-(4-allylpiperazin-1-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (1.83). 
KTL-01-236.  Prepared according to the representative procedure outlined for alkylation 
of piperazines with alkyl bromides. The crude material was purified via flash column 
chromatography eluting EtOAc:TEA:hexanes (15:1:84) to give 56 mg (65%) of 1.83 as a 
clear oil:  1H NMR (400 MHz) δ 7.42 (comp, 5 H), 7.03 (d, J =7.6 Hz, 1 H), 6.79 (d, J 
=8.4 Hz, 1 H), 6.65 (d, J =21.7 Hz, 1 H), 5.90 (m, 1 H), 5.23 (comp, 2 H), 5.18 (s, 2 H), 
4.61 (s, 2 H), 3.71 (s, 2 H), 3.22 – 3.12 (comp, 4 H), 3.06 (d, J =6.6 Hz, 2 H), 2.77 (s, 2 
H), 2.66 – 2.56 (comp, 4 H); 13C NMR (101 MHz) δ 155.5, 149.9, 136.8, 134.8, 134.0, 
133.6, 129.4, 129.0, 128.5, 128.0, 127.9, 125.8, 125.6, 118.3, 115.0, 115.0, 113.6, 113.3, 
61.8, 53.0, 49.4, 46.1, 46.0, 42.0, 41.7, 28.1, 27.9; 
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NMR Assignment. 1H NMR (400 MHz) δ 7.42 (comp, 5 H, C13-H thru C17-H), 
7.03 (d, J =7.6 Hz, 1 H, C6-H), 6.79 (d, J =8.4 Hz, 1 H, C1-H), 6.65 (d, J =21.7 Hz, 1 H, 
C3-H), 5.90 (m, 1 H, C23-H), 5.23 (comp, 2 H, C24-H), 5.18 (s, 2 H, C11-H), 4.61 (s, 2 
H, C7-H), 3.71 (s, 2 H, C9-H), 3.22 – 3.12 (comp, 4 H, C18-H and C21-H), 3.06 (d, J =6.6 
Hz, 2 H, C22-H), 2.77 (s, 2 H, C8-H), 2.66 – 2.56 (comp, 4 H, C19-H and C20-H); 13C 
NMR (101 MHz) δ 155.5 (C10), 149.9 (C2), 136.8 (C12), 134.8 (C23), 134.0 (C4), 133.6 
(C4), 129.4 (C6), 129.0 (C6), 128.5 (C13 and C17), 128.0 (C14 and C16), 127.9 (C15), 
125.8 (C5), 125.6 (C5), 118.3 (24), 115.0 (C1), 113.6 (C3), 113.3 (C3), 61.8 (C11), 53.0 
(C22), 49.4 (C18 and C21), 46.1 (C19 and C20), 46.0 (C7), 42.0 (C9), 41.7 (C9), 28.1 (C8), 
27.9 (C8).  
 
Benzyl 6-(4-allylpiperazin-1-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (1.111). 
KTL-02-072. Prepared according to the representative procedure outlined for alkylation 
of piperazines with alkyl bromides. The crude material was purified via flash column 
chromatography eluting with EtOAc:TEA:hexanes (15:1:84) to give 14 mg (43%) of 1.111 
as a yellow oil: 1H NMR (400 MHz) δ 7.41-7.29 (comp, 5 H), 7.00 (dd, J  = 19.6, 8.7 Hz, 
1 H), 6.79 (dd, J  = 8.2, 2.0 Hz, 1 H), 6.68 (s, 1 H), 5.91 (ddt, J  = 16.8, 10.1, 6.6 Hz, 1 H), 
5.27 – 5.19 (comp, 2 H), 5.17 (comp, 3 H), 4.57 (s, 2 H), 3.70 (s, 2 H), 3.22 – 3.14 (comp, 
4H), 3.07 (d, J =6.5 Hz, 2H), 2.80 (s, 2H), 2.66 – 2.57 (comp, 4 H); 13C NMR (101 MHz, 
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rotamers) δ 155.6, 155.4, 149.9, 136.8, 135.3, 135.1, 134.5, 128.5, 128.0, 127.9, 127.0, 
126.8, 124.8, 124.3, 118.5, 115.9, 115.7, 114.8, 114.7, 67.1, 61.7, 52.8, 49.2, 45.2, 41.7, 
41.4, 29.4, 29.2; HRMS (ESI) m/z  C24H29N3O2 (M+H)
+ calcd for 392.2333; found 
392.2334. 
NMR Assignment. 1H NMR (400 MHz) δ 7.41-7.29 (comp, 5 H, C13-H thru C17-
H), 7.00 (dd, J  = 19.6, 8.7 Hz, 1 H, C3-H), 6.79 (dd, J  = 8.2, 2.0 Hz, 1 H, C2-H), 6.68 (s, 
1 H, C6-H), 5.91 (ddt, J  = 16.8, 10.1, 6.6 Hz, 1 H, C23-H), 5.27 – 5.19 (comp, 2 H, C24-
H), 5.17 (comp, 3 H, C11-H and C24-H), 4.57 (s, 2 H, C9-H), 3.70 (s, 2 H, C8-H), 3.22 – 
3.14 (comp, 4H, C18-H and C21-H), 3.07 (d, J =6.5 Hz, 2H, C22-H), 2.80 (s, 2H, C7-H), 
2.66 – 2.57 (comp, 4 H, C19-H and C20-H); 13C NMR (101 MHz, rotamers) δ 155.5 (C10), 
155.4 (C10), 149.9 (C1), 136.8 (C12), 135.3 (C4), 135.1 (C4), 134.5 (C23), 128.5 (C14 
and C16), 128.0 (C13 and C16), 127.9 (C15), 127.0 (C3), 126.8 (C3), 124.8 (C5), 124.3 
(C5), 118.5 (C24), 115.9 (C2), 115.7 (C2), 114.8 (C6), 114.7 (C6), 67.1 (C11), 61.7 (C22), 
53.0 (C18 and C21), 49.2 (C19 and C20), 45.2 (C9), 41.7 (C8), 41.4 (C8), 29.4 (C7), 29.2 
(C7). 
 
Benzyl 8-(4-allylpiperazin-1-yl)-1,3,4,5-tetrahydro-2H-benzo[c]azepine-2-
carboxylate (1.84). KTL-02-038. Prepared according to the representative procedure 
outlined for alkylation of piperazines with alkyl bromides. The crude material was purified 
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via flash column chromatography eluting with EtOAc:TEA:hexanes (10:1:89) to give 21 
mg (44%) of 1.84 as a clear oil: 1H NMR (400 MHz, rotamers) δ 7.37 – 7.27 (comp, 5 H), 
7.02 (d, J = 8.2 Hz, 1 H), 6.95 (d, J = 2.6 Hz, 0.35 H), 6.71 – 6.67 (comp, 1 H), 6.65 (d, J 
= 2.7 Hz, 0.60 H), 5.90 (ddt, J = 16.8, 10.2, 6.6 Hz, 1 H), 5.27 – 5.15 (comp, 2 H), 5.06 (s, 
0.75 H), 5.03 (s, 1.25 H), 4.44 (s, 0.75 H), 4.39 (s, 1.25 H), 3.80 – 3.68 (comp, 2 H), 3.27 
– 3.17 (comp, 1.50 H), 3.05 (dt, J = 6.6, 1.3 Hz, 2 H), 3.03 – 2.97 (comp, 2.50 H), 2.90 – 
2.83 (comp, 2 H), 2.62 – 2.57 (comp, 1.50 H), 2.56 – 2.50 (comp, 2.5 H), 1.83 – 1.68 (m, 
2 H); LRMS (ESI+APCI) m/z  C25H31N3O2 (M+H)
+ calcd for 406.55; found 406.3. 
 NMR Assignment. 1H NMR (400 MHz, rotamers) δ 7.37 – 7.27 (comp, 5 H, C14-
H thru C18-H), 7.02 (d, J = 8.2 Hz, 1 H, C3-H), 6.95 (d, J = 2.6 Hz, 0.35 H, C6-H), 6.71 – 
6.67 (comp, 1 H, C2-H and C6-H), 6.65 (d, J = 2.7 Hz, 0.60 H, C6-H), 5.90 (ddt, J = 16.8, 
10.2, 6.6 Hz, 1 H, C28-H), 5.27 – 5.15 (comp, 2 H, C25-H), 5.06 (s, 0.75 H, C12-H), 5.03 
(s, 1.25 H, C12-H), 4.44 (s, 0.75 H, C10-H), 4.39 (s, 1.25 H, C10-H), 3.80 – 3.68 (comp, 
2 H, C9-H), 3.27 – 3.17 (comp, 1.50 H, C19-H and C22-H), 3.05 (dt, J = 6.6, 1.3 Hz, 2 H, 
C23-H), 3.03 – 2.97 (comp, 2.50 H, C19-H and C22-H), 2.90 – 2.83 (comp, 2 H, C7-H), 
2.62 – 2.57 (comp, 1.50 H, C20-H and C21-H), 2.56 – 2.50 (comp, 2.5 H, C20-H and C21-
H), 1.83 – 1.68 (m, 2 H, C8-H).  
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Benzyl 7-(4-allylpiperazin-1-yl)-1,3,4,5-tetrahydro-2H-benzo[c]azepine-2-
carboxylate (1.115). KTL-02-102. Prepared according to the representative procedure 
outlined for alkylation of piperazines with alkyl bromides. The crude material was purified 
via flash column chromatography eluting with EtOAc:TEA:hexanes (10:1:89) to give 20 
mg (51%) of 1.115 as a clear oil: 1H NMR (400 MHz, rotamers) δ 7.38 – 7.28 (comp, 5 
H), 7.24 (d, J = 8.2 Hz, 0.35 H), 6.99 (d, J = 8.2 Hz, 0.65 H), 6.74 (d, J = 2.4 Hz, 1 H), 
6.69 (dd, J = 8.2, 2.6 Hz, 0.65 H), 6.62 (dd, J = 8.2, 2.6 Hz, 0.65 H), 5.96 – 5.84 (m, 1 H), 
5.27 – 5.16 (comp, 2 H), 5.05 (s, 2 H), 4.41 (s, 0.80 H), 4.38 (s, 1.20 H), 3.77–3.68 (comp, 
2 H), 3.22–2.17 (comp, 4 H), 3.08-3.02 (comp, 2 H), 2.93 – 2.87 (comp, 2 H), 2.63 – 2.57 
(comp, 4 H), 1.85 – 1.71 (comp, 2 H); 13C NMR (126 MHz, rotamers) δ 155.6, 155.4, 150.8, 
142.8, 142.4, 137.09, 137.06, 134.9, 130.5, 130.2, 129.7, 129.5, 128.5, 128.5, 127.95, 
127.92, 118.4, 117.6, 113.2, 112.9, 67.2, 67.0, 61.9, 53.2, 52.1, 51.5, 50.8, 50.3, 49.2, 36.0, 
35.9, 28.9, 28.4; LRMS (ESI+APCI) m/z  C25H31N3O2 (M+H)+¬ calcd for 406.55; found 
406.3.  
NMR Assignment. 1H NMR (400 MHz, rotamers) δ 7.38 – 7.28 (comp, 5 H, C14-
H thru C18-H), 7.24 (d, J = 8.2 Hz, 0.35 H, C6-H), 6.99 (d, J = 8.2 Hz, 0.65 H, C6-H), 
6.74 (d, J = 2.4 Hz, 1 H, C3-H), 6.69 (dd, J = 8.2, 2.6 Hz, 0.65 H, C1-H), 6.62 (dd, J = 8.2, 
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2.6 Hz, 0.65 H, C1-H), 5.96 – 5.84 (m, 1 H, C29-H), 5.27 – 5.16 (comp, 2 H, C30-H), 5.05 
(s, 2 H, C12-H), 4.41 (s, 0.80 H, C10-H), 4.38 (s, 1.20 H, C10-H), 3.77–3.68 (comp, 2 H, 
C9-H), 3.22–2.17 (comp, 4 H, C19-H and C22-H), 3.08-3.02 (comp, 2 H, C28-H), 2.93 – 
2.87 (comp, 2 H, C7-H), 2.63 – 2.57 (comp, 4 H, C20-H and C21-H), 1.85 – 1.71 (comp, 
2 H, C8-H); 13C NMR (126 MHz, rotamers) δ 155.6 (C11), 155.4 (C11), 150.8 (C20), 142.8 
(C4), 142.4 (C4), 137.09 (C13), 137.06 (C13), 134.9 (C29), 130.5 (C6), 130.2 (C6), 129.7 
(C5), 129.5 (C5), 128.5 (C15 and C17), 128.5 (C15 and C17), 127.95 (C14 and C18), 
127.92 (C16), 118.4 (C3), 117.6 (C30), 113.2 (C1), 112.9 (C1), 67.2 (C12), 67.0 (C12), 
61.9 (C28), 53.2 (C19 and C22), 52.1 (C10), 51.5 (C10), 50.8 (C9), 50.3 (C9), 49.2 (C20 
and C21), 36.0 (C7), 35.9 (C7), 28.9 (C8), 28.4 (C8).  
Representative procedure for reductive alkylation of piperazines 
 
Benzyl 8-(4-cyclopentylpiperazin-1-yl)-1,3,4,5-tetrahydro-2H-benzo[c]azepine-2-
carboxylate (1.87). KTL-02-037. A solution of intermediate 1.76 (25 mg, 0.07 mmol), 
NaBH(OAc)3 (44 mg, 0.21 mmol), cyclopentanone (19 mg, 0.22 mmol) and 10 μL AcOH 
was stirred for 4 h at room temperature. The reaction was quenched with an aqueous 
solution of sat. NaHCO3 (1 mL) and the layers were separated. The aqueous layer was 
extracted with CH2Cl2 (3 x 5 mL). The combined organic extracts were dried (K2CO3) and 
concentrated under reduced pressure. The crude material was purified via flash column 
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chromatography eluting EtOAc:TEA:hexanes (25:1:74) to give 22 mg (81%) of 1.87 as a 
clear oil: 1H NMR (400 MHz, rotamers) δ 7.27 (s, 5 H), 7.02 (d, J =8.1 Hz, 1 H), 6.94 (d, 
J =2.4 Hz, 0.37 H), 6.71 – 6.67 (m, 1 H), 6.65 (d, J =2.5 Hz, 0.63 H), 5.05 (s, 0.7 H), 5.03 
(s, 1.3 H), 4.44 (s, 0.7 H), 4.39 (s, 1.3 H), 3.80 (comp, 2 H), 3.23 – 3.17 (m, 1.5 H), 3.05 – 
2.98 (m, 2.5 H), 2.87 (comp, 2H), 2.67 – 2.62 (m, 1.5 H), 2.61 – 2.56 (m, 2.5 H), 2.56-2.48 
(m, 1 H), 1.95 – 1.86 (comp, 2 H), 1.81-1.66 (comp, 4 H), 1.60 – 1.53 (comp, 2 H), 1.50-
1.39 (comp, 2 H); 13C NMR (101 MHz, rotamers) δ 155.4, 155.2, 149.6, 149.5, 138.9, 
138.6, 136.9, 136.8, 132.8, 132.4, 130.2, 130.0, 128.4, 127.9, 127.79, 127.76, 117.7, 117.4, 
114.3, 114.0, 67.7, 67.51, 67.48, 67.2, 66.9, 53.0, 52.5, 52.4, 52.3, 50.9, 50.3, 49.1, 49.0, 
34.4, 34.3, 30.4, 29.7, 28.9, 28.4, 24.2; HRMS (ESI) m/z  C27H35N3O2 (M+H)
+ calcd for 
434.2802; found 434.2805. 
NMR Assignment. 1H NMR (400 MHz, rotamers) δ 7.27 (s, 5 H, C14-H thru C18-
H), 7.02 (d, J =8.1 Hz, 1 H, C3-H), 6.94 (d, J =2.4 Hz, 0.37 H, C6-H), 6.71 – 6.67 (m, 1 
H, C2-H), 6.65 (d, J =2.5 Hz, 0.63 H, C6-H), 5.05 (s, 0.7 H, C12-H), 5.03 (s, 1.3 H, C12-
H), 4.44 (s, 0.7 H, C10-H), 4.39 (s, 1.3 H, C10-H), 3.80 (comp, 2 H, C9-H), 3.23 – 3.17 
(m, 1.5 H, C19-H and C22-H), 3.05 – 2.98 (m, 2.5 H, C19-H and C22-H), 2.87 (comp, 2H, 
C7-H), 2.67 – 2.62 (m, 1.5 H, C20-H and C21-H), 2.61 – 2.56 (m, 2.5 H, C20-H and C21-
H), 2.56-2.48 (m, 1 H, C23-H), 1.95 – 1.86 (comp, 2 H, C24-H or C27-H), 1.81-1.66 
(comp, 4 H, C8-H and C24-H or C27-H), 1.60 – 1.53 (comp, 2 H, C25-H or C26-H), 1.50-
1.39 (comp, 2 H, C25-H or C26-H); 13C NMR (101 MHz, rotamers) δ 155.43 (C11), 155.20 
(C11), 149.62 (C1), 149.48 (C1), 138.85 (C5), 138.65 (C5), 136.92 (C13), 136.81 (C13), 
132.78 (C3), 132.36 (C3), 130.16 (C4), 130.04 (C4), 128.38 (C15 and C17), 127.89 (C14 
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and C18), 127.79 (C16), 127.76 (C14 and C18), 117.86 (C2), 117.39 (C2), 114.30 (C3), 
114.03 (C3), 67.51 (C23), 67.48 (C23), 67.17 (C12), 66.91 (C12), 53.04 (C10), 52.52 
(C10), 52.37 (C19 and C22), 52.32 (C19 and C22), 50.94 (C9), 50.30 (C9), 49.07 (C20 and 
C21), 49.03 (C20 and C21), 34.35 (C7), 34.25 (C7), 30.43 (C24 and C27), 29.68 (C24 and 
C27), 28.90 (C8), 28.41 (C8), 24.15 (C25 and C26). 
 
Benzyl 5-(4-cyclopentylpiperazin-1-yl)isoindoline-2-carboxylate (1.85). KTL-01-227. 
Prepared according to the representative procedure outlined for reductive alkylation of 
piperazines. The crude material was purified via flash column chromatography eluting 
EtOAc:TEA:hexanes (25:1:74) to give 23 mg (71%) of 1.85 as a white solid: 1H NMR (400 
MHz) δ 7.44 – 7.29 (comp, 5 H), 7.12 (dd, J  = 23.4, 8.4 Hz, 1 H), 6.89 – 6.84 (m, 1 H), 
6.79 (d, J =25.9 Hz, 1H), 5.21 (s, 2 H), 4.69 (t, J =10.8 Hz, 4 H), 3.19 (comp, 4 H), 2.70 
– 2.63 (comp, 4 H), 2.53 (d, J =35.1 Hz, 1 H), 1.96 (comp, 2 H), 1.66 (comp, 2 H), 1.64 
(comp, 2 H), 1.50 (comp, 2 H); 13C NMR (101 MHz, rotamers) δ 154.9, 154.9, 151.4, 
138.0, 137.6, 136.9, 128.5, 128.0, 127.9, 127.8, 127.7, 123.2, 123.0, 116.0, 115.8, 110.1, 
109.9, 67.4, 66.9, 52.7, 52.3, 52.1, 51.6, 49.6, 49.5, 30.5, 24.2; HRMS (ESI) m/z 
C25H31N3O2 (M+H)
+ calcd for 406.2489; found 406.2496. 
NMR Assignment. 1H NMR (400 MHz) δ 7.44 – 7.29 (comp, 5 H, C12-H thru 
C16-H), 7.12 (dd, J =23.4, 8.4 Hz, 1 H, C3-H), 6.89 – 6.84 (m, 1 H, C2-H), 6.79 (d, J 
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=25.9 Hz, 1 H, C1-H), 5.21 (s, 2 H, C10-H), 4.69 (t, J =10.8 Hz, 4 H, C7-H and C8-H), 
3.19 (comp, 4 H, C17-H and C20-H), 2.70 – 2.63 (comp, 4 H, C18-H and C19-H), 2.53 (d, 
J =35.1 Hz, 1 H, C22-H), 1.96 (comp, 2 H, C21-H or C23-H), 1.66 (comp, 2 H, C21-H or 
C23-H), 1.64 (comp, 2 H, C24-H or C25-H), 1.50 (comp, 2 H, C24-H or C25-H); 13C NMR 
(101 MHz, rotamers) δ 154.91 (C9), 154.87 (C9), 151.4 (C1), 138.0 (C5), 137.6 (C5), 136.9 
(C11), 128.5 (C13 and C15), 128.0 (C14), 127.9 (C4), 127.8 (C12 and C16), 127.7 (C4), 
123.2 (C3), 123.0 (C3), 116.0 (C2), 115.8 (C2), 110.1 (C6), 109.9 (C6), 67.4 (C22), 66.9 
(C10), 52.7 (C8), 52.3 (C17 and C20), 52.1 (C7), 51.6 (C7), 49.6 (C18 and C19),  49.5 
(C18 and C19),  30.5 (C21 and C23), 24.2 (C24 and C25).  
 
Benzyl 7-(4-cyclopentylpiperazin-1-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
(1.86).  KTL-01-214.  Prepared according to the representative procedure outlined for 
reductive alkylation of piperazines. The crude material was purified via flash column 
chromatography eluting with EtOAc:TEA:hexanes (10:1:89) to give 21 mg (44%)  of 1.86 
as a clear oil:  1H NMR (400 MHz) δ 7.40-7.28 (comp, 5 H), 7.01 (d, J = 8.4, 1 H), 6.78 
(dd, J = 8.4, 2 Hz, 1 H), 6.64 (d, J = 21.5 Hz, 1 H), 5.17 (s, 2 H), 4.60 (s, 2 H), 3.70 (br s, 
2 H), 3.17 (t, J = 4.8, 4 H), 2.77 (br s, 2 H), 2.65 (t, J = 4.8, 4 H), 2.58-2.47 (m, 1 H), 1.96-
1.82 (comp, 2 H), 1.77-1.70 (comp, 2 H), 1.63-1.50 (comp, 2 H), 1.4-1.37  (comp, 2 H); 
13C NMR (101 MHz, rotomers) δ 155.5, 149.9, 136.8, 134.0, 133.5, 129.4, 129.1, 128.5, 
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127.9, 127.9, 125.8, 125.7, 114.9, 113.6, 113.3, 67.5, 67.1, 52.3, 49.4, 46.1, 46.0, 41.9, 
41.7, 30.5, 28.1, 27.8, 24.2; HRMS (ESI) m/z C21H24N2O3 (M+Na)
+ calcd for 442.2465; 
found 442.2468; IR (neat) 2926, 2857, 2763, 1702, 1508, 1450, 1429, 1242, 1101 cm-1. 
NMR Assignment.  1H NMR (400 MHz) δ 7.40-7.28 (comp, 5 H C13-H-C17-H), 
7.01 (d, J = 8.4, 1 H, C5-H), 6.78 (dd, J = 8.4, 2 Hz, 1 H, C6-H), 6.64 (d, J = 21.5 Hz, 1 H, 
C8-H), 5.17 (s, 2 H, C11-H), 4.60 (s, 2 H, C1-H), 3.70 (br s, 2 H, C3-H), 3.17 (t, J = 4.8, 4 
H, C20-H and C21-H), 2.77 (br s, 2 H, C2-H), 2.65 (t, J = 4.8, 4 H, C18-H and C19-H), 
2.58-2.47 (m, 1 H, C22-H), 1.96-1.82 (comp, 2 H, C26-H or C23-H), 1.77-1.70 (comp, 2 
H, C26-H or C23-H), 1.63-1.50 (comp, 2 H, C24-H or C25-H), 1.4-1.37 (comp, 2 H, C24-
H or C25-H); 13C NMR (101 MHz, rotomers) δ 155.5 (C10), 149.9 (C7), 136.8 (C12), 
134.0 (C9), 133.5 (C9), 129.4 (C5), 129.1 (C5), 128.5 (C13 and C17), 127.9 (C14 and 16), 
127.9 (C15), 125.6 (C4), 125.7 (C4), 114.9 (C6), 113.6 (C8), 113.3 (C8), 67.5 (C22), 67.1 
(C11), 52.3 (C20 and C21), 49.4 (C18 and C19), 46.1 (C1), 46.0 (C1), 41.9 (C2), 41.7 (C2), 
30.5 (C23 and C26), 28.1 (C3), 27.8 (C3), 24.2 (C24 and C25). 
 
Benzyl 8-(4-cyclopentylpiperazin-1-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
(1.121).  KTL-02-113.  Prepared according to the representative procedure outlined for 
reductive alkylation of piperazines. The crude material was purified via flash column 
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chromatography eluting with EtOAc:TEA:hexanes (10:1:89) to give 29 mg (72%)  of 1.212 
as a clear oil: 1H NMR (400 MHz) δ 7.43 – 7.28 (comp, 5 H), 7.17 (t, J = 7.7 Hz, 1 H), 
6.99 (d, J = 8.0 Hz, 1 H), 6.90 (s, 1 H), 5.18 (s, 2 H), 4.67 (s, 2 H), 3.68 (t, J = 6.2 Hz, 2 
H), 3.01 – 2.79 (comp, 7 H), 2.61 (comp, 4 H), 1.94 – 1.84 (comp, 2 H), 1.72 (br s, 2 H), 
1.58 (br s, 2 H), 1.43 (ddd, J = 11.9, 5.9, 2.8 Hz, 2 H); 13C NMR (126 MHz, rotamers) δ 
155.6, 150.4, 150.0, 137.1, 136.3, 136.0, 129.3, 129.0, 128.6, 128.1, 128.0, 127.6, 127.3, 
124.1, 124.0, 117.8, 67.7, 67.1, 53.0, 52.9, 52.4, 42.5, 42.3, 41.8, 30.6, 29.5, 29.1, 24.3; 
LRMS (ESI+APCI) m/z  C21H24N2O3 (M+H)
+ calcd for 420.27; found 420.3. 
 NMR Assignment. 1H NMR (400 MHz) δ 7.43 – 7.28 (comp, 5 H, C16-H thru 
C20-H), 7.17 (t, J = 7.7 Hz, 1 H, C1-H), 6.99 (d, J = 8.0 Hz, 1 H, C6-H), 6.90 (s, 1 H, C2-
H), 5.18 (s, 2 H, C14-H), 4.67 (s, 2 H, C7-H), 3.68 (t, J = 6.2 Hz, 2 H, C9-H), 3.01 – 2.79 
(comp, 7 H, C10-H, C22-H, C26-H and C27-H), 2.61 (comp, 4 H, C13-H and C25-H), 1.94 
– 1.84 (comp, 2 H, C28-H), 1.72 (br s, 2 H, C29-H), 1.58 (br s, 2 H, C30-H), 1.43 (ddd, J 
= 11.9, 5.9, 2.8 Hz, 2 H, C31-H); 13C NMR (126 MHz, rotamers) δ 155.6 (C11), 150.4 
(C3), 150.0 (C3), 137.1 (C15), 136.3 (C5, 136.0 (C5), 129.3 (C4), 129.0 (C4), 128.6 (C17 
and C19), 128.1 (C16 and C20), 128.0 (C16 and C20), 127.6 (C15), 127.3 (C1), 124.1 
(C2), 124.0 (C2), 117.8 (C6), 67.7 (C27), 67.1 (C14), 53.0 (C23 and C25), 52.9 (C23 and 
C25), 52.4 (C22 and C26), 42.5 (C7), 42.3 (C7), 41.8 (C9), 30.6 (C28 and C31), 29.5 (C10), 
29.1 (C10), 24.3 (C29 and C30).  
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Benzyl 7-(4-cyclobutylpiperazin-1-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
(1.117). KTL-02-068. Prepared according to the representative procedure outlined for 
reductive alkylation of piperazines. The crude material was purified via flash column 
chromatography eluting with EtOAc:TEA:hexanes (15:1:84) to give 31 mg (73%) of 1.117 
as a clear oil: 1H NMR (400 MHz) δ 7.40 – 7.27 (comp, 5 H), 7.01 (d, J  = 7.5 Hz, 1 H), 
6.76 (dd, J  = 8.3, 1.9 Hz, 1 H), 6.63 (d, J  = 21.8 Hz, 1 H), 5.15 (s, 2 H), 4.59 (s, 2 H), 3.69 
(s, 2 H), 3.19 – 3.09 (comp, 4 H), 2.83-2.69 (comp, 3 H), 2.52 – 2.43 (comp, 4 H), 2.08-
2.01 (comp, 2 H), 1.97 – 1.84 (comp, 2 H), 1.77 – 1.63 (comp, 2 H); 13C NMR (101 MHz) 
δ 155.5, 150.0, 136.8, 136.7, 134.0, 133.5, 129.4, 129.1, 128.5, 128.0, 127.8, 125.8, 125.6, 
115.1, 115.0, 113.6, 113.3, 67.2, 60.3, 60.2, 49.4, 49.1, 46.1, 46.0, 41.9, 41.7, 28.1, 27.9, 
27.0, 14.3; HRMS (ESI) m/z  C25H31N3O2 (M+H)
+ calcd for 406.2489; found 406.2492. 
NMR Assignment. 1H NMR (400 MHz) δ 7.40 – 7.27 (comp, 5 H, C13-H thru 
C17-H), 7.01 (d, J  = 7.5 Hz, 1 H, C6-H), 6.76 (dd, J  = 8.3, 1.9 Hz, 1 H, C1-H), 6.63 (d, J  
= 21.8 Hz, 1 H, C3-H), 5.15 (s, 2 H, C11-H), 4.59 (s, 2 H, C7-H), 3.69 (s, 2 H, C9-H), 3.19 
– 3.09 (comp, 4 H, C18-H and C21-H), 2.83-2.69 (comp, 3 H, C8-H and C22-H), 2.52 – 
2.43 (comp, 4 H, C19-H and C20-H), 2.08-2.01 (comp, 2 H, C23-H or C25-H), 1.97 – 1.84 
(comp, 2 H, C23-H or C25-H), 1.77 – 1.63 (comp, 2 H, C24-H); 13C NMR (101 MHz) δ 
155.5 (C10), 150.0 (C2), 136.8 (C12), 136.7 (C12), 134.0 (C4), 133.5 (C4), 129.4 (C6), 
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129.1 (C6), 128.5 (C14 and C16), 128.0 (13 and C17), 127.8 (C15), 125.8 (C5), 125.6 (C5), 
115.1 (C1), 115.0 (C1), 113.6 (C3), 113.3 (C3), 67.2 (C11), 60.3 (C22), 60.2 (C22), 49.4 
(C18 and C21), 49.1 (C19 and C20), 46.1 (C7), 46.0 (C7), 41.9 (C9), 41.7 (C9), 28.1 (C8), 
27.9 (C8), 27.0 (C24), 14.3 (C23 and C25). 
 
Benzyl 7-(4-cyclohexylpiperazin-1-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
(1.118). KTL-02-067. Prepared according to the representative procedure for reductive 
alkylation of piperazines. The crude material was purified via flash column 
chromatography eluting EtOAc:TEA:hexanes (15:1:74) to give 29 mg (78%) of 1.118 as a 
clear oil: 1H NMR (400 MHz) δ 7.41 – 7.29 (m, 5 H), 7.02 (d, J = 7.3 Hz, 1 H), 6.78 (dd, 
J = 8.4, 2.3 Hz, 1 H), 6.64 (d, J = 21.2 Hz, 1 H), 5.17 (s, 2 H), 4.60 (s, 2 H), 3.70 (d, J = 
4.8 Hz, 2 H), 3.16 (s, 4 H), 2.73 (s, 6 H), 2.30 (s, 1 H), 1.93 (s, 2 H), 1.81 (s, 2 H), 1.65 (d, 
J = 11.6 Hz, 1 H); 13C NMR (126 MHz, rotamers) δ 155.5, 150.0, 136.8, 134.0, 133.6, 
129.4, 129.1, 128.5, 128.0, 127.9, 125.8, 125.6, 115.1, 115.0, 113.7, 113.4, 67.2, 67.1, 63.6, 
49.8, 49.0, 46.1, 46.0, 42.0, 41.8, 28.9, 28.1, 27.9, 26.3, 25.9; HRMS (ESI) m/z  
C27H35N3O2 (M+H)
+ calcd for 434.2802; found 434.2805. 
 NMR Assignment. 1H NMR (400 MHz) δ 7.41 – 7.29 (m, 5 H, C13-H thru C17-
H), 7.02 (d, J = 7.3 Hz, 1 H, C6-H), 6.78 (dd, J = 8.4, 2.3 Hz, 1 H, C1-H), 6.64 (d, J = 21.2 
Hz, 1 H, C3-H), 5.17 (s, 2 H, C11-H), 4.60 (s, 2 H, C7-H), 3.70 (d, J = 4.8 Hz, 2 H, C9-
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H)), 3.16 (s, 4 H, C18-H and C21-H), 2.73 (s, 6 H, C8-H, C19-H, and C20-H), 2.30 (s, 1 
H, C22-H), 1.93 (s, 2 H, C23-H or C27-H), 1.81 (s, 2 H, C23-H or C27-H), 1.65 (d, J = 
11.6 Hz, 1 H), 1.24 (comp, 6 H); 13C NMR (126 MHz, rotamers) δ 155.5 (C10), 150.0 
(C2), 136.8 (C12), 134.0 (C4), 133.6 (C4), 129.4 (C6), 129.1 (C6), 128.5 (C14 and C16), 
128.0 (C13 and C17), 127.9 (C15), 125.8 (C5), 125.6 (C5), 115.1 (C1), 115.0 (C1), 113.7 
(C3), 113.4 (C3), 67.2 (C11), 67.1 (C11), 63.6 (C22), 49.8 (C18 and C21), 49.0 (C19 and 
C20), 46.1 (C7), 46.0 (C7), 42.0 (C9), 41.8 (C9), 28.9 (C23 and C27), 28.1 (C8), 27.9 (C8), 
26.3 (C25), 25.9 (C24 and C26).  
 
Benzyl 5-(4-propylpiperazin-1-yl)isoindoline-2-carboxylate (1.88). KTL-02-104. 
Prepared according to the representative procedure outlined for reductive alkylation of 
piperazines. The crude material was purified via flash column chromatography eluting 
EtOAc:TEA:hexanes (10:1:89) to give 10 mg (59%) of 1.88 as a clear oil: 1H NMR (400 
MHz) δ 7.45 – 7.28 (comp, 5 H), 7.12 (dd, J = 23.5, 8.4 Hz, 1 H), 6.87 (ddd, J = 8.5, 6.4, 
2.3 Hz, 1 H), 6.80 (dd, J = 24.2, 2.3 Hz, 1 H), 5.21 (s, 2 H), 4.74 – 4.62 (comp, 4 H), 3.19 
(td, J = 5.8, 3.3 Hz, 4 H), 2.61 (dd, J = 6.2, 3.9 Hz, 4 H), 2.39 – 2.31 (comp, 2 H), 1.56 (tt, 
J = 14.2, 6.8 Hz, 2 H), 0.93 (t, J = 7.4 Hz, 3 H); 13C NMR (101 MHz, rotamers) δ 154.9, 
154.9, 151.4, 138.0, 137.6, 136.88, 136.87, 128.5, 128.0, 127.9, 127.8, 127.7, 123.2, 123.0, 
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116.1, 115.9, 110.1, 110.0, 66.9, 60.7, 53.2, 52.7, 52.3, 52.1, 51.6, 49.6, 49.6, 20.0, 12.0; 
LRMS (ESI+APCI) m/z  C23H29N3O2 (M+H)+¬ calcd for 380.24; found 380.3. 
 NMR Assignment. 1H NMR (400 MHz) δ 7.45 – 7.28 (comp, 5 H, C12-H thru 
C16-H), 7.12 (dd, J = 23.5, 8.4 Hz, 1 H, C3-H), 6.87 (ddd, J = 8.5, 6.4, 2.3 Hz, 1 H, C2-
H), 6.80 (dd, J = 24.2, 2.3 Hz, 1 H, C6-H), 5.21 (s, 2 H, C10-H), 4.74 – 4.62 (comp, 4 H, 
C7-H and C8-H), 3.19 (td, J = 5.8, 3.3 Hz, 4 H, C17-H and C20-H), 2.61 (dd, J = 6.2, 3.9 
Hz, 4 H, C18-H and C19-H), 2.39 – 2.31 (comp, 2 H, C24-H), 1.56 (tt, J = 14.2, 6.8 Hz, 2 
H, C27-H), 0.93 (t, J = 7.4 Hz, 3 H, C28-H); 13C NMR (101 MHz, rotamers) δ 154.9 (C9), 
154.9 (C9), 151.4 (C1), 138.0 (C5), 137.6 (C5), 136.88 (C11), 136.87 (C11), 128.5 (C13 
and C15), 128.0 (C14), 127.9 (C3), 127.8 (C12 and C16), 127.7 (C3), 123.2 (C4), 123.0 
(C4), 116.1 (C2), 115.9 (C2), 110.1 (C6), 110.0 (C6), 66.9 (C10), 60.7 (C24), 53.2 (C17 
and C20), 52.7 (C7 or C8), 52.3 (C7 or C8), 52.1 (C7 or C8), 51.6 (C7 or C8), 49.6 (C18 
and C19), 49.6 (C18 and C19), 20.0 (C27), 12.0 (C28).  
 
Benzyl 7-(4-propylpiperazin-1-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (1.89). 
KTL-02-036. Prepared according to the representative procedure outlined for reductive 
alkylation of piperazines. The crude material was purified via flash column 
chromatography eluting EtOAc:TEA:hexanes (10:1:89) to give 13 mg (57%) of 1.89 as a 
clear oil:  1H NMR (400 MHz) δ 7.40-7.30 (comp, 5 H), 7.03 (d, J =7.8 Hz, 1 H), 6.78 (dd, 
J =8.4, 2.3 Hz, 1 H), 6.64 (d, J =21.3 Hz, 1 H), 5.17 (s, 2 H), 4.60 (s, 2 H), 3.71 (s, 2 H), 
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3.20 – 3.13 (comp, 4 H), 2.76 (s, 2 H), 2.64 – 2.55 (comp, 4 H), 2.41 – 2.31 (comp, 2 H), 
1.55 (comp,  2 H), 0.93 (t, J =7.4 Hz, 3 H); 13C NMR (101 MHz, rotamers) δ 155.5, 150.0, 
136.8, 134.0, 133.6, 129.4, 129.1, 128.5, 128.0, 127.9, 125.8, 125.6, 115.0, 113.6, 113.3, 
67.2, 60.6, 53.2, 49.3, 46.1, 46.0, 42.0, 41.7, 28.1, 27.8, 20.0, 11.9; HRMS (ESI) m/z  
C24H31N3O2 (M+H)
+ calcd for 416.2308;  found 416.2310. 
NMR Assignment. 1H NMR (400 MHz) δ 7.40-7.30 (comp, 5 H, C13-H thru C17-
H), 7.03 (d, J =7.8 Hz, 1 H, C6-H), 6.78 (dd, J =8.4, 2.3 Hz, 1 H, C1-H), 6.64 (d, J =21.3 
Hz, 1 H, C3-H), 5.17 (s, 2 H, C11-H), 4.60 (s, 2 H, C7-H), 3.71 (s, 2 H, C9-H), 3.20 – 3.13 
(comp, 4 H, C18-H and C21-H), 2.76 (s, 2 H, C8-H), 2.64 – 2.55 (comp, 4 H, C19-H and 
C20-H), 2.41 – 2.31 (comp, 2 H, C22-H), 1.55 (comp,  2 H, C23-H), 0.93 (t, J =7.4 Hz, 3 
H, C24-H); 13C NMR (101 MHz, rotamers) δ 155.5 (C10), 150.0 (C2), 136.8 (C12), 134.0 
(C4), 133.6 (C4), 129.4 (C6), 129.1 (C6), 128.5 (C14 and C16), 128.0 (C13 and C17), 
127.9 (C15), 125.8 (C5), 125.6 (C5), 115.0 (C1), 113.6 (C3), 113.3 (C3), 67.2 (C11), 60.6 
(C22), 53.2 (C18 and C21), 49.3 (C19 and C20), 46.1 (C7), 46.0 (C7), 42.0 (C9), 41.7 (C9), 
28.1 (C8), 27.8 (C8), 20.0 (C23), 11.9 (C24). 
 
Benzyl 8-(4-propylpiperazin-1-yl)-1,3,4,5-tetrahydro-2H-benzo[c]azepine-2-
carboxylate (1.90). KTL-02-058. Prepared according to the representative procedure 
outlined for reductive alkylation of piperazines.  The crude material was purified via flash 
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column chromatography eluting with EtOAc:TEA:hexanes (10:1:89) to give 16 mg (79%) 
of 1.90 as a clear oil: 1H NMR (400 MHz, rotamers) δ 7.32 (comp, 5 H), 7.02 (d, J = 8.2 
Hz, 1 H), 6.94 (d, J = 2.5 Hz, 0.35 H), 6.69 (dd, J = 8.1, 2.8 Hz, 1 H), 6.65 (d, J = 2.6 Hz, 
0.65 H), 5.06 (s, 0.70 H), 5.03 (s, 1.30 H), 4.44 (s, 0.70 H), 4.39 (s, 1.30 H), 3.81-3.67 
(comp, 2 H), 3.22 – 3.15 (comp, 1.50 H), 3.02-2.99 (comp, 2.50 H), 2.89-2.85 (comp, 2H), 
2.62 – 2.55 (comp, 1.50 H), 2.55 – 2.49 (comp, 2.50 H), 2.38 – 2.31 (comp, 2H), 1.82-1.67 
(comp, 2 H), 1.62 – 1.49 (m, 2 H), 0.93 (comp, 3 H); 13C NMR (101 MHz, rotamers) δ 
155.4, 155.2, 149.7, 149.6, 138.9, 138.7, 136.9, 136.8, 132.8, 132.3, 130.2, 130.0, 128.4, 
127.9, 127.8, 117.8, 117.4, 114.4, 114.1, 67.2, 66.9, 60.7, 53.3, 53.2, 53.1, 52.5, 51.0, 50.3, 
49.12, 49.08, 34.4, 34.3, 28.9, 28.4, 20.0, 12.0; HRMS (ESI) m/z  C25H33N3O2 (M+H)
+ 
calcd for 408.2646; found 408.2655. 
NMR Assignment. 1H NMR (400 MHz, rotamers) δ 7.32 (comp, 5 H, C14-H thru 
C18-H), 7.02 (d, J = 8.2 Hz, 1 H, C3-H), 6.94 (d, J = 2.5 Hz, 0.35 H, C6-H), 6.69 (dd, J = 
8.1, 2.8 Hz, 1 H, C2-H), 6.65 (d, J = 2.6 Hz, 0.65 H, C6-H), 5.06 (s, 0.70 H, C12-H), 5.03 
(s, 1.30 H, C12-H), 4.44 (s, 0.70 H, C10-H), 4.39 (s, 1.30 H, C10-H), 3.81-3.67 (comp, 2 
H, C9-H), 3.22 – 3.15 (comp, 1.50 H, C19-H and C22-H), 3.02-2.99 (comp, 2.50 H, C19-
H and C22-H), 2.89-2.85 (comp, 2H, C23-H), 2.62 – 2.55 (comp, 1.50 H, C20-H and C21-
H), 2.55 – 2.49 (comp, 2.50 H, C20-H and C21-H), 2.38 – 2.31 (comp, 2H, C7-H), 1.82-
1.67 (comp, 2 H, C8-H), 1.62 – 1.49 (m, 2 H, C24-H), 0.93 (comp, 3 H, C25-H); 13C NMR 
(101 MHz, rotamers) δ 155.44 (C11), 155.21 (C11), 149.69 (C1), 149.56 (C1), 138.86 
(C5), 138.65 (C5), 136.92 (C13), 136.77 (C13), 132.77 (C3), 132.33 (C3), 130.16 (C4), 
130.03 (C4), 128.39 (C15 and C17), 127.92 (C14, C16, and C18), 127.79 (C14, C16, and 
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C18), 117.82 (C2), 117.39 (C2), 114.39 (C6), 114.09 (C6), 67.20 (C12), 66.91 (C12), 60.69 
(C23), 53.27 (C19 and C22), 53.24 (C19 and C22), 53.05 (C10), 52.52 (C10), 50.95 (C9), 
50.32 (C9), 49.12 (C20 and C21), 49.08 (C20 and C20), 34.36 (C7), 34.25 (C7), 28.91 
(C8), 28.42 (C8), 20.03 (C24), 11.96 (C25). 
 
Benzyl 8-(4-methylpiperazin-1-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
(1.120). KTL-03-157. Prepared according to the representative procedure outlined for 
reductive alkylation of piperazines. The crude material was purified via flash column 
chromatography eluting with EtOAc:TEA:hexanes (49:1:50) to give 7 mg (56%) of 1.120 
as a yellow oil: 1H NMR (400 MHz) δ 7.45 – 7.28 (comp, 5 H), 7.17 (t, J = 7.7 Hz, 1 H), 
6.99 (d, J = 7.9 Hz, 1 H), 6.90 (s, 1 H), 5.18 (s, 2 H), 4.66 (s, 2 H), 3.68 (t, J = 6.1 Hz, 2 
H), 2.97 – 2.80 (comp, 6 H), 2.57 (d, J = 31.9 Hz, 3 H), 2.36 (s, 3 H); LRMS (ESI+APCI) 
m/z  C22H27N3O2 (M+H)
+ calcd for 366.22; found 366.3. 
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Representative procedure for conjugate addition 
 
Benzyl 8-(4-(3-ethoxy-3-oxopropyl)piperazin-1-yl)-1,3,4,5-tetrahydro-2H-
benzo[c]azepine-2-carboxylate (1.93). KTL-02-023.  Ethyl acrylate (23 mg, 0.22 mmol) 
was added to a solution of intermediate 1.76 (40 mg, 0.11 mmol)  in EtOH (1 mL). The 
solution was heated to 40 °C for 16 h. The reaction was cooled to room temperature and 
concentrated under reduced pressure. The crude material was purified via silica plug 
eluting with EtOAc:TEA:hexanes (49:1:50) to give 38 mg (74%) of 1.93 as a yellow oil: 
1H NMR (400 MHz, rotamers) δ 7.37-7.28 (comp, 5 H), 7.02 (d, J = 8.2 Hz, 1 H), 6.93 (d, 
J = 2.4 Hz, 0.35 H), 6.71 – 6.65 (m, 1 H), 6.63 (d, J = 2.5 Hz, 0.65 H), 5.05 (s, 0.70 H), 
5.03 (s, 1.30 H), 4.43 (s, 0.70 H), 4.38 (s, 1.30 H), 4.19-4.12 (comp, 2 H), 3.81 – 3.68 
(comp, 2 H), 3.22 – 3.14 (comp, 1.50 H), 3.01 – 2.94 (comp, 2.50 H), 2.89-2.85 (comp, 2 
H), 2.75 (t, J = 7.4 Hz, 2 H), 2.64 – 2.58 (comp, 1.50 H), 2.54 (comp, 4.50 H), 1.75 (comp, 
2 H), 1.27 (comp, 3 H); 13C NMR (101 MHz) δ 172.44, 172.42, 155.4, 155.1, 149.5, 149.4, 
138.9, 138.7, 136.9, 136.7, 132.9, 132.5, 130.2, 130.0, 128.4, 127.9, 127.8, 127.8, 117.8, 
117.4, 114.5, 114.2, 67.2, 66.9, 60.45, 60.42, 53.6, 53.0, 52.9, 52.5, 51.0, 50.4, 49.1, 49.1, 
34.4, 34.3, 32.4, 28.9, 28.4, 14.2; HRMS (ESI) m/z  C27H35N3O4 (M+H)
+ calcd for 
466.2700; found 466.2712. 
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NMR Assignment. 1H NMR (400 MHz, rotamers) δ 7.37-7.28 (comp, 5 H, C14-
H thru C18-H), 7.02 (d, J = 8.2 Hz, 1 H, C3-H), 6.93 (d, J = 2.4 Hz, 0.35 H, C6-H), 6.71 – 
6.65 (m, 1 H, C2-H), 6.63 (d, J = 2.5 Hz, 0.65 H, C6-H), 5.05 (s, 0.70 H, C12-H), 5.03 (s, 
1.30 H, C12-H), 4.43 (s, 0.70 H, C10-H), 4.38 (s, 1.30 H, C10-H), 4.19-4.12 (comp, 2 H, 
C26-H), 3.81 – 3.68 (comp, 2 H, C9-H), 3.22 – 3.14 (comp, 1.50 H, C19-H and C22-H), 
3.01 – 2.94 (comp, 2.50 H, C19-H and C22-H), 2.89-2.85 (comp, 2 H, C7-H), 2.75 (t, J = 
7.4 Hz, 2 H, C23-H), 2.64 – 2.58 (comp, 1.50 H, C20-H and C21-H), 2.54 (comp, 4.50 H, 
C20-H, C21-H and C24-H), 1.75 (comp, 2 H, C8-H), 1.27 (comp, 3 H, C27-H); 13C NMR 
(101 MHz, rotamers) δ 172.44 (C25), 172.42 (C25), 155.4 (C11), 155.1 (C11), 149.5 (C1), 
149.4 (C1), 138.9 (C5), 138.7 (C5), 136.9 (C13), 136.7 (C13), 132.9 (C4), 132.5 (C4), 
130.2 (C3), 130.0 (C3), 128.4 (C15 and C17), 127.9 (C14 or C18), 127.8 (C14 or C18), 
127.8 (C16), 117.8 (C2), 117.4 (C2), 114.5 (C6), 114.2 (C6), 67.2 (C12), 66.9 (C12), 60.45 
(C26), 60.42 (C26), 53.6 (C23), 53.0 (C10), 52.9 (C19 and C22), 52.5 (C10), 51.0 (C9), 
50.4 (C9), 49.1 (C20 and C21), 49.0 (C20 and C21), 34.4 (C7), 34.3 (C7), 32.4 (C24), 28.9 
(C8), 28.4 (C8), 14.2 (C27). 
 
Benzyl 5-(4-(3-ethoxy-3-oxopropyl)piperazin-1-yl)isoindoline-2-carboxylate (1.91). 
KTL-03-135. Prepared according to the representative procedure outlined for conjugate 
addition. The crude material was purified via flash column chromatography eluting 
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EtOAc:TEA:hexanes (25:1:74) to give 27 mg (83%) of 1.91 as a white solid:  1H NMR 
(400 MHz) δ 7.36 (comp, 5 H), 7.12 (dd, J =23.3, 8.4 Hz, 1 H), 6.89 – 6.82 (m, 1 H), 6.82 
– 6.74 (m, 1 H), 5.20 (s, 2 H), 4.68 (t, J =10.3 Hz, 4 H), 4.15 (q, J =7.1 Hz, 2 H), 3.17 (dd, 
J =10.0, 5.6 Hz, 4 H), 2.76 (t, J =7.3 Hz, 2 H), 2.67 – 2.60 (m, 4 H), 2.54 (t, J =7.3 Hz, 2 
H), 1.26 (t, J =7.1 Hz, 3 H); 13C NMR (101 MHz, rotamers) δ 172.4, 154.90, 154.86, 151.3, 
138., 137.6, 136.9, 136.8, 128.5, 128.04, 127.96, 127.9, 127.8, 123.2, 123.0, 116.1, 116.0, 
110.2, 110.0, 66.9, 60.5, 53.5, 52.9, 52.7, 52.3, 52.1, 51.6, 49.6, 49.5, 32.3, 14.2; HRMS 
(ESI) m/z  C25H31N3O4 (M+H)
+ calcd for 438.2387; found 438.2392. 
NMR Assignment. 1H NMR (400 MHz) δ 7.36 (d, J =48.0 Hz, 5 H, C12-H thru 
C16-H), 7.12 (dd, J =23.3, 8.4 Hz, 1 H, C3-H), 6.89 – 6.82 (m, 1 H, C2-H), 6.82 – 6.74 
(m, 1 H, C1-H), 5.20 (s, 2 H, C10-H), 4.68 (t, J =10.3 Hz, 4 H, C7-H and C8-H), 4.15 (q, 
J =7.1 Hz, 2 H, C24-H), 3.17 (dd, J =10.0, 5.6 Hz, 4 H, C17-H and C20-H), 2.76 (t, J =7.3 
Hz, 2 H, C22-H), 2.67 – 2.60 (m, 4 H, C18-H and C19-H), 2.54 (t, J =7.3 Hz, 2 H, C21-
H), 1.26 (t, J =7.1 Hz, 3 H, C25-H); 13C NMR (101 MHz, rotamers) δ 172.4 (C23), 154.90 
(C9), 154.86 (C9), 151.3 (C1), 138.0 (C5), 137.6 (C5), 136.9 (C11), 136.8 (C11), 128.5 
(C13 and C15), 128.04 (C4), 127.96 (C14), 127.9 (C12 and C16), 127.8 (C4), 123.2 (C3), 
123.0 (C3), 116.1 (C2), 116.0 (C2), 110.2 (C6), 110.0 (C6), 66.9 (C10), 60.5 (C24), 53.5 
(C21), 52.9 (C17 and C20), 52.7 (C7 or C8), 52.3 (C7 or C8), 52.1 (C7 or C8), 51.6 (C7 or 
C8), 49.6 (C18 and C19), 49.5 (C18 and C19), 32.3 (C22), 14.2 (C25).  
 138 
 
Benzyl 7-(4-(3-ethoxy-3-oxopropyl)piperazin-1-yl)-3,4-dihydroisoquinoline-2(1H)-
carboxylate (1.92). KTL-03-139.  Prepared according to the representative procedure 
outlined for conjugate addition. The crude material was purified via flash column 
chromatography eluting EtOAc:TEA:hexanes (20:1:79) to give 20 mg (65%) of 1.92 as a 
clear oil:  1H NMR (400 MHz) δ 7.42-7.29 (comp, 5 H), 7.02 (d, J =7.8 Hz, 1 H), 6.77 (m, 
J =8.4 Hz, 1 H), 6.64 (d, J =21.1 Hz, 1 H), 5.17 (s, 2 H), 4.60 (s, 2 H), 4.15 (q, J =7.1 Hz, 
2 H), 3.69 (s, 2 H), 3.18 – 3.09 (comp, 4 H), 2.75 (t, J =7.3 Hz, 4 H), 2.64 – 2.58 (comp, 4 
H), 2.53 (t, J =7.4 Hz, 2 H), 1.26 (t, J =8.0, 3 H); 13C NMR (126 MHz, rotamers) δ 172.5, 
155.5, 149.9, 136.8, 134.0, 133.6, 129.4, 129.2, 128.5, 128.0, 127.9, 125.9, 125.7, 115.1, 
113.6, 113.4, 67.2, 60.5, 53.6, 52.9, 49.4, 46.1, 46.0, 42.0, 41.7, 32.4, 28.1, 27.9, 14.3; 
HRMS (ESI) m/z  C26H33N3O4 (M+H)
+ calcd for 452.2544; found 452.2549. 
NMR Assignment. 1H NMR (400 MHz) δ 7.42-7.29 (comp, 5 H, C13-H thru C17-
H), 7.02 (d, J =7.8 Hz, 1 H, C6-H), 6.77 (dd, J =10.8, 2.4 Hz, 1 H, C1-H), 6.64 (d, J =21.1 
Hz, 1 H, C3-H), 5.17 (s, 2 H, C11-H), 4.60 (s, 2 H, C7-H), 4.15 (q, J =7.1 Hz, 2 H, C25-
H), 3.69 (s, 2 H, C9-H), 3.18 – 3.09 (comp, 4 H, C18-H and C21-H), 2.75 (t, J =7.3 Hz, 4 
H, C22-H), 2.64 – 2.58 (comp, 4 H, C19-H and C20-H), 2.53 (t, J =7.4 Hz, 2 H, C23-H), 
1.26 (t, J =8.0, 3 H, C26-H);  13C NMR (126 MHz, rotamers) δ 172.5 (C24), 155.5 (C10), 
149.9 (C2), 136.8 (C12), 134.0 (C4), 133.6 (C4), 129.4 (C6), 129.2 (C6), 128.5 (C14 and 
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C16), 128.0 (C13 and C17), 127.9 (C15), 125.9 (C5), 125.7 (C5), 115.1 (C1), 113.6 (C3), 
113.4 (C3), 67.2 (C11), 60.5 (C25), 53.6 (C22), 52.9 (C18 and C21), 49.4 (C19 and C20), 
46.1 (C7), 46.0 (C7), 42.0 (C9), 41.7 (C9), 32.4 (C23), 28.1 (C8), 27.9 (C8), 14.3 (C26).  
 
Benzyl 8-(4-(3-ethoxy-3-oxopropyl)piperazin-1-yl)-3,4-dihydroisoquinoline-2(1H)-
carboxylate (1.122). KTL-02-119.  Prepared according to the representative procedure 
outlined for alkylation of piperazines with acrylates. The crude material was purified via 
flash column chromatography eluting EtOAc:TEA:hexanes (20:1:79) to give 30 mg (84%) 
of 1.122 as a clear oil: 1H NMR (499 MHz, rotamers) δ 7.43 – 7.29 (m, 5 H), 7.17 (t, J = 
7.7 Hz, 1 H), 6.97 (d, J = 7.9 Hz, 1 H), 6.90 (s, 1 H), 5.18 (s, 2 H), 4.66 (s, 2 H), 4.17 (q, J 
= 7.1 Hz, 2 H), 3.68 (t, J = 6.1 Hz, 2 H), 2.93 – 2.80 (comp, 6 H), 2.76 (s, 2 H), 2.70 – 2.55 
(comp, 4 H), 2.53 (t, J = 7.4 Hz, 2 H), 1.28 (t, J = 7.1 Hz,  3 H); 13C NMR (126 MHz, 
rotamers) δ 172.5, 155.5, 150.2, 149.8, 136.9, 136.2, 136.0, 129.2, 129.0, 128.5, 127.9, 
127.6, 127.2, 124.1, 124.0, 117.7, 67.0, 60.5, 53.6, 53.4, 52.2, 42.4, 42.2, 41.7, 32.4, 29.4, 
29.0, 14.3; LRMS (ESI+APCI) m/z  C26H33N3O4 (M+H)
+ calcd for 452.25; found 452.3. 
NMR Assignment. 1H NMR (499 MHz, rotamers) δ 7.43 – 7.29 (m, 5 H, C16-H 
thru C20-H), 7.17 (t, J = 7.7 Hz, 1 H, C1-H), 6.97 (d, J = 7.9 Hz, 1 H, C6-H), 6.90 (s, 1 H, 
C2-H), 5.18 (s, 2 H, C14-H), 4.66 (s, 2 H, C7-H), 4.17 (q, J = 7.1 Hz, 2 H, C32-H), 3.68 
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(t, J = 6.1 Hz, 2 H, C9-H), 2.93 – 2.80 (comp, 6 H, C10-H, C22-H, and C26-H), 2.76 (s, 2 
H, C27-H), 2.70 – 2.55 (comp, 4 H, C23-H and C25-H), 2.53 (t, J = 7.4 Hz, 2 H, C28-H), 
1.28 (t, J = 7.1 Hz,  3 H, C33-H); 13C NMR (126 MHz, rotamers) δ 172.5 (C29), 155.5 
(C11), 150.2 (C3), 149.8 (C3), 136.9 (C15), 136.2 (C5), 136.0 (C5), 129.2 (C4), 129.0 (4), 
128.5 (C17 and C19), 127.9 (C16 and C20), 127.6 (C18), 127.2 (C2), 124.1 (C2), 124.0 
(C2), 117.7 (C6), 67.0 (C14), 60.5 (C32), 53.6 (C27), 53.4 (C23 and C25), 52.2 (C22 and 
C26), 42.4 (C7), 42.2 (C7), 41.7 (C9), 32.4 (C28), 29.4 (C10), 29.0 (C10), 14.3 (C33).  
Representative procedure for TMSI promoted benzylation 
 
4-(2-Benzyl-1,2,3,4-tetrahydroisoquinolin-7-yl)morpholine (1.94). KTL-01-175.  
(Reaction carried out in the dark.) A solution of carbamate 1.73 (70 mg, 0.2 mmol) in 
CH2Cl2 (3.3 mL) was cooled to 0 °C and TMSI (160 mg 0.8 mmol) was added. The solution 
was allowed warm to room temperature and stirred until consumption of starting material 
was observed. MeOH (2.4 mL) and sat. NaHCO3 (2.4 mL) were added, and the mixture 
was stirred overnight. The methanol was removed under reduced pressure, and the aqueous 
mixture was extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts were dried 
(K2CO3) and concentrated under reduced pressure. The crude product was purified by 
column chromatography eluting with TEA:EtOAc:hexanes (1:5:94) to give 19mg (31%) 
of 1.94 as a white solid that turned green upon standing: 1H NMR (400 MHz) δ 7.39 (d, J 
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= 6.8 Hz, 2 H), 7.33 (t, J = 7.1 Hz, 2 H), 7.28 (d, J = 7.0 Hz, 1 H), 6.91 (d, J = 8.4 Hz, 1 
H), 6.72 (dd, J = 8.4, 2.6 Hz, 1 H), 6.65 (d, J = 2.4 Hz, 1 H), 3.85 (t, J = 4 Hz 4 H), 3.68 
(s, 2 H), 3.57 (s, 2 H), 3.10 (t, J = 4 Hz, 4 H), 2.86 (t, J = 5.9 Hz, 2 H), 2.72 (t, J = 5.9 Hz, 
2 H); 13C NMR (101 MHz) δ 149.8, 138.5, 135.1, 129.1, 128.3, 127.3, 127.0, 126.9, 115.7, 
114.1, 66.9, 62.8, 55.6, 50.7, 49.8, 29.5; HRMS (ESI) m/z C21H24N2O3 (M+Na)
+ calcd for 
361.1523; found 361.1526; IR (neat) 2955, 2918, 2853, 2817, 1613, 1509, 1451, 1365, 
1262, 1239, 1121 cm-1. 
NMR Assignment. 1H NMR (400 MHz) δ 7.39 (d, J = 6.8 Hz, 2 H, C12-H and 
C16-H), 7.33 (t, J = 7.1 Hz, 2 H, C13-H and C15-H), 7.28 (d, J = 7.0 Hz, 1 H, C14-H), 
6.91 (d, J = 8.4 Hz, 1 H, C8-H), 6.72 (dd, J = 8.4, 2.6 Hz, 1 H, C7-H), 6.65 (d, J = 2.4 Hz, 
1 H, C5-H), 3.85 (t, J = 4 Hz, 4 H C20-H and C19-H), 3.68 (s, 2 H, C10-H), 3.57 (s, 2 H, 
C1-H), 3.10 (t, J = 4 Hz, 4 H, C17-H and C18-H), 2.86 (t, J = 5.9 Hz, 2 H, C3-H), 2.72 (t, 
J = 5.9 Hz, 2 H, C3-H); 13C NMR (101 MHz) δ 149.8 (C6), 138.5 (C11), 135.1 (C4), 129.1 
(C12 and C16), 128.3 (C13 and C15), 127.3 (C14), 127.0 (C8), 126.9 (C9), 115.7 (C5), 
114.1 (C7), 66.9 (C19 and C20), 62.8 (C10), 55.6 (C1), 50.7 (C3), 49.8 (C17 and C18), 
29.5 (C2). 
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2-Benzyl-6-(3-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline (1.95). KTL-01-176. 
Prepared according to the representative procedure outlined for TMSI promoted 
benzylation. The crude material was purified via flash column chromatography eluting 
with TEA:hexanes (1:99) to give 13 mg (33%)  of 1.95 as a clear oil:  1H NMR (400 MHz) 
δ 7.44 – 7.27 (comp, 8 H), 7.16 (dd, J = 7.6, 0.9 Hz, 1 H), 7.12 – 7.09 (m, 1 H), 7.07 (d, J 
= 8.4 Hz, 1 H), 6.88 (dd, J = 8.2, 2.6 Hz, 1 H), 3.87 (s, 3 H), 3.72 (s, 2 H), 3.68 (s, 2 H), 
2.98 (t, J = 5.8 Hz, 2 H), 2.79 (t, J = 5.9 Hz, 2 H); 13C NMR (101 MHz) δ 159.9, 142.7, 
139.0, 138.4, 134.8, 134.3, 129.7, 129.1, 128.3, 127.4, 127.1, 127.0, 124.5, 119.5, 112.7, 
112.4, 62.8, 55.9, 55.3, 50.7, 29.3; HRMS (ESI) m/z C21H24N2O3 (M+Na)
+ calcd for 
338.1515; found 338.1534; IR (neat) 3027, 2921, 2832, 2801, 2733, 1603, 1571, 1482, 
1453, 1224 cm-1. 
NMR Assignment.  1H NMR (400 MHz) δ 7.44 – 7.27 (comp, 8 H, C5-H, C12-H 
thru C16-H, C18-H, C19-H), 7.16 (dd, J = 7.6, 0.9 Hz, 1 H, C20-H), 7.12 – 7.09 (t, J = 1.6 
Hz, 1 H, C22-H), 7.07 (d, J = 8.4 Hz, 1 H, C8-H), 6.88 (dt, J = 8.2, 2.6 Hz, 1 H, C20-H), 
3.87 (s, 3 H, C23-H), 3.72 (s, 2 H, C10-H), 3.68 (s, 2 H, C1-H), 2.98 (t, J = 5.8 Hz, 2 H, 
C2-H), 2.79 (t, J = 5.9 Hz, 2 H, C3-H); 13C NMR (101 MHz) δ 159.9 (C21), 142.7 (C17), 
139.0 (C11), 138.4 (C6), 134.8 (C9), 134.3 (C4), 129.7 (C19), 129.1 (C13 and C15), 128.3 
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(C12 and C16), 127.4 (C14), 127.1 (C5), 127.0 (C8), 124.5 (C7), 119.5 (C19), 112.7 (C22), 
112.4 (C20), 62.8 (C11), 55.9 (C23), 55.3 (C1), 50.7 (C2), 29.3 (C3). 
Representative procedure for deprotection/N-benzylation  
 
4-(2-(3,5-Dichlorobenzyl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-8-yl)morpholine 
(1.102). KTL-02-054. A solution of carbamate 1.77 (40 mg, 0.11 mmol) in EtOH (3.3 mL) 
and 10% Pd/C (12 mg) was stirred under an atmosphere of H2 until consumption of starting 
material was observed. The reaction was filtered through a pad of celite and the filtrate was 
concentrated under reduced pressure to provide 20 mg (78%) of the secondary amine 
intermediate as a yellow solid that was of sufficient purity for use in subsequent reactions. 
A solution of the secondary amine (12 mg, 0.05 mmol), NaBH(OAc)3 (22 mg, 0.10 mmol), 
3,5-dichlorobenzaldehyde (18 mg, 0.10 mmol) and 10 μL AcOH in DCE (0.5 mL) was 
stirred overnight at room temperature. The reaction was quenched with an aqueous solution 
of sat. NaHCO3 (1 mL) and the layers were separated. The aqueous layer was extracted 
with CH2Cl2 (3 x 5 mL). The combined organic extracts were dried (K2CO3) and 
concentrated under reduced pressure. The crude material was purified via flash column 
chromatography eluting with EtOAc:TEA:hexanes (5:1:94) to give 11 mg (54%) of 1.102 
as a clear oil: 1H NMR (500 MHz) δ 7.25 (t, J = 1.9 Hz, 1 H), 7.22-7.20 (comp, 2 H), 7.06 
(d, J = 8.2 Hz, 1 H), 6.71 (dd, J = 8.2, 2.7 Hz, 1 H), 6.45 (d, J = 2.6 Hz, 1 H), 3.87 – 3.83 
(comp, 4 H), 3.79 (s, 2 H), 3.47 (s, 2 H), 3.19 – 3.15 (comp, 2 H), 3.12 – 3.08 (comp, 4 H), 
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2.88 – 2.83 (comp, 2 H), 1.75 – 1.69 (comp, 2 H); 13C NMR (125 MHz) δ 149.4, 134.9, 
134.7, 134.5, 129.3, 127.3, 127.2, 127.0, 117.8, 114.0, 67.0, 59.4, 58.8, 56.0, 49.6, 35.1, 
25.3; HRMS (ESI) m/z  C21H24Cl2N2O (M+H)
+ calcd for 391.1338 and 393.1313; found 
391.1341 and 393.1317. 
NMR Assignment. 1H NMR (500 MHz) δ 7.25 (t, J = 1.9 Hz, 1 H, C15-H), 7.22-
7.20 (comp, 2 H, C13-H and C17-H), 7.06 (d, J = 8.2 Hz, 1 H, C3-H), 6.71 (dd, J = 8.2, 
2.7 Hz, 1 H, C2-H), 6.45 (d, J = 2.6 Hz, 1 H, C6-H), 3.87 – 3.83 (comp, 4 H, C19-H and 
C20-H), 3.79 (s, 2 H, C10-H), 3.47 (s, 2 H, C11-H), 3.19 – 3.15 (comp, 2 H, C9-H), 3.12 
– 3.08 (comp, 4 H, C18-H and C21-H), 2.88 – 2.83 (comp, 2 H, C7-H), 1.75 – 1.69 (comp, 
2 H, C8-H); 13C NMR (125 MHz) δ 149.4 (C1), 134.9, 134.7, 134.5, 129.3, 127.3 (C14 
and C16), 127.2, 127.0, 117.8 (C2), 114.0 (C6), 67.0 (C18 and C21), 59.4 (C10), 58.8 
(C11), 56.0 (C9), 49.6 (C18 and C21), 35.1 (C7), 25.3 (C8).   
 
4-(2-(3,5-Dichlorobenzyl)isoindolin-5-yl)morpholine (1.100). KTL-01-121. Prepared 
according to the representative procedure outlined for deprotection/N-benzylation. The 
crude material was purified via flash column chromatography eluting with 
EtOAc:TEA:hexanes (10:1:89) to give 25 mg (35% over two-steps) of 1.100 as a clear oil: 
1H NMR (400 MHz) δ 7.32 (d, J = 1.9 Hz, 2 H), 7.27 (t, J = 2 Hz, 1 H), 7.09 (d, J = 8.9 
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Hz, 1 H), 6.78 (comp, 2 H), 3.89 (s, 2 H), 3.86 (comp, 8 H), 3.11 (t, J = 4.8 Hz, 4 H); 13C 
NMR (101 MHz) δ 151.0, 142.9, 140.9, 134.9, 131.6, 127.2, 126.9, 122.8, 115.1, 110.3, 
66.9, 59.2, 59.2, 58.5, 50.1; HRMS (ESI) m/z C21H24N2O3 (M+H)
+ calcd for 363.1025 and 
365.0999; found 363.1036 and 365.1006; IR (neat) 2923, 2853, 2817, 1567, 1497, 1445, 
1430, 1241, 1122 cm-1. 
NMR Assignment.  1H NMR (400 MHz) δ 7.32 (d, J = 1.9 Hz, 2 H, C11-H and 
C15-H), 7.27 (t, J = 2 Hz, 1 H, C13-H), 7.09 (d, J = 8.9 Hz, 1 H, C4-H), 6.78 (comp, 2 H, 
C5-H and C7-H), 3.89 (s, 2 H, C1-H), 3.86 (comp, 8 H, C2-H, C9-H, C18-H, and C19-H), 
3.11 (t, J = 4.8 Hz, 4 H, C16-H and C17-H); 13C NMR (101 MHz) δ 151.1 (C6), 142.9 
(C8), 140.99 (C10), 134.9 (C11 and C15), 131.62 (C3), 127.2 (C13), 126.9 (C12 and C14), 
122.8 (C4), 115.1 (C7), 110.3 (C5), 66.9 (C18 and C17), 59.2 (C9), 59.2 (C1), 58.5 (C2), 
50.1 (C17 and C18). 
 
4-(2-(3,5-Dichlorobenzyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)morpholine (1.101). 
KTL-01-184.  Prepared according to the representative procedure outlined for 
deprotection/N-benzylation. The crude material was purified via flash column 
chromatography eluting with EtOAc:TEA:hexanes (5:1:94) to give 47 mg (35% over two-
steps) of 1.101 as a yellow oil: 1H NMR (400 MHz) δ 7.31 (d, J = 1.9 Hz, 2 H), 7.27 (t, J 
= 1.9 Hz, 1 H), 7.04 (d, J = 8.4 Hz, 1 H), 6.77 (dd, J = 8.4, 2.4 Hz, 1 H), 6.55 (d, J = 2.4 
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Hz, 1 H), 3.85 (t, J = 4.8, 4 H), 3.62 (s, 2 H), 3.57 (s, 2 H), 3.09 (t, J = 4.8, 4 H), 2.84 (t, J 
= 5.8 Hz, 2 H), 2.74 (t, J = 5.8 Hz, 2 H); 13C NMR (101 MHz) δ 149.5, 142.4, 135.1, 134.8, 
129.4, 127.3, 127.2, 125.9, 114.8, 113.7, 66.9, 61.6, 56.2, 51.1, 49.8, 28.2; HRMS (ESI) 
m/z C21H24N2O3 (M+H)
+ calcd for 377.1182 and 379.1156; found 377.1183 and 379.1159; 
IR (neat) 2957, 2913, 2853, 2817, 1613, 1567, 1508, 1429, 1261, 1242, 1121 cm-1. 
NMR Assignment.  1H NMR (400 MHz) δ 7.31 (d, J = 1.9 Hz, 2 H, C12-H and 
C16-H), 7.27 (t, J = 1.9 Hz, 1 H, C14-H), 7.04 (d, J = 8.4 Hz, 1 H, C5-H), 6.77 (dd, J = 
8.4, 2.4 Hz, 1 H, C6-H), 6.55 (d, J = 2.4 Hz, 1 H, C8-H), 3.85 (t, J = 4.8, 4 H, C19-H and 
C20-H), 3.62 (s, 2H , C10-H), 3.57 (s, 2 H, C1-H), 3.09 (t, J = 4.8, 4 H, C17-H and C18-
H), 2.84 (t, J = 5.8 Hz, 2 H, C2-H), 2.74 (t, J = 5.8 Hz, 2 H, C3-H); 13C NMR (101 MHz) 
δ 149.5 (C7), 142.4 (C11), 135.1 (C9), 134.8 (C13 and C15), 129.4 (C5), 127.3 (C14), 
127.2 (C12 and C16), 125.9 (C4), 114.8 (C6), 113.7 (C8), 66.9 (C19 and C20), 61.6 (C10), 
56.2 (C1), 51.1 (C2), 49.8 (C17 and C18), 28.2 (C3). 
 
4-(2-Benzylisoindolin-5-yl)morpholine (1.96). KTL-01-153.  Prepared according to the 
representative procedure outlined for deprotection/N-benzylation. The crude material was 
purified via flash column chromatography eluting with EtOAc:TEA:hexanes (10:1:89) to 
give 15 mg (63%, over two-steps) of 1.96 as a white solid that turned blue upon standing: 
1H NMR (400 MHz, c6d6) δ 7.41 (d, J = 7.6 Hz, 2 H), 7.20 (t, J = 7.6 Hz, 2 H), 6.90 (d, J 
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= 8.2 Hz, 1 H), 6.54 (d, J = 8.2 Hz, 1 H), 6.48 (s, 1H), 3.77 (d, J = 9.1 Hz, 4 H), 3.70 (s, 2 
H), 3.56 – 3.50 (t, J = 4.8 Hz, 4 H), 2.74 – 2.66 (t, J = 4.8 Hz, 4 H); 13C NMR (101 MHz, 
cdcl3) δ 150.9, 141.4, 139.2, 132.2, 128.8, 128.4, 127.1, 122.8, 114.9, 110.4, 66.9, 60.4, 
59.2, 58.5, 50.2; HRMS (ESI) m/z C21H24N2O3 (M+H)
+ calcd for 295.1805; found 
295.1822; IR (neat) 2955, 2922, 2855, 2780, 1453, 1262, 1244, 1123 cm -1. 
NMR Assignment. 1H NMR (400 MHz, c6d6) δ 7.41 (d, J = 7.6 Hz, 2 H, C11-H 
and C15-H), 7.20 (t, J = 7.6 Hz, 2 H, C12-H and C14-H), 7.15 (C13-H under benzene 
peak), 6.90 (d, J = 8.2 Hz, 1 H, C6-H), 6.54 (d, J = 8.2 Hz, 1 H, C5-H), 6.48 (s, 1 H, C7-
H), 3.78 (s, 2 H, C1-H), 3.76 (s, 2 H, C2-H), 3.70 (s, 2 H, C9-H), 3.54 (t, J = 4.8 Hz, 4 H, 
C18-H and C19-H), 2.74 – 2.66 (t, J = 4.8 Hz, 4 H, C16-H and C17-H); 13C NMR (101 
MHz, cdcl3) δ 150.9 (C6), 141.4 (C8), 139.2 (C10), 132.2 (C3), 128.8 (C11 and C15), 
128.4 (C12 and C14), 127.1 (C4), 122. 8 (C10), 114.9 (C5), 110.4 (C4), 66.9 (C18 and 
C19), 60.4 (C9), 59.2 (C1), 58.5 (C2), 50.2 (C16 and C17). 
 
4-(2-Benzyl-2,3,4,5-tetrahydro-1H-benzo[c]azepin-7-yl)morpholine (1.97). KTL-02-
094. Prepared according to the representative procedure outlined for deprotection/N-
benzylation The crude material was purified via flash column chromatography eluting 
EtOAc:TEA:hexanes (10:1:89) to give 18 mg (51% over two-steps) of 1.97 as a clear oil: 
1H NMR (400 MHz) δ 7.33-7.21 (comp, 5 H), 6.86 (d, J = 8.2 Hz, 1 H), 6.74 (d, J = 2.6 
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Hz, 1 H), 6.62 (dd, J = 8.1, 2.6 Hz, 1 H), 3.89 – 3.84 (comp, 4 H), 3.81 (s, 2 H), 3.51 (s, 2 
H), 3.18 – 3.13 (comp, 4 H), 3.12 – 3.07 (comp, 2 H), 2.90 – 2.84 (comp, 2 H), 1.80 – 1.72 
(comp, 2 H); 13C NMR (101 MHz) δ 150.3, 143.9, 139.4, 130.9, 130.9, 129.0, 128.1, 126.8, 
116.5, 112.4, 67.0, 58.7, 58.5, 57.5, 49.5, 36.8, 25.3; HRMS (ESI) m/z  C21H26N2O (M+H)
+ 
calcd for 323.2118; found 323.2120. 
NMR Assignment. 1H NMR (400 MHz) δ 7.33-7.21 (comp, 5 H, C13-H thru C17-
H), 6.86 (d, J = 8.2 Hz, 1 H, C6-H), 6.74 (d, J = 2.6 Hz, 1 H, C3-H), 6.62 (dd, J = 8.1, 2.6 
Hz, 1 H, C1-H), 3.89 – 3.84 (comp, 4 H, C19 and C20), 3.81 (s, 2 H, C10-H), 3.51 (s, 2 H, 
C11-H), 3.18 – 3.13 (comp, 4 H, C18-H and C21-H), 3.12 – 3.07 (comp, 2 H, C9-H), 2.90 
– 2.84 (comp, 2 H, C7-H), 1.80 – 1.72 (comp, 2 H, C8-H); 13C NMR (101 MHz) δ 150.3 
(C2), 143.9 (C4), 139.4 (C12), 130.9 (C6), 130.8 (C5), 129.0 (C14 and C16), 128.1 (C13 
and C17), 126.8 (C15), 116.5 (C3), 112.4 (C1), 67.0 (C19 and C20), 58.7 (C10), 58.5 
(C11), 57.5 (C9), 49.5 (C18 and C21), 36.8 (C7), 25.3 (C8).  
 
2-Benzyl-5-(3-methoxyphenyl)isoindoline (1.98). KTL-01-166. Prepared according to 
the representative procedure outlined for compound 32. The crude material was purified 
via flash column chromatography eluting with TEA:hexanes (1:99) to give 26 mg (65% 
over two-steps) of 1.98 as a yellow oil: 1H NMR (400 MHz) δ 7.47 – 7.30 (comp, 8 H), 
7.26 (dd, J = 4.2, 3.3 Hz, 1 H), 7.16 (ddd, J = 7.7, 1.6, 0.9 Hz, 1 H), 7.11 (t, J = 2 Hz, 1 H), 
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6.90 (ddd, J = 8.2, 2.6, 0.8 Hz, 1 H), 4.00 (s, 2 H), 3.99 (s, 2 H), 3.96 (s, 2 H), 3.87 (s, 3 
H); 13C NMR (101 MHz) δ 159.9, 142.9, 141.0, 139.9, 139.7, 139.1, 129.7, 128.8, 128.42, 
127.1, 125.9, 122.6, 121.2, 119.7, 112.9, 112.5, 60.3, 58.9, 58.7, 55.2; HRMS (ESI) m/z 
C21H24N2O3 (M+Na)
+ calcd for 361.1423; found 361.1526; IR (neat) 3060, 3028, 2935, 
2833, 2786, 1601, 1574, 1493, 1479, 1348, 1269, 1180 cm-1. 
NMR Assignment. 1H NMR (400 MHz) δ 7.47 – 7.30 (comp, 8 H, C4-H, C5-H, 
C7-H, and C11-H thru C15-H), 7.26 (dd, J = 4.2, 3.3 Hz, 1 H, C21-H), 7.16 (ddd, J = 7.7, 
1.6, 0.9 Hz, 1 H, C20-H), 7.11 (t, J = 2 Hz, 1 H, C17-H), 6.90 (ddd, J = 8.2, 2.6, 0.8 Hz, 1 
H, C19-H), 4.00 (s, 2 H, C1-H), 3.99 (s, 2 H, C2-H), 3.96 (s, 2 H, C9-H), 3.87 (s, 3 H, C23-
H); 13C NMR (101 MHz) δ 159.9 (C18), 142.9 (C16), 141.0 (C1 or C4), 139.9 (C1 or C4), 
139.7 (C10), 139.1 (C3), 129.71 (C20), 128.8 (C12 and C14), 128.4 (C11 and C15), 127.1 
(C13), 125.9 (C5), 122.6 (C7), 121.2 (C4), 119.7 (C21), 112.9 (C17), 112.5 (C19), 60.3 
(C9), 58.9 (C1), 58.7 (C2), 55.3 (C22). 
 
2-Benzyl-7-(3-methoxyphenyl)-2,3,4,5-tetrahydro-1H-benzo[c]azepine (1.99). KTL-
02-095. Prepared according to the representative procedure outlined for deprotection/N-
benzylation. The crude material was purified via flash column chromatography eluting 
with EtOAc:TEA:hexanes (2:1:97) to give 16 mg (36% over two-steps) of 1.99 as a clear 
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oil: 1H NMR (400 MHz) δ 7.32 (comp, 8 H), 7.20 (ddd, J = 7.7, 1.6, 1.0 Hz, 1 H), 7.14 (t, 
J = 2.4, 1 H), 7.01 (d, J = 7.7 Hz, 1 H), 6.89 (ddd, J = 8.2, 2.6, 0.9 Hz, 1 H), 3.92 (s, 2 H), 
3.88 (s, 3 H), 3.58 (s, 2 H), 3.18 – 3.12 (comp, 2 H), 3.03 – 2.96 (comp, 2  H), 1.85 – 1.77 
(comp, 2 H); 13C NMR (101 MHz, cdcl3) δ 159.9, 143. 5, 142.6, 139.9, 139.2, 138.6, 130.4, 
129.7, 129.0, 128.2, 127.7, 126.9, 124.5, 119.6, 112.7, 112.6, 58.9, 58.9, 57.9, 55.3, 36.3, 
25.4. HRMS (ESI) m/z C24H25Cl2NO (M+H)
+ calcd for 344.2009; found 344.2017. 
NMR Assignment. 1H NMR (400 MHz) δ 7.39-7.24 (comp, 8 H, C1-H, C3-H, 
C13-H thru C17-H, and C21-H), 7.20 (ddd, J = 7.7, 1.6, 1.0 Hz, 1 H, C20-H), 7.14 (t, J = 
2.4, 1 H, C18-H), 7.01 (d, J = 7.7 Hz, 1 H, C6-H), 6.89 (ddd, J = 8.2, 2.6, 0.9 Hz, 1 H, 
C22-H), 3.92 (s, 2 H, C10-H), 3.88 (s, 3 H, C24-H), 3.58 (s, 2 H, C11-H), 3.18 – 3.12 
(comp, 2 H, C9-H), 3.03 – 2.96 (comp, 2 H, C7-H), 1.85 – 1.77 (comp, 2 H, C8-H);  13C 
NMR (101 MHz) δ 159.9 (C23), 143.5 (C4), 142.6 (C19), 139.9 (C5), 139.2 (C12), 138.6 
(C2), 130.4 (C21), 129.7 (C3), 129.0 (C14 and C16), 128.2 (C13 and C17), 127.7 (C6), 
126.9 (C15), 124.5 (C1), 119.6 (C20), 112.7 (C18), 112.6 (C22), 58.9 (C10), 58.9 (C11), 
57.9 (C9), 55.3 (C24), 36.3 (C7), 25.4 (C8). 
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Representative procedure for deprotection/N-sulfonylation of methyl piperazine 
derivatives 
 
2-((3,5-Dichlorophenyl)sulfonyl)-5-(4-methylpiperazin-1-yl)isoindoline (1.103). KTL-
01-253. A solution of carbamate 1.66 (20 mg, 0.06 mmol) in EtOH (1.0 mL) and 10% Pd/C 
(8 mg) was stirred under an atmosphere of H2 for 24 h. The reaction was filtered through a 
pad of celite and the filtrate was concentrated under reduced pressure to provide 11 mg 
(89%) of secondary amine intermediate as a pink oil that was of sufficient purity for use in 
subsequent reactions. 3,5-dichlorobenzenesulfonylchloride (13 mg, 0.05 mmol) and Et3N 
(13 mg, 0.09 mmol) were added to a solution of secondary amine (11 mg, 0.05 mmol) in 
CH2Cl2 (1 mL). The solution was stirred at room temperature overnight and then 
concentrated under reduced pressure. The crude material was purified via flash column 
chromatography eluting EtOAc:TEA:hexanes (60:1:39) to give 17 mg (56%) of 1.103 as 
an off white solid: 1H NMR (400 MHz) δ 7.74 (d, J =1.9 Hz, 2 H), 7.54 (t, J =1.9 Hz, 1 
H), 7.07 (d, J =8.5 Hz, 1 H), 6.84 (dd, J =8.5, 2.3 Hz, 1 H), 6.72 (d, J =2.0 Hz, 1 H), 4.60 
(s, 2 H), 4.57 (s, 2 H), 3.20 – 3.14 (comp, 4 H), 2.59 – 2.52 (comp, 4 H), 2.35 (s, 3 H); 13C 
NMR (101 MHz) δ 151.6, 139.8, 136.6, 136.2, 132.7, 126.2, 125.7, 123.2, 116.4, 109.7, 
54.9, 54.0, 53.4, 49.2, 46.0; HRMS (ESI) m/z C19H21Cl2N3O2S (M+H)
+ calcd for 426.0804 
and 428.0777; found 426.0807 and 420.0778. 
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NMR Assignment. 1H NMR (400 MHz) δ 7.74 (d, J =1.9 Hz, 2 H, C10-H and 
C14-H), 7.54 (t, J =1.9 Hz, 1 H, C12-H), 7.07 (d, J =8.5 Hz, 1 H, C3-H), 6.84 (dd, J =8.5, 
2.3 Hz, 1 H, C2-H), 6.72 (d, J =2.0 Hz, 1 H, C6-H), 4.60 (s, 2 H, C7-H or C8-H), 4.57 (s, 
2 H, C7-H or C8-H), 3.20 – 3.14 (comp, 4 H, C15-H and C18-H), 2.59 – 2.52 (comp, 4 H, 
C16-H and C17-H), 2.35 (s, 3 H, C19-H); 13C NMR (101 MHz, cdcl3) δ 151.6 (C1), 139.8 
(C9), 136.6 (C5), 136.2 (11 and C13), 132.7 (C12), 126.2 (C4), 125.7 (C10 and C14), 123.2 
(C3), 116.4 (C2), 109.7 (C6), 54.9 (C15 and C18)), 54.0 (C7 or C8), 53.4 (C7 or C8), 49.2 
(C16 and C17), 46.0 (C19). 
 
2-((3,5-Dichlorophenyl)sulfonyl)-7-(4-methylpiperazin-1-yl)-1,2,3,4-
tetrahydroisoquinoline (1.104). KTL-01-257. Prepared according to the representative 
procedure outlined for N-sulfonylation. The crude material was purified via flash column 
chromatography eluting EtOAc:TEA:hexanes (49:1:50) to give 26 mg (46% over two-
steps) of 1.104 as an off white solid: 1H NMR (400 MHz) δ 7.68 (d, J =1.9 Hz, 2 H), 7.54 
(t, J =1.9 Hz, 1 H), 6.97 (d, J =8.5 Hz, 1 H), 6.77 (dd, J =8.5, 2.6 Hz, 1 H), 6.58 (d, J =2.4 
Hz, 1 H), 4.27 (s, 2 H), 3.41 (t, J =6.0 Hz, 2 H), 3.19 – 3.11 (comp, 4 H), 2.83 (t, J =5.9 
Hz, 2 H), 2.60 – 2.53 (comp, 4 H), 2.35 (s, 3 H); 13C NMR (101 MHz) δ 149.9, 139.9, 
136.1, 132.7, 131.5, 129.5, 125.8, 123.9, 115.6, 113.2, 54.9, 49.1, 47.7, 46.0, 44.1, 27.7; 
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HRMS (ESI) m/z  C2H23Cl2N3O2S (M+H)
+ calcd for 440.0961 and 442.0934; found 
440.0956 and 442.0931. 
 NMR Assignment. 1H NMR (400 MHz) δ 7.68 (d, J =1.9 Hz, 2 H, C11-H and 
C15-H), 7.54 (t, J =1.9 Hz, 1 H, C13-H), 6.97 (d, J =8.5 Hz, 1 H, C6-H), 6.77 (dd, J =8.5, 
2.6 Hz, 1 H, C8-H), 6.58 (d, J =2.4 Hz, 1 H, C7-H), 4.27 (s, 2 H, C7-H), 3.41 (t, J =6.0 
Hz, 2 H, C9-H), 3.19 – 3.11 (comp, 4 H, C16-H and C19-H), 2.83 (t, J =5.9 Hz, 2 H, C8-
H), 2.60 – 2.53 (comp, 4 H, C16-H and C19-H), 2.35 (s, 3 H, C20-H); 13C NMR (101 
MHz) δ 149.9 (C2), 139.9 (C10), 136.1 (C12 and C14), 132.7 (C4), 131.5 (C6), 129.5 
(C13), 125.8 (C11 and C15), 123.9 (C5), 115.6 (C1), 113.2 (C3), 54.9 (C16 and C19), 49.1 
(C17 and C18), 47.7 (C7), 46.0 (C20), 44.1 (C9), 27.7 (C8). 
 
2-((3,5-Dichlorophenyl)sulfonyl)-8-(4-methylpiperazin-1-yl)-2,3,4,5-tetrahydro-1H-
benzo[c]azepine (1.105). KTL-02-049. Prepared according to the representative 
procedure outlined for N-sulfonylation. The crude material was purified via flash column 
chromatography eluting EtOAc:TEA:hexanes (40:1:59) to give 17 mg (67% over two-
steps) of 1.105 as a yellow solid: 1H NMR (400 MHz) δ 7.39 (comp, J =6.2 Hz, 3H), 6.92 
(d, J =8.3 Hz, 1H), 6.88 (d, J =2.6 Hz, 1H), 6.71 (dd, J =8.2, 2.7 Hz, 1H), 4.47 (s, 2H), 
3.68 – 3.62 (comp, 2H), 3.23 – 3.18 (comp, 4H), 2.75 (comp, 2H), 2.60 – 2.55 (comp, 4H), 
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2.36 (s, 3H), 1.56 – 1.50 (comp, 2H); 13C NMR (101 MHz) δ 149.8, 143.4, 137.1, 135.5, 
132.1, 132.1, 130.3, 125.6, 117.5, 115.2, 55.0, 53.9, 52.0, 48.9, 46.0, 33.7, 27.4; HRMS 
(ESI) m/z C21H25Cl2N3O2S (M+H)
+ calcd for 454.1117 and 456.1091; found 454.1118 and 
454.1093. 
NMR Assignment. 1H NMR (400 MHz) δ 7.39 (comp, J =6.2 Hz, 3H, C12-H, 
C14-H and C16-H), 6.92 (d, J =8.3 Hz, 1H, C3-H), 6.88 (d, J =2.6 Hz, 1H, C6-H), 6.71 
(dd, J =8.2, 2.7 Hz, 1H, C2-H), 4.47 (s, 2H, C10-H), 3.68 – 3.62 (comp, 2H, C9-H), 3.23 
– 3.18 (comp, 4H, C17-H and C18-H), 2.75 (comp, 2H, C7-H), 2.60 – 2.55 (comp, 4H, 
C19-H and C20-H), 2.36 (s, 3H, C21-H), 1.56 – 1.50 (comp, 2H, C8-H); 13C NMR (101 
MHz) δ 149.8 (C1), 143.4 (C11), 137.1 (C5), 135.5 (C13 and C15), 132.1 (C4), 132.0 
(C14), 130.3 (C3), 125.6 (C12 and C16), 117.5 (C2), 115.2 (C3), 55.0 (C17 and C18), 53.9 
(C10), 52.0 (C9), 48.9 (C19 and C20), 46.0 (C21), 33.7 (C7), 27.4 (C8).  
Representative procedure for deprotection/N-sulfonylation of allyl piperazine 
derivatives 
 
7-(4-Allylpiperazin-1-yl)-2-((3,5-dichlorophenyl)sulfonyl)-1,2,3,4-
tetrahydroisoquinoline (1.107). KTL-01-264. A solution of carbamate 1.83 (61 mg, 0.18 
mmol) in CH2Cl2 (3.0 mL) was brought to 0 °C and TMSI (141 mg 0.71 mmol) was added 
(reaction carried out in the dark). The solution was warmed to room temperature and 
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stirred for 2 h. The reaction was poured into cold aqueous HCl (6 mL, 2 M) that was 
vigorously stirring. The aqueous layer was washed with Et2O (4 x 10 mL), basified, and 
extracted with CH2Cl2 (4 x 10 mL). The combined organic fractions were dried (Na2SO4) 
and concentrated under reduced pressure to give 35 mg (74%) of secondary amine 
intermediate as a yellow oil of sufficient purity for use in subsequent reactions. 3,5-
dichlorobenzenesulfonylchloride (13 mg, 0.05 mmol) and Et3N (13 mg, 0.09 mmol) were 
added to a solution of secondary amine (11 mg, 0.05 mmol) in CH2Cl2 (1 mL). The solution 
was stirred at room temperature overnight and then concentrated under reduced pressure. 
The crude material was purified via flash column chromatography eluting 
EtOAc:TEA:hexanes (25:1:74) to give 40 mg (61%) of 1.107 as a clear oil: 1H NMR (400 
MHz) δ 7.68 (d, J =1.9 Hz, 2 H), 7.54 (t, J =1.9 Hz, 1 H), 6.97 (d, J =8.5 Hz, 1 H), 6.77 
(dd, J =8.5, 2.6 Hz, 1 H), 6.57 (d, J =2.5 Hz, 1 H), 5.89 (ddt, J =16.8, 10.1, 6.6 Hz, 1 H), 
5.24 (comp, 2 H), 4.27 (s, 2 H), 3.40 (t, J =6.0 Hz, 2 H), 3.18 – 3.11 (comp, 4 H), 3.05 (dt, 
J =6.6, 1.2 Hz, 2 H), 2.83 (t, J =5.9 Hz, 2 H), 2.62 – 2.56 (comp, 4 H); 13C NMR (101 
MHz) δ 150.0, 139.9, 136.1, 134.7, 132.7, 131.5, 129.5, 125.8, 123.7, 118.3, 115.6, 113.1, 
61.7, 52.9, 49.2, 47.7, 44.1, 27.7; HRMS (ESI) m/z C22H25Cl2N3O2S (M+H)
+ calcd for 
466.1117 and 468.1091; found 466.1121 and 468.1095. 
NMR Assignment. 1H NMR (400 MHz) δ 7.68 (d, J =1.9 Hz, 2 H, C11-H and 
C15-H), 7.54 (t, J =1.9 Hz, 1 H, C13-H), 6.97 (d, J =8.5 Hz, 1 H, C6-H), 6.77 (dd, J =8.5, 
2.6 Hz, 1 H, C1-H), 6.57 (d, J =2.5 Hz, 1 H, C3-H), 5.89 (ddt, J =16.8, 10.1, 6.6 Hz, 1 H, 
C21-H), 5.24 (comp, 2 H, C22-H), 4.27 (s, 2 H, C7-H), 3.40 (t, J =6.0 Hz, 2 H, C9-H), 
3.18 – 3.11 (comp, 4 H, C16-H and C19-H), 3.05 (dt, J =6.6, 1.2 Hz, 2 H, C20-H), 2.83 (t, 
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J =5.9 Hz, 2 H, C8-H), 2.62 – 2.56 (comp, 4 H, C17-H and C18-H); 13C NMR (101 MHz) 
δ 150.0 (C2), 139.9 (C10), 136.1 (C23 and C25), 134.7 (C4), 132.7 (C21), 131.5 (C6), 
129.5 (C13), 125.8 (C11 and C15), 123.7 (C5), 118.3 (C22), 115.6 (C1), 113.1 (C3), 61.7 
(C20), 52.9 (C16 and C19), 49.2 (C17 and C18), 47.7 (C7), 44.1 (C9), 27.7 (C8).  
 
5-(4-Allylpiperazin-1-yl)-2-((3,5-dichlorophenyl)sulfonyl)isoindoline (1.106). KTL-
01-276. Prepared according to the representative procedure outlined for deprotection/N-
sulfonylation of allyl piperazine derivatives.. The crude material was purified via flash 
column chromatography eluting EtOAc:TEA:hexanes (49:1:50) to give 29 mg (53% over 
two-steps) of 1.106 as a yellow solid:  1H NMR (400 MHz, CDCl3) δ 7.74 (d, J =1.9 Hz, 
2 H), 7.53 (t, J =1.9 Hz, 1 H), 7.06 (d, J =8.5 Hz, 1 H), 6.84 (dd, J =8.5, 2.2 Hz, 1 H), 6.72 
(d, J =1.7 Hz, 1 H), 5.88 (d, J =40.5 Hz, 1 H), 5.20 (t, J =13.7 Hz, 2 H), 4.60 (s, 2 H), 4.57 
(s, 2 H), 3.19 – 3.13 (comp, 4 H), 3.04 (d, J =6.6 Hz, 2 H), 2.62 – 2.56 (comp, 4 H); 13C 
NMR (101 MHz) δ 151.7, 139.8, 136.6, 136.2, 134.7, 132.7, 126.2, 125.7, 123.1, 118.3, 
116.3, 109.7, 61.7, 54.0, 53.5, 52.9, 49.3; HRMS (ESI) m/z C21H23Cl2N3O2S (M+H)
+ calcd 
for 45.0961 and 454.0935; found 452.0959 and 454.0933. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J =1.9 Hz, 2 H, C10-H 
and C14-H), 7.53 (t, J =1.9 Hz, 1 H, C12-H), 7.06 (d, J =8.5 Hz, 1 H, C3-H), 6.84 (dd, J 
=8.5, 2.2 Hz, 1 H, C2-H), 6.72 (d, J =1.7 Hz, 1 H, C6-H), 5.88 (m, 1 H, C20-H), 5.20 
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(comp, 2 H, C21-H), 4.60 (s, 2 H, C7-H or C8-H), 4.57 (s, 2 H, C7-H or C8-H), 3.19 – 
3.13 (m, 4 H, C15-H and C18-H), 3.04 (d, J =6.6 Hz, 2 H, C19-H), 2.62 – 2.56 (m, 4 H, 
C16-H and C17-H); 13C NMR (101 MHz) δ 151.7 (C1), 139.8 (C9), 136.6 (C5), 136.2 
(C11 and C13), 134.7 (C20), 132.7 (C12), 126.2 (C4), 125.7 (C10 and C14), 123.1 (C3), 
118.3 (C21), 116.3 (C2), 109.7 (C6), 61.7 (C16), 54.0 (C7 or C8), 53.5 (C7 or C8), 52.9 
(C15 and C18), 49.3 (C16 and C17). 
 
8-(4-Allylpiperazin-1-yl)-2-((3,5-dichlorophenyl)sulfonyl)-2,3,4,5-tetrahydro-1H-
benzo[c]azepine (1.108). KTL-02-055. Prepared according to the representative 
procedure outlined for deprotection/N-sulfonylation of allyl piperazine derivatives. The 
crude material was purified via flash column chromatography eluting EtOAc:TEA:hexanes 
(5:1:94) to give 17 mg (50% over two-steps) of 1.108 as a clear oil:  1H NMR (400 MHz) 
δ 7.39 (s, 3 H), 6.92 (d, J =8.3 Hz, 1 H), 6.88 (d, J =2.6 Hz, 1 H), 6.70 (dd, J =8.2, 2.6 Hz, 
1 H), 5.96-5.84 (m, 1 H), 5.22 (comp, 2 H), 4.47 (s, 2 H), 3.70 – 3.60 (comp, 2 H), 3.25 – 
3.18 (comp, 4 H), 3.07 (dt, J =8.0, 2 Hz, 2 H), 2.75 (d, J =11.2 Hz, 2 H), 2.65 – 2.55 (comp, 
4 H), 1.54 (comp, 2 H);  13C NMR (101 MHz) δ 150.0, 143.4, 137.0, 135.5, 134.8, 132.0, 
131.9, 130.2, 125.6, 118.2, 117.4, 115.1, 61.8, 53.9, 53.0, 52.0, 49.1, 33.7, 27.4; HRMS 
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(ESI) m/z C23H27Cl2N3O2S (M+H)
+ calcd for 480.1274 and 482.1248; found 480.1277 and 
482.1251. 
NMR Assignment. 1H NMR (400 MHz) δ 7.39 (s, 3 H, C12-H, C14-H, and C16-
H), 6.92 (d, J =8.3 Hz, 1 H, C3-H), 6.88 (d, J =2.6 Hz, 1 H, C6-H), 6.70 (dd, J =8.2, 2.6 
Hz, 1 H, C2-H), 5.96-5.84 (m, 1 H, C22-H), 5.22 (comp, 2 H, C23-H), 4.47 (s, 2 H, C10-
H), 3.70 – 3.60 (comp, 2 H, C9-H), 3.25 – 3.18 (comp, 4 H, C17-H and C20-H), 3.07 (dt, 
J =8.0, 2 Hz, 2 H, C21-H), 2.75 (comp, 2 H, C7-H), 2.65 – 2.55 (comp, 4 H, C18-H and 
C19-H), 1.54 (comp, 2 H, C8-H); 13C NMR (101 MHz) δ 150.0 (C1), 143.4 (C11), 137.0 
(C5), 135.5 (C13 and C15), 134.8 (C23), 132.0 (C4), 131.9 (C14), 130.2 (C3), 125.6 (C12 
and C16), 118.2 (C23), 117.4 (C2), 115.1 (C6), 61.8 (C21), 53.9 (C10), 53.0 (C17 and 
C20), 52.0 (C9), 49.1 (C18 and C19), 33.7 (C7), 27.4 (C8).  
Preparation of Dihalogenated Tetrahydroisoquinoline Scaffold 
 
1-(5-Bromo-7-chloro-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethan-1-one 
(2.32). KTL-02-181. A solution of 2.31 (700 mg, 2.6 mmol) in CH2Cl2 was cooled 0 °C, 
and triethylamine (787 mg, 7.8 mmol) and trifluoroacetic anhydride (601 mg, 2.9 mmol) 
were added. This reaction was stirred at room temperature for 90 min and then washed 
with 1 M HCl (2 x 10 mL) and brine (1 x 10 mL). The organic layer was dried (Na2SO4) 
and concentrated to give 750 mg (88 %) of the desired amide as a yellow solid of sufficient 
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purity. The amide (750 mg, 2.27 mmol) and paraformaldehyde (681 mg, 22.7 mmol) were 
added to a solution of sulfuric acid (4.2 mL) and acetic acid (2.8 mL). The resulting solution 
was stirred at room temperature for 24 h and then poured into ice (ca. 50 g). The resulting 
aqueous suspension was extracted with EtOAc (3 x 50mL). The combined organic layers 
were washed with a saturated aqueous solution of NaHCO3 (1 x 50 mL), water (1 x 50 mL), 
and brine (1 x 50 mL). The organic layer was dried (Na2SO4) and concentrated under 
reduced pressure. The crude material was purified via flash column chromatography 
eluting with EtOAc:hexanes (10:90) to give 450 mg (60%) of 2.32 as a white solid: 1H 
NMR (400 MHz, rotamers) δ 7.49 (d, J = 2.0 Hz, 0.33 H), 7.47 (d, J = 2.1 Hz, 0.66 H), 
7.12 – 7.10 (m, 0.66 H), 7.09 (d, J = 2.0 Hz, 0.33 H), 4.75 (s, 1.33 H), 4.69 (s, 0.66 H), 
3.90 (t, J = 6.2 Hz, 0.66 H), 3.85 (t, J = 5.7 Hz, 1.33 H), 2.99 – 2.82 (comp, 2 H); 13C NMR 
(101 MHz) δ 156.1, 155.8, 135.5, 135.2, 135.0, 133.3, 133.2, 132.5, 131.8, 131.4, 131.0, 
125.9, 125.8, 125.5, 118.0, 115.1, 110.0, 47.0, 45.3, 43.3, 43.3, 41.6, 29.9, 28.4; HRMS 
(ESI) m/z  C11H8BrClF3NO (M+Na)
+ calcd for 363.9322 and 365.9300; found 363.9326 
and 365.9313. 
NMR Assignment. 1H NMR (400 MHz, rotamers) δ 7.49 (d, J = 2.0 Hz, 0.33 H, 
C1-H), 7.47 (d, J = 2.1 Hz, 0.66 H, C1-H), 7.12 – 7.10 (m, 0.66 H, C3-H), 7.09 (d, J = 2.0 
Hz, 0.33 H, C3-H), 4.75 (s, 1.33 H, C8-H), 4.69 (s, 0.66 H, C8-H), 3.90 (t, J = 6.2 Hz, 0.66 
H, C10-H), 3.85 (t, J = 5.7 Hz, 1.33 H, C10-H), 2.99 – 2.82 (comp, 2 H, C11-H). 
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Benzyl 5-bromo-7-chloro-3,4-dihydroisoquinoline-2(1H)-carboxylate (2.28). KTL-
02-240. A saturated solution of Na2CO3 (5 mL) was added to a solution of 2.32 (450 mg, 
1.31 mmol) in MeOH (5 mL) and the resulting mixture was heated under reflux for 16 h. 
The reaction was cooled to room temperature and the organics were removed under 
reduced pressure. The remaining aqueous fraction was extracted with CH2Cl2 (3 x 25 mL). 
The combined organic fractions were dried (K2CO3) and concentrated under reduced 
pressure to give 311 mg (96%) of secondary amine intermediate as a white solid of 
sufficient purity for use in subsequent reactions. A solution of amine intermediate (570 mg, 
2.31 mmol) in CH2Cl2 (20 mL) was cooled to 0 °C, and iPr2NEt (651 mg, 4.6 mmol) and 
Cbz-Cl (864 mg, 4.6 mmol) were added. The reaction was stirred at room temperature for 
16 h. The reaction concentrated under reduced pressure, and the crude mixture was purified 
via flash column chromatography eluting with EtOAc:hexanes (10:90) to give 800 mg 
(91%) of 2.28 as a white solid: 1H NMR (300 MHz) δ 7.48 (d, J = 2.1 Hz, 1 H), 7.43 – 7.32 
(comp, 5 H), 7.09 (s, 1 H), 5.20 (s, 2 H), 4.63 (s, 2 H), 3.76 (t, J = 6.0 Hz, 2 H), 2.84 (t, J 
= 5.6 Hz, 2 H); 13C NMR (101 MHz) δ 155.1, 137.0, 136.6, 136.4, 132.8, 132.6, 132.4, 
130.2, 128.6, 128.2, 128.1, 127.8, 127.7, 125.4, 67.5, 45.6, 41.3, 41.1, 29.1, 28.9; HRMS 
(ESI) m/z  C17H15BrClNO2 (M+Na)
+ calcd for 401.9867 and 403.9846; found 401.9864 
and 403.9845. 
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NMR Assignment. 1H NMR (300 MHz) δ 7.48 (d, J = 2.1 Hz, 1 H, C1-H), 7.43 – 
7.32 (comp, 5 H, C18-H thru C22-H), 7.09 (s, 1 H, C3-H), 5.20 (s, 2 H, C16-H), 4.63 (s, 2 
H, C8-H), 3.76 (t, J = 6.0 Hz, 2 H, C10-H), 2.84 (t, J = 5.6 Hz, 2 H, C11-H); 13C NMR 
(101 MHz) δ 155.1 (C13), 137.0 (C4), 136.6 (C4), 136.4 (C17), 132.8 (C2), 132.6 (C2), 
132.4 (C5), 130.2 (C6), 128.6 (C19 and C1), 128.2 (C20), 128.1 (C18 and C20), 127.8 
(C1), 127.7 (C1), 125.4 (C3), 67.5 (C16), 45.6 (C8), 41.3 (C10), 41.1 (C10), 29.1 (C11), 
28.9 (C11).  
Representative procedure for Heck cross-coupling with acrylates 
 
Benzyl (E)-7-chloro-5-(3-methoxy-3-oxoprop-1-en-1-yl)-3,4-dihydroisoquinoline-
2(1H)-carboxylate (2.33). KTL-02-228. A solution of carbamate 2.28 (50 mg, 0.13 mmol) 
in DMF (0.93 mL) was added to a CEM microwave vial containing tetrabutylammonium 
chloride (36 mg, 0.13 mmol), Pd(OAc)2 (3 mg, 0.013 mmol) and P(o-tol)3 (8 mg, 0.026 
mmol). iPr2NEt (34 mg, 0.26 mmol) and methyl acrylate (13 mg, 0.16 mmol) were added 
and the vial was capped and flushed with argon. The mixture was stirred for 2 min at room 
temperature and then heated in the microwave (300 W) at 125 °C for 1 h. The mixture was 
poured into water and extracted with CH2Cl2 (3 x 5 mL). The combined organic layers were 
dried (Na2SO4) and concentrated under reduced pressure. The crude material was purified 
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by flash column chromatography eluting with EtOAc:hexanes (10:90) to give 30 mg (60%) 
of 2.33 as a yellow oil: 1H NMR (300 MHz) δ 7.85 (d, J = 15.8 Hz, 1 H), 7.44 – 7.31 
(comp, 6 H), 7.13 (s, 1 H), 6.36 (d, J = 15.8 Hz, 1 H), 5.19 (s, 2 H), 4.64 (s, 2 H), 3.83 (s, 
3 H), 3.75 (t, J = 6.0 Hz, 2 H), 2.90 (t, J = 5.5 Hz, 2 H); 13C NMR (101 MHz) δ 166.8, 
155.1, 140.1, 136.5, 132.3, 128.5, 128.1, 128.0, 124.8, 121.2, 67.4, 51.9, 45.6, 41.1, 41.0, 
25.8, 25.7; HRMS (ESI) m/z  C21H20ClNO4 (M+Na)
+ calcd for 408.0973 and 410.0952; 
found 408.0978 and 410.0959.  
NMR Assignment. 1H NMR (300 MHz) δ 7.85 (d, J = 15.8 Hz, 1 H, C12-H), 7.44 
– 7.31 (comp, 6 H, C1-H and C18-H thru C22-H), 7.13 (s, 1 H, C3-H), 6.36 (d, J = 15.8 
Hz, 1 H, C23-H), 5.19 (s, 2 H, C16-H), 4.64 (s, 2 H, C8-H), 3.83 (s, 3 H, C27-H), 3.75 (t, 
J = 6.0 Hz, 2 H, C10-H), 2.90 (t, J = 5.5 Hz, 2 H, C11-H); 13C NMR (101 MHz) δ 166.8 
(C24), 155.1 (C13), 140.1, 136.5 (C17), 132.3, 128.5 (C19 and C21), 128.1 (C20), 128.0 
(C18 and C22), 124.8, 121.2 (C23), 67.4 (C16), 51.9 (C27), 45.6 (C8), 41.1 (C10), 41.0 
(C10), 25.8 (C11), 25.7 (C11). 
 
Benzyl (E)-7-chloro-5-(3-methoxy-3-oxoprop-1-en-1-yl)-3,4-dihydroisoquinoline-
2(1H)-carboxylate (2.37). KTL-02-295. Prepared according to the representative 
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procedure outlined for Heck cross-coupling with acrylates. The crude material was purified 
by flash column chromatography eluting with EtOAc:hexanes (10:90) to give 137 mg 
(61%) of 2.37 as a yellow oil: 1H NMR (400 MHz) δ 7.73 (d, J = 15.8 Hz, 1 H), 7.42 – 
7.30 (comp, 6 H), 7.09 (d, J = 11.9 Hz, 1 H), 6.27 (d, J = 15.7 Hz, 1 H), 5.17 (d, J = 1.1 
Hz, 2 H), 4.61 (s, 2 H), 3.72 (t, J = 6.0 Hz, 2 H), 2.87 (br s, 2 H), 1.52 (s, 9 H).  
NMR Assignment. 1H NMR (400 MHz) δ 7.73 (d, J = 15.8 Hz, 1 H, C12-H), 7.42 
– 7.30 (comp, 6 H, C1-H and C20-H thru C24-H), 7.09 (d, J = 11.9 Hz, 1 H, C3-H), 6.27 
(d, J = 15.7 Hz, 1 H, C13-H), 5.17 (d, J = 1.1 Hz, 2 H, C18-H), 4.61 (s, 2 H, C7-H), 3.72 
(t, J = 6.0 Hz, 2 H, C9-H), 2.87 (br s, 2 H, C10-H), 1.52 (s, 9 H, C28-H thru C30-H).  
Representative procedure for enoate reduction 
 
Benzyl 7-chloro-5-(3-methoxy-3-oxopropyl)-3,4-dihydroisoquinoline-2(1H)-
carboxylate (2.35). KTL-02-250. A solution of 2.33 (110 mg, 0.28 mmol) in EtOH (2.8 
mL) and Pt2O·2H2O (13 mg, 0.057 mmol) was stirred under an atmosphere of H2 until 
consumption of starting material was observed. The reaction was filtered through a pad of 
celite and the filtrate was concentrated under reduced pressure. The crude material was run 
through a silica plug eluting EtOAc:hexanes (1:1) to provide 85 mg (78%) of 2.35 as a 
yellow oil: 1H NMR (400 MHz,) δ 7.41 – 7.30 (m, 5 H), 7.03 (d, J = 2.1 Hz, 1 H), 6.97 (s,  
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1 H), 5.17 (s, 2 H), 4.60 (s, 2 H), 3.72 (t, J = 5.6 Hz, 2 H), 3.68 (s, 3 H), 2.88 (t, J = 7.9 Hz, 
2 H), 2.76 (s, 2 H), 2.56 (t, J = 7.9 Hz, 2 H); 13C NMR (101 MHz) δ 172.8, 155.2, 140.6, 
140.4, 136.6, 135.7, 135.2, 131.9, 131.1, 128.5, 128.1, 128.02, 128.0, 126.8, 124.5, 67.3, 
51.8, 45.8, 41.4, 41.2, 34.0, 27.3, 25.4, 25.2; HRMS (ESI) m/z  C21H22ClNO4 (M+Na)
+ 
calcd for 410.1130 and 412.1109; found 410.1137 and 412.1112. 
NMR Assignment. 1H NMR (400 MHz,) δ 7.41 – 7.30 (m, 5 H, C18-H thru C22-
H), 7.03 (d, J = 2.1 Hz, 1 H, C1-H), 6.97 (s, 1 H, C3-H), 5.17 (s, 2 H, C16-H), 4.60 (s, 2 
H, C8-H), 3.72 (t, J = 5.6 Hz, 2 H, C10-H), 3.68 (s, 3 H, C27-H), 2.88 (t, J = 7.9 Hz, 2 H, 
C12-H), 2.76 (s, 2 H, C11-H), 2.56 (t, J = 7.9 Hz, 2 H, C23-H); 13C NMR (101 MHz) δ 
172.8 (C24), 155.2 (C13), 140.6 (C4), 140.4 (C4), 136.6 (C17), 135.7 (C5), 135.2 (C5), 
131.9 (C6), 131.1 (C2), 128.5 (C19 and C21), 128.1 (C20), 128.02 (C18 and C20), 128.0 
(C18 and C20), 126.8 (C1), 124.5 (C3), 67.3 (C16), 51.8 (C27), 45.8 (C11), 41.4 (C10), 
41.2 (C10), 34.0 (C23), 27.3 (C12), 25.4 (C11), 25.2 (C11). 
 
Benzyl 7-chloro-5-(3-methoxy-3-oxopropyl)-3,4-dihydroisoquinoline-2(1H)-
carboxylate (2.38). KTL-02-296. Prepared according to the representative procedure 
outlined for enoate reduction. The crude material was run through a silica plug eluting 
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EtOAc:hexanes (1:1) to provide 70 mg (51%) of 2.38 as a yellow oil: 1H NMR (300 MHz) 
δ 7.43 – 7.34 (m, 5 H), 7.07 (br s, J = 2.0 Hz, 1 H), 6.99 (br s, 1 H), 5.20 (s, J = 1.4 Hz, 2 
H), 4.63 (s, 2 H), 3.74 (t, J = 6.0 Hz, 2 H), 2.92 – 2.72 (t, J = 6.0 Hz, 2 H), 2.79 (br s, 2 
H), 2.49 (t, J = 6.0 Hz, 2 H), 1.46 (s, 9 H).  
NMR Assignment. 1H NMR (300 MHz) δ 7.43 – 7.34 (m, 5 H, C20-H thru C24-
H), 7.07 (br s, J = 2.0 Hz, 1 H, C1-H), 6.99 (br s, 1 H, C3-H), 5.20 (s, J = 1.4 Hz, 2 H, 
C18-H), 4.63 (s, 2 H, C7-H), 3.74 (t, J = 6.0 Hz, 2 H, C9-H), 2.87 (t, J = 6.0 Hz, 2 H, C13-
H), 2.79 (br s, 2 H, C10-H), 2.49 (t, J = 6.0 Hz, 2 H, C12-H), 1.46 (s, 9 H, C28-H thru 
C30-H).  
Preparation of Sig1R ligand for conjugation 
 
3-(2-Benzylisoindolin-5-yl)phenol (2.40). KTL-02-136. A solution of carbamate 2.47 
(260 mg, 0.72 mmol) in CH2Cl2 (9 mL) was cooled to 0 °C, BBr3 (902 mg, 3.6 mmol) was 
added and the reaction was stirred at room temperature for 2 h. The reaction was cooled to 
0 °C and H2O (10 mL) was added. The resulting solid was collected via vacuum filtration 
to give 125 mg (82%) of the desired secondary amine intermediate as an off white solid. A 
solution of amine intermediate (76 mg, 0.33 mmol), NaBH(OAc)3 (140 mg, 0.66 mmol), 
benzaldehyde (69 mg, 0.66 mmol) and 33 μL AcOH in DCE (3.3 mL) was stirred overnight 
at room temperature. The reaction was quenched with an aqueous solution of sat. NaHCO3 
 166 
(3 mL), and the layers were separated. The aqueous layer was extracted with CH2Cl2 (3 x 
5 mL). The combined organic extracts were dried (K2CO3) and concentrated under reduced 
pressure. The crude material was purified via flash column chromatography eluting 
EtOAc:TEA:hexanes (49:1:50) to give 41 mg (42%) of 2.40 as an orange oil: 1H NMR 
(400 MHz, DMSO-d6) δ 7.41 – 7.23 (comp, 8 H), 7.17 (t, J = 7.8 Hz, 1 H), 6.96 – 6.92 
(comp, 2 H), 6.72 – 6.67 (m, 1 H), 3.91 (s, 2 H), 3.85-3.48 (comp, 4 H). 
NMR Assignment. 1H NMR (400 MHz, DMSO-d6) δ 7.41 – 7.23 (comp, 8 H, C1-
H, C3-H, C6-H, and C19-H thru C23-H), 7.17 (t, J = 7.8 Hz, 1 H, C12-H), 6.96 – 6.92 
(comp, 2 H, C11-H and C15-H), 6.72 – 6.67 (m, 1 H, C13-H), 3.91 (s, 2 H, C17-H), 3.85-
3.48 (comp, 4 H, C7-H and C9-H).  
 
Ethyl 2-(3-(2-benzylisoindolin-5-yl)phenoxy)acetate (2.53). KTL-02-121. A mixture of 
2.40 (11 mg, 0.037 mmol), ethyl bromoacetate (6 mg, 0.037 mmol), and K2CO3 (10 mg, 
0.074 mmol) in DMF (0.5 mL) was stirred at room temperature for 3 h. The mixture was 
filtered and concentrated, and the crude material was purified via flash column 
chromatography eluting EtOAc:TEA:hexanes (49:2:29) to give 2.53 as a clear oil: 1H NMR 
(400 MHz) δ 7.50 – 7.29 (comp, 8 H), 7.23 (d, J = 8.0 Hz, 1 H), 7.21 – 7.16 (m, 1 H), 7.11 
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(dd, J = 2.7, 1.6 Hz, 1 H), 6.85 (d, J = 2.5 Hz, 1 H), 4.66 (s, 2 H), 4.28 (q, J = 7.1 Hz, 2 H), 
4.02 – 3.95 (m, 4 H), 3.94 (s, 2 H), 1.30 (t, J = 7.1, 3 H). 
NMR Assignment. 1H NMR (400 MHz) δ 7.50 – 7.29 (comp, 8 H, C1-H, C3-H, 
C6-H, and C19-H thru C23-H), 7.23 (d, J = 8.0 Hz, 1 H, C12-H), 7.21 – 7.16 (m, 1 H, C15-
H), 7.11 (dd, J = 2.7, 1.6 Hz, 1 H, C11-H), 6.85 (d, J = 2.5 Hz, 1 H, C13-H), 4.66 (s, 2 H, 
C24-H), 4.28 (q, J = 7.1 Hz, 2 H, C28-H), 4.02 – 3.95 (m, 4 H, C7-H and C9-H), 3.94 (s, 
2 H, C17-H), 1.30 (t, J = 7.1, 3 H, C29-H).  
 
Benzyl 5-(3-hydroxyphenyl)isoindoline-2-carboxylate (2.56). KTL-02-165. A solution 
of 2.56 (250 mg, 0.75 mmol), 3-hydroxyphenylboronic acid (207 mg, 1.50 mmol), Cs2CO3 
(490 mg, 1.59 mmol), and palladium (bis)(t-butyl)3 phosphine (19 mg, 0.0375 mmol) in 
degassed 1,4-dioxane (2.3 mL) was stirred for 24 h at 90 °C. The reaction was cooled to 
room temperature and poured into water (5 mL). The material was extracted with CH2Cl2 
(3 x 15 mL), and the combined organic layers were dried (MgSO4) and concentrated under 
reduced pressure. The crude material was purified via flash column chromatography 
eluting with EtOAc:hexanes (1:1) to give 197 mg (75%) of 2.56 as a white solid: 1H NMR 
(400 MHz) δ 7.51 – 7.27 (comp, 9 H), 7.13 (t, J = 6.2 Hz, 1 H), 7.05 (d, J = 7.5 Hz, 1 H), 
6.83 (d, J = 8.0 Hz, 1 H), 5.23 (s, 2 H), 4.84 – 4.77 (comp, 4 H). 
 168 
NMR Assignment. 1H NMR (400 MHz) δ 7.51 – 7.27 (comp, 9 H, C1-H, C3-H, 
C6-H, C12-H, and C22-H thru C26-H), 7.13 (t, J = 6.2 Hz, 1 H, C15-H), 7.05 (d, J = 7.5 
Hz, 1 H, C11-H), 6.83 (d, J = 8.0 Hz, 1 H, C13-H), 5.23 (s, 2 H, C20-H), 4.84 – 4.77 (comp, 
4 H, C7-H and C9-H).  
 
Benzyl 5-(3-(2-methoxy-2-oxoethoxy)phenyl)isoindoline-2-carboxylate (2.57). KTL-
02-192. Prepared according to the general procedure outlined for compound 2.53. The 
crude mixture was purified via flash column chromatography eluting EtOA:hexanes 
(20:80) to give 131 mg (77%) of 2.57 as a light yellow oil: 1H NMR (400 MHz) δ 7.51 – 
7.26 (comp, 9 H), 7.23 – 7.17 (m, 1 H), 7.12 (ddd, J = 4.1, 2.6, 1.7 Hz, 1 H), 6.90 – 6.86 
(m, 1 H), 5.23 (s, 2 H), 4.84 – 4.77 (comp, 4 H), 4.70 (d, J = 1.3 Hz, 2 H), 3.82 (s, 3 H); 
13C NMR (101 MHz, rotamers) δ 169.3, 158.2, 154.9, 142.53, 142.50, 140.5, 140.4, 137.7, 
137.3, 136.8, 136.3, 136.0, 129.9, 128.5, 128.0, 127.9, 126.7, 126.7, 123.1, 122.9, 121.5, 
121.3, 120.75, 120.74, 114.0, 113.9, 113.21, 113.15, 67.1, 65.4, 52.5, 52.4, 52.3, 52.1, 51.9. 
NMR Assignment. 1H NMR (400 MHz) δ 7.51 – 7.26 (comp, 9 H, C1-H, C3-H, 
C6-H, C12-H, and C22-H thru C26-H), 7.23 – 7.17 (m, 1 H, C15-H), 7.12 (ddd, J = 4.1, 
2.6, 1.7 Hz, 1 H, C11-H), 6.90 – 6.86 (m, 1 H, C13-H), 5.23 (s, 2 H, C20-H), 4.84 – 4.77 
(comp, 4 H, C7-H and C9-H), 4.70 (d, J = 1.3 Hz, 2 H, C27-H), 3.82 (s, 3 H, C31-H). 
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Methyl 2-(3-(2-benzylisoindolin-5-yl)phenoxy)acetate (2.58). KTL-02-200. A solution 
of carbamate 2.56 (130 mg, 0.31 mmol) in EtOH (10 mL) and 10% Pd/C (33 mg) was 
stirred under an atmosphere of H2 until consumption of starting material was observed. The 
reaction was filtered and the filtrate was concentrated under reduced pressure to provide 
70 mg (79%) of the desired secondary amine intermediate sufficient purity for use in 
subsequent reactions. A solution of amine intermediate (70 mg, 0.25 mmol), NaBH(OAc)3 
(106 mg, 0.5 mmol), benzaldehyde (52 mg, 0.5 mmol) and 10 μL AcOH in DCE (2.5 mL) 
was stirred overnight at room temperature. The reaction was quenched with an aqueous 
solution of sat. NaHCO3 (3 mL), and the layers were separated. The aqueous layer was 
extracted with CH2Cl2 (3 x 5 mL). The combined organic extracts were dried (K2CO3) and 
concentrated under reduced pressure. The crude mixture was purified via flash column 
chromatography eluting EtOA:TEA:hexanes (20:1:79) to give 55 mg (60%) of 2.58 as a 
brown oil: 1H NMR (400 MHz) δ 7.47 – 7.28 (comp, 10 H), 7.25 – 7.22 (m, 1 H), 7.19 
(ddd, J = 7.7, 1.7, 0.9 Hz, 1 H), 7.10 (dd, J = 2.6, 1.7 Hz, 1 H), 6.88 – 6.84 (m, 1 H), 4.68 
(s, 2 H), 4.01 (d, J = 6.9 Hz, 4 H), 3.97 (s, 2 H), 3.82 (d, J = 0.7 Hz, 3 H); 13C NMR (101 
MHz) δ 169.4, 158.1, 143.2, 141.0, 139.7, 139.6, 139.0, 129.8, 128.8, 128.4, 127.2, 125.9, 
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122.6, 121.2, 120.8, 113.9, 112.9, 65.4, 60.3, 58.9, 58.7, 52.3; HRMS (ESI) m/z  
C24H23NO3 (M+H)
+ calcd for 374.1751; found 374.1760. 
NMR Assignment. 1H NMR (400 MHz) δ 7.47 – 7.28 (m, 9 H, C1-H, C3-H, C6-
H, C24-H thru C28-H), 7.25 – 7.22 (m, 1 H, C12-H), 7.19 (ddd, J = 7.7, 1.7, 0.9 Hz, 1 H, 
C15-H), 7.10 (dd, J = 2.6, 1.7 Hz, 1 H, C11-H), 6.88 – 6.84 (m, 1 H, C13-H), 4.68 (s, 2 H, 
C17-H), 4.01 (d, J = 6.9 Hz, 4 H, C7-H and C9-H), 3.97 (s, 2 H, C22-H), 3.82 (d, J = 0.7 
Hz, 3 H,  C21-H); 13C NMR (101 MHz) δ 169.4 (C18), 158.1 (C14), 143.2 (C10), 141.0 
(C4), 139.7 (C2), 139.6 (C23), 139.0 (C5), 129.8 (C12), 128.8 (C25 and C27), 128.4 (C24 
and C28), 127.2 (C26), 125.9 (C1), 122.6 (C3), 121.2 (C6), 120.8 (C11), 113.9 (C15), 
112.9 (C13), 65.4 (C17), 60.3 (C22), 58.9 (C9), 58.7 (C7), 52.3 (C21). 
 
2-(3-(2-Benzylisoindolin-5-yl)phenoxy)acetic acid (2.58). KTL-02-266. A solution of 
2.58 (24 mg, 0.06 mmol) and LiOH (18 mg, 0.75 mmol) in MeOH/H2O (3:1, 0.8 mL) was 
stirred at room temperature for 45 min. The MeOH was removed in vacuo and NH4Cl (0.5 
mL) was added. The resulting solid was filtered and dried to give 30 mg of 2.58 as a brown 
solid: 1H NMR (400 MHz, Methanol-d4) δ 7.60 (ddd, J = 5.6, 4.2, 2.0 Hz, 3 H), 7.57 (s, 2 
H), 7.47 (dd, J = 5.1, 2.1 Hz, 3 H), 7.39 (d, J = 8.3 Hz, 1 H), 7.32 (t, J = 7.9 Hz, 1 H), 7.16 
(dt, J = 7.9, 1.1 Hz, 1 H), 7.13 (t, J = 2.1 Hz, 1 H), 6.91 (ddd, J = 8.2, 2.6, 0.9 Hz, 1 H), 
4.60 – 4.56 (m, 4 H), 4.53 (s, 2 H), 4.44 (s, 2 H). 
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Representative procedure for reductive amination of tetralones 
 
tert-Butyl 6-((7-(4-propylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-
yl)amino)hexanoate (2.80). KTL-03-118. Ti(OtBu)4 (159 mg, 0.37 mmol) was added to 
a solution of 2.71 (25 mg, 0.09 mmol) and tert-butyl 6-aminohexanoate (69 mg, 0.37 
mmol) in DCE (1 mL) and the reaction was heated to 80 °C for 18 h. The reaction was 
cooled to room temperature and NaBH(OAc)3 (78 mg, 1.4 mmol) and TFA (45 mg, 0.39 
mmol) were added and the reaction was stirred for 2 h. Sat. NaHCO3(aq) (1 mL) was added 
and the reaction was stirred for 20 mins. The reaction was diluted with CH2Cl2 and filtered 
through a pad of celite. The filtrate was washed with sat. NaHCO3 (1 x 2 mL) and the 
organic layer was dried (Na2SO4) and concentrated. The crude material was purified by 
flash column chromatography eluting EtOAc:TEA:hexanes (20:1:79) to give 31 mg (80%) 
of 2.80 as a yellow oil:  1H NMR (400 MHz) δ 6.96 (d, J = 8.4 Hz, 1 H), 6.92 (d, J = 2.6 
Hz, 1 H), 6.76 (dd, J = 8.4, 2.7 Hz, 1 H), 3.69 (t, J = 5.0 Hz, 1 H), 3.19 – 3.12 (comp, 4 
H), 2.75 – 2.62 (comp, 4 H), 2.60 (comp, 4 H), 2.38 – 2.32 (comp, 2 H), 2.20 (t, J = 7.5 
Hz, 2 H), 1.91 (m, 1 H), 1.86 – 1.77 (comp, 2 H), 1.71 – 1.63 (m, 1 H), 1.63 – 1.47 (comp, 
7 H), 1.43 (s, 9 H), 1.36 (comp, 2 H), 0.92 (t, J = 7.4 Hz, 3 H); 13C NMR (101 MHz) δ 
173.2, 149.6, 139.9, 129.6, 128.8, 116.3, 115.4, 79.9, 60.7, 55.8, 53.3, 49.7, 47.0, 35.5, 
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30.3, 28.5, 28.1, 27.0, 25.0, 20.0, 19.3, 12.0; HRMS (ESI) m/z  C27H45N3O2 (M+H)
+ calcd 
for 444.3585; found 444.3595. 
NMR Assignment. 1H NMR (400 MHz) δ 6.96 (d, J = 8.4 Hz, 1 H, C3-H), 6.92 
(d, J = 2.6 Hz, 1 H, C6-H), 6.76 (dd, J = 8.4, 2.7 Hz, 1 H, C2-H), 3.69 (t, J = 5.0 Hz, 1 H, 
C10-H), 3.19 – 3.12 (comp, 4 H, C13-H and C17-H), 2.75 – 2.62 (comp, 4 H, C7-H and 
C21-H), 2.60 (comp, 4 H, C14-H and C16-H), 2.38 – 2.32 (comp, 2 H, C18-H), 2.20 (t, J 
= 7.5 Hz, 2 H, C25-H), 1.91 (m, 1 H, C8-H), 1.86 – 1.77 (comp, 2 H, C9-H), 1.71 – 1.63 
(m, 1 H, C8-H), 1.63 – 1.47 (comp, 7 H, C19-H, C22-H and C24-H), 1.43 (s, 9 H, C30-H 
thru C32-H), 1.36 (comp, 2 H, C23-H), 0.92 (t, J = 7.4 Hz, 3 H, C20-H); 13C NMR (101 
MHz) δ 173.2 (C26), 149.6 (C1), 139.9 (C4), 129.6 (C3), 128.8 (C5), 116.3 (C6), 115.4 
(C2), 79.9 (C29), 60.7 (C18), 55.8 (C10), 53.3 (C14 and C16), 49.7 (C13 and C17), 47.0 
(C21) , 35.5 (C25), 30.3 (C22), 28.5 (C7 and C9), 28.1 (C30 thru C32), 27.0 (C23), 25.0 
(C24), 20.0 (C19), 19.3 (C8), 12.0 (C20).  
 
tert-Butyl 11-((7-(4-propylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-
yl)amino)undecanoate (2.81). KTL-03-130. Prepared according to the representative 
procedure outlined for reductive amination of tetralones. The crude material was purified 
by flash column chromatography eluting EtOAc:hexanes:TEA (15:1:84) to give 27 mg 
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(62%) of 2.81 as a yellow oil: 1H NMR (400 MHz) δ 6.96 (d, J = 8.4 Hz, 1 H), 6.93 (d, J 
= 2.6 Hz, 1 H), 6.76 (dd, J = 8.4, 2.6 Hz, 1 H), 3.70 (t, J = 5.0 Hz, 1 H), 3.19 – 3.12 (comp, 
4 H), 2.81 – 2.56 (comp, 9 H), 2.38 – 2.31 (comp, 2 H), 2.19 (t, J = 7.5 Hz,  2 H), 1.97 – 
1.86 (m, 1 H), 1.84-1.80 (comp, 2 H), 1.72 – 1.63 (m, 1 H), 1.62 – 1.45 (comp, 9 H), 1.43 
(s, 11 H), 1.27 (comp, 17 H), 0.92 (t, J = 7.4 Hz, 3 H); 13C NMR (101 MHz) δ 173.3, 149.6, 
139.9, 129.6, 128.9, 116.2, 115.4, 79.8, 60.7, 55.8, 53.3, 49.7, 47.2, 35.6, 30.5, 29.6, 29.4, 
29.3, 29.1, 28.5, 28.1, 27.5, 25.1, 20.0, 19.3, 12.0; HRMS (ESI) m/z  C32H55N3O2 (M+H)
+ 
calcd for 514.4367; found 514.4377. 
NMR Assignment. 1H NMR (400 MHz) δ 6.96 (d, J = 8.4 Hz, 1 H, C3-H), 6.93 
(d, J = 2.6 Hz, 1 H, C6-H), 6.76 (dd, J = 8.4, 2.6 Hz, 1 H, C2-H), 3.70 (t, J = 5.0 Hz, 1 H, 
C10-H), 3.19 – 3.12 (comp, 4 H, C13-H and C17-H), 2.81 – 2.56 (comp, 9 H, C7-H, C14-
H, C16-H and C21-H), 2.38 – 2.31 (comp, 2 H, C18-H), 2.19 (t, J = 7.5 Hz,  2 H, C30-H), 
1.97 – 1.86 (m, 1 H, C8-H), 1.84-1.80 (comp, 2 H, C9-H), 1.72 – 1.63 (m, 1 H, C8-H), 
1.62 – 1.45 (comp, 9 H, C22-H, C19-H, C29-H), 1.43 (s, 11 H, C35-H thru C37-H), 1.27 
(comp, 17 H, C23-H thru C28-H), 0.92 (t, J = 7.4 Hz, 3 H, C20-H); 13C NMR (101 MHz) 
δ 173.3 (C31), 149.6 (C1), 139.9 (C4), 129.6 (C3), 128.9 (C5), 116.2 (C6), 115.4 (C2), 
79.8 (C24), 60.7 (C18), 55.8 (C10), 53.3 (C14 and C16), 49.7 (C13 and C17), 47.2 (C21), 
35.6 (C30), 30.5 (C22), 29.6 (C25 and C6), 29.4 (C24), 29.3 (C27), 29.1 (C28), 28.5 (C7 
and C9), 28.1 (C35 thru C37), 27.5 (C23), 25.1 (C29), 20.0 (C19), 19.3 (C8), 12.0 (C20).  
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Representative procedure for -Cbz protection 
 
tert-Butyl 6-(((benzyloxy)carbonyl)(7-(4-propylpiperazin-1-yl)-1,2,3,4-
tetrahydronaphthalen-1-yl)amino)hexanoate (2.82). KTL-03-098. A solution of amine 
2.80 (37 mg, 0.08 mmol) in CH2Cl2 (1 mL) was cooled to 0 °C and iPr2NEt (22 mg, 0.17 
mmol) and Cbz-Cl (30 mg, 0.17 mmol) were added. The reaction was stirred at room 
temperature for 1 h. The reaction was quenched with sat NaHCO3 (1 mL) and the aqueous 
layer was extracted with CH2Cl2 (2 x 2 mL). The combined organic layers were dried 
(K2CO3) and concentrated under reduced pressure. The crude mixture was purified via 
flash column chromatography eluting with EtOAc:TEA:hexanes (10:1:89) to give 37 mg 
(77%) of 2.82 as a light yellow oil: 1H NMR (400 MHz) δ 7.43 – 7.24 (comp, 5 H), 6.97 
(d, J = 8.4 Hz, 1 H), 6.76 (dd, J = 8.4, 2.6 Hz, 1 H), 6.58 (s, 1 H), 5.41 – 5.01 (comp, 3 H), 
3.26 – 2.99 (comp, 5 H), 2.72 – 2.59 (comp, 3 H), 2.55 (q, J = 4.5, 3.9 Hz, 4 H), 2.38 – 
2.30 (comp, 2 H), 2.13 (dt, J = 25.2, 7.5 Hz, 2 H), 2.06 – 1.91 (comp, 2 H), 1.85 – 1.62 
(comp, 3 H), 1.52 (comp, 5 H), 1.42 (s, 9 H), 1.26 – 1.10 (comp, 2 H), 0.93 (t, J = 7.4 Hz, 
3 H); 13C NMR (101 MHz, rotamers) δ 173.0, 172.9, 157.1, 156.5, 149.8, 149.7, 137.1, 
136.9, 136.4, 129.8, 129.7, 129.3, 128.5, 128.4, 127.8, 127.8, 115.6, 115.3, 114.3, 113.8, 
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80.0, 79.9, 67.0, 66.9, 60.7, 56.3, 53.2, 49.5, 49.4, 44.6, 35.5, 35.3, 30.1, 29.7, 29.5, 29.1, 
28.7, 28.6, 28.1, 26.7, 24.8, 24.6, 22.6, 22.3, 20.0, 12.0; HRMS (ESI) m/z  C35H51N3O4 
(M+H)+ calcd for 578.3952; found 578.3954.  
NMR Assignment. : 1H NMR (400 MHz) δ 7.43 – 7.24 (comp, 5 H, C38-H thru 
C42-H), 6.97 (d, J = 8.4 Hz, 1 H, C3-H), 6.76 (dd, J = 8.4, 2.6 Hz, 1 H, C2-H), 6.58 (s, 1 
H, C6-H), 5.41 – 5.01 (comp, 3 H, C10-H and C36-H), 3.26 – 2.99 (comp, 5 H, C13-H, 
C17-H, and C21-H), 2.72 – 2.59 (comp, 3 H, C7-H and C21-H), 2.55 (q, J = 4.5, 3.9 Hz, 
4 H, C14-H and C16-H), 2.38 – 2.30 (comp, 2 H, C18-H), 2.13 (dt, J = 25.2, 7.5 Hz, 2 H, 
C25-H), 2.06 – 1.91 (comp, 2 H, C9-H), 1.85 – 1.62 (comp, 3 H, C8-H, and C24-H), 1.52 
(comp, 5 H, C8-H and C22-H), 1.42 (s, 9 H, C30-H thru C32-H,), 1.26 – 1.10 (comp, 2 H, 
C23-H), 0.93 (t, J = 7.4 Hz, 3 H, C20-H); 13C NMR (101 MHz, rotamers) δ 173.0 (C30 
thru C32), 172.9(C30 thru C32), 157.1 (C33), 156.5 (C33), 149.8 (C1), 149.7 (C1), 137.1 
(C4), 136.9 (C4), 136.4 (C37), 129.8 (C3), 129.7 (C3), 129.3 (C5), 128.5 (C39 and C41), 
128.4 (C39 and C41), 127.8 (C38, C40, and C42), 127.8 (C38, C40, and C42), 115.6 (C2), 
115.3 (C2), 114.3 (C6), 113.8 (C6), 80.0 (C29), 79.9 (C29), 67.0 (C36), 66.9 (C36), 60.7 
(C18), 56.3 (C10), 53.2 (C14 and C16), 49.5 (C13 and C17), 49.4 (C13 and C17), 44.6 
(C21), 35.5 (C25), 35.3 (C25), 30.1 (C22), 29.5 (C9), 29.1 (C9), 28.7 (C7), 28.6 (C7), 28.1 
(C30 thru C32), 26.7 (C23), 24.8 (C24), 24.6 (C24), 22.6 (C8), 22.3 (C8), 20.0 (C19), 12.0 
(C20).  
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tert-Butyl 11-(((benzyloxy)carbonyl)(7-(4-propylpiperazin-1-yl)-1,2,3,4-
tetrahydronaphthalen-1-yl)amino)undecanoate (2.83). KTL-03-104. Prepared 
according to the representative procedure outlined for -Cbz protection. The crude mixture 
was purified via flash column chromatography eluting EtOAc:TEA:hexanes (10:1:89) to 
give 46 mg (76%) of 2.83 as a light yellow oil: 1H NMR (400 MHz) δ 7.43 – 7.19 (comp, 
5 H), 6.97 (d, J = 8.7 Hz, 1 H), 6.76 (dd, J = 8.3, 2.5 Hz, 1 H), 6.59 (d, J = 2.4 Hz, 1 H), 
5.42 – 5.01 (comp, 3 H), 3.29 – 3.00 (comp, 6 H), 2.85 – 2.50 (comp, 8 H), 2.38 – 2.32 
(comp, 2 H), 2.19 (t, J = 7.5 Hz, 2 H), 2.11 – 1.99 (m, 1 H), 1.99 – 1.90 (m, 1 H), 1.76 
(comp, 3 H), 1.55 (p, J = 7.4 Hz, 6 H), 1.44 (s, 11 H), 1.32 – 1.04 (comp, 15 H), 0.93 (t, J 
= 7.4 Hz, 3 H); 13C NMR (101 MHz, rotamers) δ 173.3, 157.2, 156.4, 149.8, 149.7, 137.2, 
136.9, 136.5, 129.8, 129.7, 128.4, 128.3, 127.8, 127.8, 115.6, 115.2, 114.3, 113.8, 79.8, 
66.9, 66.8, 60.7, 56.3, 53.2, 49.5, 49.4, 44.8, 35.6, 30.4, 29.5, 29.5, 29.4, 29.3, 29.2, 29.1, 
28.7, 28.6, 28.1, 27.2, 25.1, 22.6, 22.3, 20.0, 12.0; HRMS (ESI) m/z  C40H61N3O4 (M+H)
+ 
calcd for 648.4735; found 648.4739. 
NMR Assignment. : 1H NMR (400 MHz) δ 7.43 – 7.19 (comp, 5 H, C43-H thru 
C47-H), 6.97 (d, J = 8.7 Hz, 1 H, C3-H), 6.76 (dd, J = 8.3, 2.5 Hz, 1 H, C2-H), 6.59 (d, J 
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= 2.4 Hz, 1 H, C6-H), 5.42 – 5.01 (comp, 3 H, C10-H and C41-H), 3.29 – 3.00 (comp, 5 
H, C13-H, C17-H, and C21-H), 2.85 – 2.50 (comp, 7 H, C7-H, C14-H, C16-H, and C21-
H), 2.38 – 2.32 (comp, 2 H, C18-H), 2.19 (t, J = 7.5 Hz, 2 H, C30-H), 2.11 – 1.99 (m, 1 H, 
C9-H), 1.99 – 1.90 (m, 1 H, C8-H), 1.76 (comp, 3 H, C8-H and C9-H), 1.55 (p, J = 7.4 Hz, 
6 H, C19-H, C22-H and C29-H), 1.44 (s, 11 H, C35-H thru C37-H), 1.32 – 1.04 (comp, 15 
H, C23-H thru C28-H), 0.93 (t, J = 7.4 Hz, 3 H, C20-H); 13C NMR (101 MHz, rotamers) 
δ 173.3 (C31), 157.2 (C11), 156.4 (C11), 149.8 (C1), 149.7 (C1), 137.2 (C4), 136.9 (C4), 
136.5 (C42), 129.8 (C3), 129.7 (C5), 128.4 (C44 and C46), 128.3 (C44 and C46), 127.8 
(C43, C45, and C47), 127.8 (C43, C45, and C47), 115.6 (C2), 115.2 (C2), 114.3 (C6), 
113.8 (C6), 79.8 (C34), 66.9 (C41), 66.8 (C41), 60.7 (C18), 56.3 (C10), 53.2 (C14 and 
C16), 49.5 (C13 and C17), 49.4 (C13 and C17), 44.8 (C21), 35.6 (C30), 30.4 (C22), 29.5 
(C9), 29.5 (C25), 29.4 (C26), 29.3 (C9), 29.2 (C24), 29.1 (C28), 28.7 (C7), 28.6 (C7), 28.1 
(C35 thru C37), 27.2 (C23), 25.1 (C29), 22.6 (C8), 22.3 (C8), 20.0 (C19), 12.0 (C20).  
Representative procedure for deprotection of tert-butyl ester 
 
6-(((Benzyloxy)carbonyl)(7-(4-propylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-
1-yl)amino)hexanoic acid (2.84). KTL-03-143. TFA (0.8 mL) was added dropwise to a 
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solution of carbamate 2.82 (129 mg, 0.22 mmol) in CH2Cl2 (2 mL). The reaction was stirred 
at room temperature overnight. The reaction was concentrated and dried under vacuum 
overnight. The crude residue was taken up in CH2Cl2 (10 mL) and washed with sat. 
NaHCO3(aq) (2 x 2 mL) and 1M HCl(aq) (2 x 2 mL). The organic layer was dried (Na2SO4) 
and concentrated to give 118 mg (95%) of 2.84 as the HCl salt as a brown foam that turned 
to an oil: 1H NMR (499 MHz, rotamers) δ 7.41 – 7.27 (comp, 4 H), 7.21 – 7.07 (m, 1 H), 
6.98 (d, J = 8.3 Hz, 1 H), 6.74 (d, J = 8.3 Hz, 1 H), 6.63 (s, 1 H), 5.33 – 4.83 (comp, 3 H), 
3.64 – 3.5 (comp, 2 H), 3.53 – 3.28 (comp, 4 H), 3.25 – 3.03 (m, 1 H), 2.98 (t, J = 8.5 Hz, 
4 H), 2.82 (d, J = 8.6 Hz, 1 H), 2.76 – 2.57 (m, 2 H), 2.27 (m, 1 H), 2.20 (m, 1 H), 2.02 (m, 
1 H), 1.93 (dq, J = 12.3, 7.6, 7.0 Hz, 3 H), 1.84 – 1.62 (m, 2 H), 1.62 – 1.41 (m, 4 H), 1.32 
– 1.24 (m, 1 H), 1.21 – 1.10 (m, 1 H), 1.00 (t, J = 7.2 Hz, 3 H); 13C NMR (126 MHz, 
rotamers) δ 177.0, 157.0, 156.5, 147.6, 147.1, 137.6, 137.1, 136.9, 136.7, 132.2, 131.8, 
130.2, 128.5, 128.4, 128.0, 127.9, 116.4, 116.2, 115.6, 67.2, 67.0, 58.9, 57.1, 56.5, 51.6, 
47.4, 46.9, 46.8, 44.9, 33.8, 29.7, 29.0, 28.7, 28.6, 26.6, 24.4, 24.3, 22.3, 22.2, 17.1, 11.2; 
HRMS (ESI) m/z  C31H43N3O4 (M+H)
+ calcd for 522.3326; found 522.3331. 
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11-(((Benzyloxy)carbonyl)(7-(4-propylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-
1-yl)amino)undecanoic acid (2.85). KTL-03-149. Prepared according to the 
representative procedure outlined for deprotection of tert-butyl ester. Compound 2.85 was 
isolated as the HCl salt (148 mg, 97%) as a brown foam that turned to an oil: 1H NMR (499 
MHz, rotamers) δ 7.45 – 7.08 (m, 5 H), 6.98 (d, J = 8.3 Hz, 1 H), 6.71 (dd, J = 8.4, 2.5 Hz, 
1 H), 6.55 (d, J = 4.6 Hz, 1 H), 5.37 – 4.99 (comp, 3 H), 3.72 – 3.52 (comp, 2 H), 3.51 – 
3.32 (comp, 4 H), 3.30 – 3.16 (m, 1 H), 3.16 – 3.06 (m, 1 H), 3.06 – 2.75 (comp, 4 H), 2.75 
– 2.59 (comp, 2 H), 2.29 (t, J = 7.4 Hz, 2 H), 2.09 – 2.00 (m, 1 H), 2.00 – 1.87 (comp, 3 
H), 1.87 – 1.65 (comp, 2 H), 1.58 (p, J = 7.3 Hz, 2 H), 1.54 – 1.38 (m, 1 H), 1.38 – 1.05 
(comp, 13 H), 1.00 (t, J = 7.3 Hz, 3 H); 13C NMR (126 MHz, rotamers) δ 177.9, 177.9, 
157.2, 156.4, 147.8, 147.5, 137.1, 137.0, 136.8, 131.7, 131.4, 130.1, 128.5, 128.4, 127.9, 
127.9, 127.8, 115.9, 115.6, 115.5, 67.1, 66.9, 58.8, 58.8, 56.2, 51.6, 51.5, 46.8, 44.9, 34.1, 
30.3, 29.7, 29.3, 29.3, 29.2, 29.2, 29.1, 29.0, 29.0, 28.9, 28.8, 28.7, 28.6, 27.1, 24.8, 22.4, 
22.3, 17.1, 11.2; HRMS (ESI) m/z  C36H53N3O4 (M+Na)
+ calcd for 614.3941; found 
614.3928. 
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Representative procedure for gemcitabine conjugation 
 
Benzyl (11-((1-((2R,4R,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-
butyldimethylsilyl)oxy)methyl)-3,3-difluorotetrahydrofuran-2-yl)-2-oxo-1,2-
dihydropyrimidin-4-yl)amino)-11-oxoundecyl)(7-(4-propylpiperazin-1-yl)-1,2,3,4-
tetrahydronaphthalen-1-yl)carbamate (2.88). KTL-03-158. A solution of 2.84 (49 mg, 
0.09 mmol), TBS-gemcitabine (25 mg, 0.05 mmol), EDCI·HCl (43 mg, 0.22 mmol), and 
HOBt (24 mg, 0.17 mmol) in THF (0.6 mL) was stirred at room temperature for 16 h under 
an atmosphere of N2. The reaction was concentrated under reduced pressure. The crude 
residue was purified by flash column chromatography eluting EtOAc:TEA:hexanes 
(30:1:69) to give 38 mg (77%) of 2.88 as a yellow oil: 1H NMR (499 MHz, rotamers) δ 
8.05 (d, J = 7.6 Hz, 1 H), 7.44 – 7.22 (comp, 6 H), 6.97 (d, J = 8.3 Hz, 1 H), 6.78 (d, J = 
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5.0 Hz, 1 H), 6.63 – 6.55 (m, 1 H), 6.33 (dd, J = 10.4, 3.5 Hz, 1 H), 5.43 – 5.01 (comp, 3 
H), 4.33 (td, J = 11.5, 8.1 Hz, 1 H), 4.02 (dd, J = 12.0, 2.2 Hz, 1 H), 3.95 (d, J = 8.2 Hz, 1 
H), 3.80 (dd, J = 11.9, 1.9 Hz, 1 H), 3.20 – 3.01 (comp, 5 H), 2.92 – 2.60 (comp, 3 H), 2.57 
(q, J = 5.5 Hz, 4 H), 2.41 (t, J = 7.6 Hz, 1 H), 2.37 – 2.28 (comp, 3 H), 2.07 – 1.98 (m, 1 
H), 1.97 – 1.88 (m, 1 H), 1.87 – 1.66 (comp, 3 H), 1.66 – 1.59 (comp, 2 H), 1.54 (dq, J = 
14.3, 7.2 Hz, 5 H), 1.32 – 1.22 (m, 2 H), 1.22 – 1.11 (m, 1 H), 1.00 – 0.84 (m, 22 H), 0.27 
– -0.00 (m, 12 H); 13C NMR (126 MHz, rotamers) δ 173.6, 162.9, 157.2, 156.5, 154.9, 
149.8, 149.7, 143.9, 137.1, 136.9, 136.7, 136.3, 129.9, 129.8, 129.4, 128.5, 128.4, 127.9, 
127.8, 124.0, 121.9, 119.9, 115.8, 115.5, 114.4, 113.9, 96.9, 85.0, 84.8, 84.6, 84.4, 81.4, 
81.3, 69.6, 69.5, 69.4, 69.3, 67.0, 66.9, 60.7, 60.0, 56.8, 56.3, 53.2, 49.5, 49.4, 45.9, 44.4, 
37.3, 37.2, 29.5, 29.1, 28.9, 28.7, 28.6, 26.4, 26.3, 25.9, 25.5, 24.15, 24.07, 22.5, 22.3, 20.0, 
18.3, 18.0, 12.0, -4.8, -5.3, -5.44, -5.45; HRMS (ESI) m/z  C52H80F2N6O7Si2 (M+Na)
+ calcd 
for 1017.5499; found 1017.5487. 
NMR Assignment. 1H NMR (499 MHz, rotamers) δ 8.05 (d, J = 7.6 Hz, 1 H, C58-
H), 7.44 – 7.22 (comp, 6 H, C39-H thru C43-H and C57-H), 6.97 (d, J = 8.3 Hz, 1 H, C3-
H), 6.78 (d, J = 5.0 Hz, 1 H, C2-H), 6.63 – 6.55 (m, 1 H, C6-H), 6.33 (dd, J = 10.4, 3.5 Hz, 
1 H, C50-H), 5.43 – 5.01 (comp, 3 H, C10-H and C37-H), 4.33 (td, J = 11.5, 8.1 Hz, 1 H, 
C46-H), 4.02 (dd, J = 12.0, 2.2 Hz, 1 H, C45-H), 3.95 (d, J = 8.2 Hz, 1 H, C47-H), 3.80 
(dd, J = 11.9, 1.9 Hz, 1 H, C45-H), 3.20 – 3.01 (comp, 5 H, C13-H, C17-H, and C21-H), 
2.92 – 2.60 (comp, 3 H, C7-H and C21-H), 2.57 (q, J = 5.5 Hz, 4 H, C14-H and C16-H), 
2.41 (t, J = 7.6 Hz, 1 H, C25-H), 2.37 – 2.28 (comp, 3 H, C18-H and C25-H), 2.07 – 1.98 
(m, 1 H, C9-H), 1.97 – 1.88 (m, 1 H, C8-H), 1.87 – 1.66 (comp, 3 H, C8-H and C9-H), 
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1.66 – 1.59 (comp, 2 H, C22-H), 1.54 (dq, J = 14.3, 7.2 Hz, 5 H, C19-H and C24-H), 1.32 
– 1.22 (m, 2 H, C23-H), 1.22 – 1.11 (m, 1 H, C23-H), 1.00 – 0.84 (m, 22 H, C20-H, C66-
H thru C68-H, and C72-H thru C74-H), 0.27 – -0.00 (m, 12 H, C64-H, C65-H, C70-H, and 
C71-H); 13C NMR (126 MHz, rotamers) δ 173.6 (C26), 162.9 (C56), 157.2 (C34), 156.5 
(C34), 154.9 (C53), 149.8 (C1), 149.7 (C1), 143.9 (C58), 137.1 (C4), 136.9 (C4), 136.7 
(C38), 136.3 (C38), 129.9 (C3), 129.8 (C5), 129.4 (C3), 128.5 (C40 and C42), 128.4 (C40 
and C42), 127.9 (C39, C41, and C43), 127.8 (C39, C41, and C43), 124.0 (C49), 121.9 
(C49), 119.9 (C49), 115.8 (C2), 115.5 (C2), 114.4 (C6), 113.9 (C6), 96.9 (C57), 85.0 
(C50), 84.8 (C50), 84.6 (C50), 84.4 (C50), 81.4 (C47), 81.3 (C47), 69.6 (C46), 69.5 (C46), 
69.4 (C46), 69.3 (C46), 67.0 (C37), 66.9 (C37), 60.7 (C18), 60.0 (C45), 56.8 (C10), 56.3 
(C10), 53.2 (C14 and C16), 49.5 (C13 and C17), 49.4 (C13 and C17), 45.9 (C21), 44.4 
(C21), 37.3 (C25), 37.2 (C25), 29.5 (C22), 29.1 (C22), 28.9 (C9), 28.7 (C9), 28.7 (C7), 
28.6 (C7), 26.4 (C23), 26.3 (C23), 25.9 (C66 thru C68 and C72 thru C74), 25.5 (C66 thru 
C68 and C72 thru C74), 24.15 (C24), 24.07 (C24), 22.5 (C8), 22.3 (C8), 20.0 (C19), 18.3 
(C63 or C75), 18.0 (C63 or C75), 12.0 (C20), -4.8 (C64, C65, C70, and C71), -5.3 (C64, 
C65, C70, and C71), -5.44 (C64, C65, C70, and C71), -5.45 (C64, C65, C70, and C71).  
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Benzyl (11-((1-((2R,4R,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-
butyldimethylsilyl)oxy)methyl)-3,3-difluorotetrahydrofuran-2-yl)-2-oxo-1,2-
dihydropyrimidin-4-yl)amino)-11-oxoundecyl)(7-(4-propylpiperazin-1-yl)-1,2,3,4-
tetrahydronaphthalen-1-yl)carbamate (2.89). KTL-03-151. Prepared according to the 
representative procedure outlined for gemcitabine conjugation. The crude residue was 
purified by flash column chromatography eluting EtOAc:TEA:hexanes (30:1:69) to give 
48 mg (74%) of 2.89 as a yellow oil: 1H NMR (499 MHz, rotamers) δ 8.96 (s, 1 H), 8.07 
(d, J = 7.6 Hz, 1 H), 7.47 – 7.22 (comp, 6 H), 6.97 (dd, J = 8.6, 2.1 Hz, 1 H), 6.76 (dd, J = 
8.5, 2.5 Hz, 1 H), 6.59 (d, J = 2.6 Hz, 1 H), 6.33 (dd, J = 10.4, 3.5 Hz, 1 H), 5.41 – 5.01 
(comp, 3 H), 4.33 (td, J = 11.6, 8.1 Hz, 1 H), 4.02 (d, J = 11.9 Hz, 1 H), 3.95 (d, J = 8.1 
Hz, 1 H), 3.81 (dd, J = 11.9, 2.0 Hz, 1 H), 3.26 – 3.09 (m, 1 H), 3.09 – 2.98 (comp, 4 H), 
2.84 – 2.58 (comp, 3 H), 2.55 (q, J = 4.6 Hz, 4 H), 2.44 (td, J = 7.4, 4.7 Hz, 2 H), 2.37 – 
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2.31 (comp, 2 H), 2.04 (s, 1 H), 1.95 (s, 1 H), 1.83 (s, 2 H), 1.74 (s, 2 H), 1.65 (p, J = 7.5 
Hz, 3 H), 1.54 (p, J = 7.6 Hz, 2 H), 1.50 – 1.41 (m, 1 H), 1.36 – 1.04 (m, 15 H), 0.97 – 0.85 
(m, 22 H), 0.15 – 0.08 (m, 12 H); 13C NMR (126 MHz, rotamers) δ 176.2, 173.5, 162.6, 
157.2, 156.5, 154.8, 149.8, 149.6, 144.1, 137.2, 137.0, 136.5, 129.9, 129.7, 129.4, 128.4, 
128.37, 127.8, 124.0, 121.9, 119.8, 115.6, 115.2, 114.4, 113.9, 96.7, 85.0, 84.8, 84.6, 84.4, 
81.4, 69.7, 69.4, 69.3, 66.9, 66.8, 60.6, 60.0, 56.9, 56.3, 53.1, 49.3, 45.6, 44.8, 37.7, 30.4, 
29.7, 29.5, 29.3, 29.0, 28.7, 27.2, 25.9, 25.5, 24.8, 22.6, 22.4, 19.9, 18.3, 18.0, 12.0, -4.8, -
5.3, -5.4; HRMS (ESI) m/z  C57H90F2N6O7Si2 (M+Na)
+ calcd for 1087.6290; found 
1087.6270. 
 NMR Assignment. 1H NMR (499 MHz, rotamers) δ 8.96 (s, 1 H, C58-H), 8.07 (d, 
J = 7.6 Hz, 1 H, C57-H), 7.47 – 7.22 (comp, 6 H, C39-H thru C43-H), 6.97 (dd, J = 8.6, 
2.1 Hz, 1 H, C3-H), 6.76 (dd, J = 8.5, 2.5 Hz, 1 H, C2-H), 6.59 (d, J = 2.6 Hz, 1 H, C6-H), 
6.33 (dd, J = 10.4, 3.5 Hz, 1 H, C50-H), 5.41 – 5.01 (comp, 3 H, C10-H and C37-H), 4.33 
(td, J = 11.6, 8.1 Hz, 1 H, C46-H), 4.02 (d, J = 11.9 Hz, 1 H, C45-H), 3.95 (d, J = 8.1 Hz, 
1 H, C47-H), 3.81 (dd, J = 11.9, 2.0 Hz, 1 H, C45-H), 3.26 – 3.09 (m, 1 H, C21-H), 3.09 – 
2.98 (comp, 4 H, C13-H and C17-H), 2.84 – 2.58 (comp, 3 H, C7-H and C21-H), 2.55 (q, 
J = 4.6 Hz, 4 H, C14-H and C16-H), 2.44 (td, J = 7.4, 4.7 Hz, 2 H, C30-H), 2.37 – 2.31 
(comp, 2 H, C18-H), 2.04 (s, 1 H, C9-H), 1.95 (s, 1 H, C8-H), 1.83 (s, 2 H, C21-H), 1.74 
(s, 2 H, C8-H and C9-H), 1.65 (p, J = 7.5 Hz, 3 H, C29-H), 1.54 (p, J = 7.6 Hz, 2 H, C19-
H), 1.50 – 1.41 (m, 1 H, C21-H), 1.36 – 1.04 (m, 15 H, C23-H thru C28-H), 0.97 – 0.85 
(m, 22 H, C20-H, C66-H thru C68-H, and C72-H thru C74-H), 0.15 – 0.08 (m, 12 H, C64-
H, C65-H, C70-H, and C71-H); 13C NMR (126 MHz, rotamers) δ 176.2 (C31), 173.5(C31), 
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162.6 (C56), 157.2 (C34), 156.5 (C34), 154.8 (C53), 149.8 (C1), 149.6 (C1), 144.1 (C58), 
137.2 (C34), 137.0 (C34), 136.5 (C4), 129.9 (C5), 129.7 (C3), 129.4 (C4), 128.4, 128.37, 
127.8, 124.0 (C49), 121.9 (C49), 119.8 (C49), 115.6 (C2), 115.2 (C2), 114.4 (C6), 113.9 
(C6), 96.7 (C57), 85.0 (C50), 84.8 (C50), 84.6 (C50), 84.4 (C50), 81.4 (C47), 69.7 (C46), 
69.4 (C46), 69.3 (C46), 66.9 (C37), 66.8 (C37), 60.6 (C18), 60.0 (C45), 56.9 (C10), 56.3 
(C10), 53.1 (C14 and C16), 49.3 (C13 and C17), 45.6 (C21), 44.8 (C21), 37.7 (C30), 30.4 
(C22), 29.7 (C9), 29.5 (C9), 29.3 (C24 thru C28), 29.0 (C24 thru C28), 28.7 (C7), 27.2 
(C7), 25.9 (C66 thru C68 and C72 thru C74), 25.5 (C66 thru C68 and C72 thru C74), 24.8 
(C29), 22.6 (C8), 22.4 (C8), 19.9 (C19), 18.3 (C63 or C75), 18.0 (C63 or C75), 12.0 (C20), 
-4.8 (C64, C65, C70, and C71), -5.3 (C64, C65, C70, and C71), -5.4 (C64, C65, C70, and 
C71). 
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Representative procedure for TBAF deprotection 
 
Benzyl (6-((1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-
(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)amino)-6-
oxohexyl)(7-(4-propylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate 
(2.90). KTL-03-152. TBAF (90 mL, 1M solution in THF) was added to a solution of 2.88 
(34 mg, 0.03 mmol) in THF (1.5 mL). The reaction was stirred at room temperature for 1 
h and concentrated under reduced pressure. The crude residue was purified by HPLC using 
a solvent gradient of MeCN (0.1%TFA)/H2O (0.1% TFA) 10:90 to MeCN 
(0.1%TFA)/H2O (0.1% TFA) 95:5 over 30 min. The product containing fractions were 
combined and basified with sat. NaHCO3(aq) and the MeCN was removed under reduced 
pressure. The resulting aqueous fraction was extracted with CH2Cl2 (5 x 10 mL). The 
combined organic layers were dried (Na2SO4) and concentrated under reduced pressure to 
 187 
give 15 mg (65%) of 2.90 as a white solid:  1H NMR (499 MHz, rotamers) δ 8.09 (d, J = 
7.5 Hz, 1 H), 7.45 – 7.15 (comp, 6 H), 6.96 (d, J = 8.4 Hz, 1 H), 6.79 – 6.74 (m, 1 H), 6.59 
– 6.51 (m, 1 H), 6.22 (s, 1 H), 5.37 – 5.00 (comp, 3 H), 4.46 (s, 1 H), 4.05 – 3.96 (comp, 2 
H), 3.87 (d, J = 12.7 Hz, 1 H), 3.15 (s, 1 H), 3.10 – 2.96 (comp, 5 H), 2.82 – 2.50 (comp, 
8 H), 2.44 – 2.25 (comp, 5 H), 2.01 (s, 1 H), 1.93 (s, 1 H), 1.83 – 1.64 (comp, 3 H), 1.64 – 
1.46 (comp, 7 H), 1.24 (s, 5 H), 1.14 (s, 2 H), 0.92 (t, J = 7.4 Hz, 4 H); 13C NMR (126 
MHz, rotamers) δ 173.9, 173.8, 163.1, 157.3, 156.7, 155.6, 155.4, 149.7, 149.4, 145.0, 
137.0, 136.6, 136.3, 130.1, 129.9, 128.5, 128.4, 127.9, 127.7, 124.7, 122.6, 120.5, 116.1, 
115.9, 114.4, 113.9, 113.8, 97.4, 85.4, 81.6, 68.6, 68.5, 68.3, 67.1, 60.6, 59.4, 56.9, 56.4, 
53.1, 49.3, 45.8, 44.5, 37.2, 29.7, 29.4, 29.0, 28.7, 28.6, 26.4, 26.3, 24.1, 22.4, 22.3, 19.7, 
11.9; HRMS (ESI) m/z  C40H52F2N6O7 (M+H)
+ calcd for 767.3938; found 767.3950. 
 NMR Assignment. 1H NMR (499 MHz, rotamers) δ 8.09 (d, J = 7.5 Hz, 1 H, C58-
H), 7.45 – 7.15 (comp, 6 H,  C39-H thru C43-H and C57-H), 6.96 (d, J = 8.4 Hz, 1 H, C3-
H), 6.79 – 6.74 (m, 1 H, C2-H), 6.59 – 6.51 (m, 1 H, C6-H), 6.22 (s, 1 H, C50-H), 5.37 – 
5.00 (comp, 3 H, C10-H and C37-H), 4.46 (s, 1 H, C46-H), 4.05 – 3.96 (comp, 2 H, C45-
H and C47-H), 3.87 (d, J = 12.7 Hz, 1 H, C45-H), 3.15 (s, 1 H, C21-H), 3.10 – 2.96 (comp, 
5 H, C13-H and C17-H), 2.82 – 2.50 (comp, 8 H, C7-H, C14-H, C16-H, and C21-H), 2.44 
– 2.25 (comp, 5 H, C18-H and C25-H), 2.01 (s, 1 H, C9-H), 1.93 (s, 1 H, C8-H), 1.83 – 
1.64 (comp, 3 H, C8-H and C9-H), 1.64 – 1.46 (comp, 7 H, C19-H, C22-H, and C24-H), 
1.24 (s, 5 H, C23-H), 1.14 (s, 2 H, C23-H), 0.92 (t, J = 7.4 Hz, 4 H, C20-H); 13C NMR 
(126 MHz, rotamers) δ 173.9 (C26), 173.8 (C26), 163.1 (C56), 157.3 (C34), 156.7 (C34), 
155.6 (C53), 155.4 (C53), 149.7 (C1), 149.4 (C1), 145.0 (C58), 137.0 (C4), 136.6 (C5 and 
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C37), 136.3 (C37), 130.1 (C5), 129.9 (C3), 128.5 (C40 and C42), 128.4 (C40 and C42), 
127.9 (C39, C41, and C43), 127.7, 124.7 (C49), 122.6 (C49), 120.5 (C49), 116.1 (C2), 
115.9 (C2), 114.4 (C6), 113.9 (C6), 113.8 (C6), 97.4 (C57), 85.4 (C50), 81.6 (C47), 68.6 
(C46), 68.5 (C46), 68.3 (C46), 67.1 (C37), 60.6 (C18), 59.4 (C45), 56.9 (C10), 56.4 (C10), 
53.1 (C14 and C16), 49.3 (C13 and C17), 45.8 (C21), 44.5 (C21), 37.2 (C25), 29.7 (C22), 
29.4 (C9), 29.0 (C9), 28.7 (C7), 28.6 (C7), 26.4 (C23), 26.3 (C23), 24.1 (C24), 22.4 (C8), 
22.3 (C8), 19.7 (C19), 11.9 (C20). 
 
 
Benzyl (11-((1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-
(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)amino)-11-
oxoundecyl)(7-(4-propylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-
yl)carbamate (2.91). KTL-03-153. Prepared according to the representative procedure 
outlined for TBAF deprotection. The combined organic layers were dried (Na2SO4) and 
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concentrated under reduced pressure to give 20 mg (54%) of 2.91 as a clear oil: 1H NMR 
(499 MHz, rotamers) δ 8.21 – 8.11 (m, 1 H), 7.45 (d, J = 7.6 Hz, 1 H), 7.41 – 7.12 (m, 5 
H), 6.96 (d, J = 8.4 Hz, 1 H), 6.80 – 6.72 (m, 1 H), 6.62 – 6.53 (m, 1 H), 6.30 – 6.18 (m, 1 
H), 5.40 – 4.98 (m, 3 H), 4.46 (q, J = 11.5, 10.7 Hz, 1 H), 4.06 – 3.95 (m, 2 H), 3.87 (d, J 
= 12.1 Hz, 1 H), 3.28 – 2.94 (m, 5 H), 2.85 – 2.62 (m, 3 H), 2.62 – 2.52 (m, 5 H), 2.44 (t, 
J = 7.2 Hz, 2 H), 2.40 – 2.32 (m, 2 H), 2.03 (s, 1 H), 1.95 (s, 1 H), 1.88 – 1.41 (m, 9 H), 
1.31 – 1.05 (m, 15 H), 0.92 (t, J = 7.4 Hz, 3 H); 13C NMR (126 MHz, rotamers) δ 174.1, 
173.8, 163.1, 163.0, 157.3, 156.8, 155.5, 149.8, 149.5, 145.1, 137.1, 136.74, 136.67, 136.5, 
130.1, 129.8, 128.5, 128.4, 127.9, 127.83, 127.76, 124.5, 122.5, 120.4, 116.0, 115.9, 115.7, 
114.5, 114.4, 114.0, 113.9, 97.5, 97.4, 85.4, 81.5, 68.9, 68.7, 68.6, 67.0, 60.6, 59.5, 57.1, 
56.4, 53.1, 49.4, 44.9, 37.6, 30.3, 29.7, 29.4, 29.3, 29.2, 29.1, 29.0, 28.9, 28.85, 28.8, 28.7, 
28.6, 27.1, 24.7, 22.5, 22.4, 19.7, 12.0; HRMS (ESI) m/z  C45H62F2N6O7 (M+H)
+ calcd for 
837.4725; found 837.4721. 
NMR Assignment. 1H NMR (499 MHz, rotamers) δ 8.21 – 8.11 (m, 1 H, C58-H), 
7.45 (d, J = 7.6 Hz, 1 H, C57-H), 7.41 – 7.12 (m, 5 H, C39-H thru C43-H), 6.96 (d, J = 8.4 
Hz, 1 H, C3-H), 6.80 – 6.72 (m, 1 H, C2-H), 6.62 – 6.53 (m, 1 H, C6-H), 6.30 – 6.18 (m, 
1 H, C50-H), 5.40 – 4.98 (m, 3 H, C10-H and C37-H), 4.46 (q, J = 11.5, 10.7 Hz, 1 H, 
C46-H), 4.06 – 3.95 (m, 2 H, C45-H and C47-H), 3.87 (d, J = 12.1 Hz, 1 H, C45-H), 3.28 
– 2.94 (m, 5 H, C13-H, C17-H, and C21-H), 2.85 – 2.62 (m, 3 H, C7-H and C21-H), 2.62 
– 2.52 (m, 5 H, C14-H and C16-H), 2.44 (t, J = 7.2 Hz, 2 H, C30-H), 2.40 – 2.32 (m, 2 H, 
C18-H), 2.03 (s, 1 H, C9-H), 1.95 (s, 1 H, C8-H), 1.88 – 1.41 (m, 9 H, C8-H, C9-H, C19-
H, C22-H, and C29-H), 1.31 – 1.05 (m, 15 H, C23-H thru C28-H), 0.92 (t, J = 7.4 Hz, 3 H, 
 190 
C20-H); 13C NMR (126 MHz, rotamers) δ 174.1 (C31), 173.8 (C31), 163.1 (C56), 163.0 
(C56), 157.3 (C34), 156.8 (C34), 155.5 (C53), 149.8 (C1), 149.5 (C1), 145.1 (C58), 137.1 
(C5), 136.74, (C4) 136.67 (C38), 136.5 (C38), 130.1 (C5), 129.8 (C3), 128.5 (C40 and 
C42), 128.4 (C40 and C42), 127.9 (C39, C41, and C43), 127.83 (C39, C41, and C43), 
127.76 (C39, C41, and C43), 124.5 (C49), 122.5 (C49), 120.4 (C49), 116.0 (C2), 115.9 
(C2), 115.7 (C2), 114.5 (C6), 114.4 (C6), 114.0 (C6), 113.9 (C6), 97.5 (C57), 97.4 (C57), 
85.4 (C50), 81.5 (C47), 68.9 (C46), 68.7 (C46), 68.6 (C46), 67.0 (C37), 60.6 (C18), 59.5 
(C45), 57.1 (C10), 56.4 (C10), 53.1 (C14 and C16), 49.4 (C13 and C17), 44.9 (C21), 37.6 
(C30), 30.3 (C22), 29.7 (C22), 29.4 (C24 thru C28), 29.3 (C24 thru C28), 29.2 (C24 thru 
C28), 29.1 (C24 thru C28), 29.0 (C24 thru C28), 28.9 (C9), 28.85 (C9), 28.8 (C9), 28.7 
(C7), 28.6 (C7), 27.1, (C23) 24.7 (C29), 22.5 (C8), 22.4 (C8), 19.7 (C19), 12.0 (C20). 
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